<article title='Chemotherapy'><paragraph><template><target>About</target><arg>cancer treatment</arg><arg>antimicrobial chemotherapy</arg><arg>antimicrobial chemotherapy (disambiguation){{!}}Antimicrobial chemotherapy</arg><arg>treatment against helminthiasis</arg><arg>preventive chemotherapy</arg></template><template><target>Use dmy dates</target><arg name="date">November 2013</arg></template><link><target>File:Chemotherapy with acral cooling.jpg</target><part>thumb</part><part>A woman being treated with<space/><link><target>docetaxel</target></link><space/>chemotherapy for<space/><link><target>breast cancer</target></link>. Cold mittens and<space/><link><target>wine accessory#Wine coolers</target><part>wine coolers</part></link><space/>are placed on her hands and feet to reduce harm to her nails.</part></link><bold>Chemotherapy</bold><space/>(often abbreviated to<space/><bold>chemo</bold><space/>and sometimes<space/><bold>CTX</bold><space/>or<space/><bold>CTx</bold>) is a category of<space/><link><target>cancer treatment</target></link><space/>that uses<space/><link><target>chemical substance</target><trail>s</trail></link>, especially one or more anti-cancer drugs (<link><target>list of chemotherapeutic agents</target><part>chemotherapeutic agents</part></link>) that are given as part of a standardized<space/><link><target>chemotherapy regimen</target></link>. Chemotherapy may be given with a<space/><link><target>cure</target><part>curative</part></link><space/>intent, or it may aim to prolong life or to<space/><link><target>Palliative care</target><part>reduce symptoms</part></link><space/>(palliative chemotherapy). Along with<space/><link><target>hormonal therapy (oncology)</target><part>hormonal therapy</part></link><space/>and<space/><link><target>targeted therapy</target></link>, it is one of the major categories of<space/><link><target>oncology#Specialties</target><part>medical oncology</part></link><space/>(<link><target>pharmacotherapy</target></link><space/>for cancer). These modalities are often used in conjunction with other cancer treatments, such as<space/><link><target>radiation therapy</target></link>,<space/><link><target>surgery</target></link>, and/or<space/><link><target>hyperthermia therapy</target></link>. Chemotherapy is also used to treat other conditions, including<space/><link><target>AL amyloidosis</target></link>,<space/><link><target>ankylosing spondylitis</target></link>,<space/><link><target>multiple sclerosis</target></link>,<space/><link><target>Crohn's disease</target></link>,<space/><link><target>psoriasis</target></link>,<space/><link><target>psoriatic arthritis</target></link>,<space/><link><target>systemic lupus erythematosus</target></link>,<space/><link><target>rheumatoid arthritis</target></link>, and<space/><link><target>scleroderma</target></link>.</paragraph><paragraph>Traditional chemotherapeutic agents are<space/><link><target>cytotoxicity</target><part>cytotoxic</part></link>, that is to say they act by killing cells that divide rapidly, one of the main properties of most cancer cells. This means that chemotherapy also harms cells that divide rapidly under normal circumstances: cells in the<space/><link><target>bone marrow</target></link>,<space/><link><target>digestive tract</target></link>, and<space/><link><target>hair follicle</target><trail>s</trail></link>. This results in the most common side-effects of chemotherapy:<space/><link><target>myelosuppression</target></link><space/>(decreased production of blood cells, hence also<space/><link><target>immunosuppression</target></link>),<space/><link><target>mucositis</target></link><space/>(inflammation of the lining of the digestive tract), and<space/><link><target>alopecia</target></link><space/>(hair loss).</paragraph><paragraph>Some newer anticancer drugs (for example, various<space/><link><target>Monoclonal antibody therapy</target><part>monoclonal antibodies</part></link>) are not indiscriminately cytotoxic, but rather target proteins that are abnormally expressed in cancer cells and that are essential for their growth. Such treatments are often referred to as<space/><link><target>targeted therapy</target></link><space/>(as distinct from classic chemotherapy) and are often used alongside traditional chemotherapeutic agents in antineoplastic treatment regimens.</paragraph><paragraph>Chemotherapy may use one drug at a time (single-agent chemotherapy) or several drugs at once (combination chemotherapy or polychemotherapy). The combination of chemotherapy and<space/><link><target>radiation therapy</target><part>radiotherapy</part></link><space/>is<space/><link><target>chemoradiotherapy</target></link>. Chemotherapy using drugs that convert to cytotoxic activity only upon light exposure is called photochemotherapy or<space/><link><target>photodynamic therapy</target></link>.</paragraph><paragraph><template><target>TOC limit</target><arg>3</arg></template></paragraph><heading level='2'>Treatment strategies</heading><table border="1" class="wikitable" align="right"><tablecaption>Common combination chemotherapy regimens<extension extension_name='ref' name="Corrie"></extension></tablecaption><tablerow><tablehead>Cancer type</tablehead><tablehead>Drugs</tablehead><tablehead>Acronym</tablehead></tablerow><tablerow><tablehead rowspan="2"><link><target>Breast cancer</target></link></tablehead><tablecell><link><target>Cyclophosphamide</target></link>,<space/><link><target>methotrexate</target></link>,<space/><link><target>5-fluorouracil</target></link></tablecell><tablecell>CMF</tablecell></tablerow><tablerow><tablecell><link><target>Doxorubicin</target></link>, cyclophosphamide</tablecell><tablecell>AC</tablecell></tablerow><tablerow><tablehead rowspan="2"><link><target>Hodgkin's disease</target></link></tablehead><tablecell>Mustine,<space/><link><target>vincristine</target></link>,<space/><link><target>procarbazine</target></link>,<space/><link><target>prednisolone</target></link></tablecell><tablecell>MOPP</tablecell></tablerow><tablerow><tablecell>Doxorubicin,<space/><link><target>bleomycin</target></link>,<space/><link><target>vinblastine</target></link>,<space/><link><target>dacarbazine</target></link></tablecell><tablecell>ABVD</tablecell></tablerow><tablerow><tablehead><link><target>Non-Hodgkin's lymphoma</target></link></tablehead><tablecell>Cyclophosphamide, doxorubicin, vincristine, prednisolone</tablecell><tablecell>CHOP</tablecell></tablerow><tablerow><tablehead><link><target>Germ cell tumor</target></link></tablehead><tablecell>Bleomycin,<space/><link><target>etoposide</target></link>,<space/><link><target>cisplatin</target></link></tablecell><tablecell>BEP</tablecell></tablerow><tablerow><tablehead rowspan="2"><link><target>Stomach cancer</target></link></tablehead><tablecell><link><target>Epirubicin</target></link>, cisplatin, 5-fluorouracil</tablecell><tablecell>ECF</tablecell></tablerow><tablerow><tablecell>Epirubicin, cisplatin,<space/><link><target>capecitabine</target></link></tablecell><tablecell>ECX</tablecell></tablerow><tablerow><tablehead><link><target>Bladder cancer</target></link></tablehead><tablecell><link><target>Methotrexate</target></link>, vincristine, doxorubicin, cisplatin</tablecell><tablecell>MVAC</tablecell></tablerow><tablerow><tablehead><link><target>Lung cancer</target></link></tablehead><tablecell>Cyclophosphamide, doxorubicin, vincristine,</tablecell><tablecell>CAV</tablecell></tablerow><tablerow><tablehead><link><target>Colorectal cancer</target></link></tablehead><tablecell>5-fluorouracil,<space/><link><target>folinic acid</target></link>,<space/><link><target>oxaliplatin</target></link></tablecell><tablecell>FOLFOX</tablecell></tablerow></table><paragraph>There are a number of strategies in the administration of chemotherapeutic drugs used today. Chemotherapy may be given with a<space/><link><target>cure</target><part>curative</part></link><space/>intent or it may aim to prolong life or to<space/><link><target>Palliative care</target><part>palliate symptoms</part></link>.</paragraph><list type='bullet'><listitem>Combined modality chemotherapy is the use of drugs with other<space/><link><target>Cancer#Treatments</target><part>cancer treatments</part></link>, such as<space/><link><target>radiation therapy</target></link>,<space/><link><target>surgery</target></link><space/>and/or<space/><link><target>hyperthermia therapy</target></link>.</listitem><listitem>Induction chemotherapy is the first line treatment of cancer with a chemotherapeutic drug. This type of chemotherapy is used for curative intent.<extension extension_name='ref' name="isbn0-470-09254-8">Airley, pp. 55-59</extension></listitem><listitem>Consolidation chemotherapy is given after remission in order to prolong the overall disease-free time and improve overall survival. The drug that is administered is the same as the drug that achieved remission.<extension extension_name='ref' name="isbn0-470-09254-8"></extension></listitem><listitem>Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is used.<extension extension_name='ref' name="isbn0-470-09254-8"></extension></listitem><listitem><link><target>Combination chemotherapy</target></link><space/>involves treating a patient with a number of different drugs simultaneously. The drugs differ in their mechanism and side-effects. The biggest advantage is minimising the chances of resistance developing to any one agent. Also, the drugs can often be used at lower doses, reducing toxicity.<extension extension_name='ref' name="isbn0-470-09254-8"></extension><extension extension_name='ref' name="isbn0-443-07101-2 6">Wood, pp. 17-18</extension></listitem><listitem><link><target>Neoadjuvant</target></link><space/>chemotherapy is given prior to a local treatment such as surgery, and is designed to shrink the primary tumor.<extension extension_name='ref' name="isbn0-470-09254-8"></extension><space/>It is also given to cancers with a high risk of micrometastatic disease.<extension extension_name='ref' name="isbn0-7817-7328-8">Perry, p. 42</extension></listitem><listitem><link><target>Adjuvant chemotherapy</target></link><space/>is given after a local treatment (radiotherapy or surgery). It can be used when there is little evidence of cancer present, but there is risk of recurrence.<extension extension_name='ref' name="isbn0-470-09254-8"></extension><space/>It is also useful in killing any cancerous cells that have spread to other parts of the body. These<space/><link><target>micrometastases</target></link><space/>can be treated with adjuvant chemotherapy and can reduce relapse rates caused by these disseminated cells.<extension extension_name='ref' name="pmid16061845"><template><target>cite journal</target><arg name="author"><space/>Epstein RJ<space/></arg><arg name="title"><space/>Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment<space/></arg><arg name="journal"><space/>Clinical Cancer Research<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/>15<space/></arg><arg name="pages"><space/>5337–41<space/></arg><arg name="date"><space/>Aug 2005<space/></arg><arg name="pmid"><space/>16061845<space/></arg><arg name="doi"><space/>10.1158/1078-0432.CCR-05-0437<space/></arg></template></extension></listitem><listitem><link><target>Maintenance therapy</target><part>Maintenance</part></link><space/>chemotherapy is a repeated low-dose treatment to prolong remission.<extension extension_name='ref' name="isbn0-470-09254-8"></extension></listitem><listitem>Salvage chemotherapy or palliative chemotherapy is given without curative intent, but simply to decrease tumor load and increase life expectancy. For these regimens, in general, a better toxicity profile is expected.<extension extension_name='ref' name="isbn0-470-09254-8"></extension></listitem></list><paragraph>All chemotherapy regimens require that the patient be capable of undergoing the treatment.<space/><link><target>Performance status</target></link><space/>is often used as a measure to determine whether a patient can receive chemotherapy, or whether dose reduction is required. Because only a fraction of the cells in a tumor die with each treatment (<link><target>fractional kill</target></link>), repeated doses must be administered to continue to reduce the size of the tumor.<extension extension_name='ref' name="skeel"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1">Skeel<space/></arg><arg name="first1"><space/>R. T.<space/></arg><arg name="year">2003<space/></arg><arg name="title"><space/>Handbook of Cancer Chemotherapy (paperback)<space/></arg><arg name="publisher">Lippincott Williams & Wilkins<space/></arg><arg name="edition">6th<space/></arg><arg name="isbn">0-7817-3629-3</arg></template></extension><space/>Current chemotherapy regimens apply drug treatment in cycles, with the frequency and duration of treatments limited by toxicity to the patient.<extension extension_name='ref' name="chabner"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1">Chabner</arg><arg name="first1"><space/>B.<space/></arg><arg name="last2"><space/>Longo<space/></arg><arg name="first2">D. L.<space/></arg><arg name="year">2005<space/></arg><arg name="edition">4th<space/></arg><arg name="title"><space/>Cancer Chemotherapy and Biotherapy: Principles and Practice</arg><arg name="location"><space/>Philadelphia<space/></arg><arg name="publisher"><space/>Lippincott Willians & Wilkins<space/></arg><arg name="isbn"><space/>0-7817-5628-6</arg></template></extension></paragraph><heading level='3'>Efficacy</heading><paragraph>The efficacy of chemotherapy depends on the type of cancer and the stage. The overall effectiveness ranges from being curative for some cancers, such as some<space/><link><target>leukemias</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Nastoupil LJ, Rose AC, Flowers CR<space/></arg><arg name="title"><space/>Diffuse large B-cell lymphoma: current treatment approaches<space/></arg><arg name="journal"><space/>Oncology<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>488–95<space/></arg><arg name="date"><space/>May 2012<space/></arg><arg name="pmid"><space/>22730604<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Freedman A<space/></arg><arg name="title"><space/>Follicular lymphoma: 2012 update on diagnosis and management<space/></arg><arg name="journal"><space/>American Journal of Hematology<space/></arg><arg name="volume"><space/>87<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>988–95<space/></arg><arg name="date"><space/>Oct 2012<space/></arg><arg name="pmid"><space/>23001911<space/></arg><arg name="doi"><space/>10.1002/ajh.23313<space/></arg></template></extension><space/>to being ineffective, such as in some<space/><link><target>brain tumors</target></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Rampling R, James A, Papanastassiou V<space/></arg><arg name="title"><space/>The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy<space/></arg><arg name="journal"><space/>Journal of Neurology, Neurosurgery, and Psychiatry<space/></arg><arg name="volume"><space/>75 Suppl 2<space/></arg><arg name="issue"><space/>Suppl 2<space/></arg><arg name="pages"><space/>ii24–30<space/></arg><arg name="date"><space/>Jun 2004<space/></arg><arg name="pmid"><space/>15146036<space/></arg><arg name="pmc"><space/>1765659<space/></arg><arg name="doi"><space/>10.1136/jnnp.2004.040535<space/></arg></template></extension><space/>to being needless in others, like most<space/><link><target>non-melanoma skin cancer</target><trail>s</trail></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Madan V, Lear JT, Szeimies RM<space/></arg><arg name="title"><space/>Non-melanoma skin cancer<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>375<space/></arg><arg name="issue"><space/>9715<space/></arg><arg name="pages"><space/>673–85<space/></arg><arg name="date"><space/>Feb 2010<space/></arg><arg name="pmid"><space/>20171403<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(09)61196-X<space/></arg></template></extension></paragraph><heading level='3'>Dosage</heading><paragraph><link><target>File:Screenshot at 2013-08-16 14 52 30.png</target><part>thumb</part><part>left</part><part>Dose response relationship of cell killing by chemotherapeutic drugs on normal and cancer cells. At high doses the percentage of normal and cancer cells killed is very similar. For this reason, doses are chosen where anti-tumour activity exceeds normal cell death.<extension extension_name='ref' name="Corrie"></extension></part></link>Dosage of chemotherapy can be difficult: If the dose is too low, it will be ineffective against the tumor, whereas, at excessive doses, the toxicity (<link><target>adverse effect</target><part>side-effects</part></link>) will be intolerable to the patient.<extension extension_name='ref' name="Corrie"></extension><space/>The standard method of determining chemotherapy dosage is based on calculated<space/><link><target>body surface area</target></link><space/>(BSA). The BSA is usually calculated with a mathematical formula or a<space/><link><target>nomogram</target></link>, using a patient's weight and height, rather than by direct measurement of body mass. This formula was originally derived in a 1916 study and attempted to translate medicinal doses established with laboratory animals to equivalent doses for humans.<extension extension_name='ref'><template><target>cite journal</target><arg name="author1">Du Bois D</arg><arg name="author2">Du Bois EF</arg><arg name="title">A formula to estimate the approximate surface area if height and weight be known. 1916.</arg><arg name="publisher">Archives Internal Medicine</arg><arg name="volume">5</arg><arg name="issue">5</arg><arg name="pages">303–11</arg></template></extension><space/>The study only included 9 human subjects.<extension extension_name='ref' name="dosing strategies"><template><target>cite journal</target><arg name="author1">Felici A.</arg><arg name="author2">J. Verweij</arg><arg name="author3">A. Sparreboom</arg><arg name="title">Dosing strategies for anticancer drugs: the good, the bad and body-surface area</arg><arg name="publisher">Eur J Cancer</arg><arg name="year">2002</arg><arg name="volume">38</arg><arg name="issue">13</arg><arg name="pages">1677–84</arg></template></extension><space/>When chemotherapy was introduced in the 1950s, the BSA formula was adopted as the official standard for chemotherapy dosing for lack of a better option.<extension extension_name='ref' name="pmid17305252"><template><target>cite journal</target><arg name="author"><space/>Kaestner SA, Sewell GJ<space/></arg><arg name="title"><space/>Chemotherapy dosing part I: scientific basis for current practice and use of body surface area<space/></arg><arg name="journal"><space/>Clinical Oncology<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>23–37<space/></arg><arg name="date"><space/>Feb 2007<space/></arg><arg name="pmid"><space/>17305252<space/></arg><arg name="doi"><space/>10.1016/j.clon.2006.10.010<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="title">The Use of Body Surface Area as a Criterion of Drug Dosage in Cancer Chemotherapy</arg><arg name="author">Donald Pinkel</arg><arg name="publisher">Cancer Res</arg><arg name="date">August 1958</arg><arg name="volume">18</arg><arg name="issue">7</arg><arg name="pages">853–6</arg></template></extension></paragraph><paragraph>Recently, the validity of this method in calculating uniform doses has been questioned. The reason for this is that the formula only takes into account the individual's weight and height. Drug absorption and clearance are influenced by multiple factors, including age, gender, metabolism, disease state, organ function, drug-to-drug interactions, genetics, and obesity, which has a major impact on the actual concentration of the drug in the patient's bloodstream.<extension extension_name='ref' name="pmid17305252"></extension><extension extension_name='ref' name="pmid11953888"><template><target>cite journal</target><arg name="author"><space/>Gurney H<space/></arg><arg name="title"><space/>How to calculate the dose of chemotherapy<space/></arg><arg name="journal"><space/>British Journal of Cancer<space/></arg><arg name="volume"><space/>86<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1297–302<space/></arg><arg name="date"><space/>Apr 2002<space/></arg><arg name="pmid"><space/>11953888<space/></arg><arg name="pmc"><space/>2375356<space/></arg><arg name="doi"><space/>10.1038/sj.bjc.6600139<space/></arg></template></extension><extension extension_name='ref' name="pmid22965963"><template><target>cite journal</target><arg name="author"><space/>Beumer JH, Chu E, Salamone SJ<space/></arg><arg name="title"><space/>Body-surface area-based chemotherapy dosing: appropriate in the 21st century?<space/></arg><arg name="journal"><space/>Journal of Clinical Oncology<space/></arg><arg name="volume"><space/>30<space/></arg><arg name="issue"><space/>31<space/></arg><arg name="pages"><space/>3896–7<space/></arg><arg name="date"><space/>Nov 2012<space/></arg><arg name="pmid"><space/>22965963<space/></arg><arg name="doi"><space/>10.1200/JCO.2012.44.2863<space/></arg></template></extension><space/>As a result, there is high variability in the systemic chemotherapy drug concentration among patients dosed by BSA, and this variability has been demonstrated to be more than 10-fold for many drugs.<extension extension_name='ref' name="dosing strategies"></extension><extension extension_name='ref' name="role of body"><template><target>cite journal</target><arg name="author1">Baker SD</arg><arg name="author2">Verweij J</arg><arg name="author3">Rowinsky EK</arg><arg name="author4">Donehower RC</arg><arg name="author5">Schellens JH</arg><arg name="author6">Grochow LB</arg><arg name="author7">Sparreboom A</arg><arg name="title">Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001</arg><arg name="publisher">J Natl Cancer Inst</arg><arg name="year">2002</arg><arg name="volume">94</arg><arg name="issue">24</arg><arg name="pages">1883–8</arg></template></extension><space/>In other words, if two patients receive the same dose of a given drug based on BSA, the concentration of that drug in the bloodstream of one patient may be 10 times higher or lower compared to that of the other patient.<extension extension_name='ref' name="role of body"></extension><space/>This variability is typical with many chemotherapy drugs dosed by BSA, and, as shown below, was demonstrated in a study of 14 common chemotherapy drugs.<extension extension_name='ref' name="dosing strategies"></extension></paragraph><paragraph><link><target>File:Improvement in Response Rate.jpg</target><part>thumb</part><part>180px</part><part>right</part><part>5-FU dose management results in significantly better response and survival rates versus BSA dosing.<extension extension_name='ref' name="individual fluorouracil"></extension></part></link>The result of this pharmacokinetic variability among patients is that many patients do not receive the right dose to achieve optimal treatment effectiveness with minimized toxic side effects. Some patients are overdosed while others are underdosed.<extension extension_name='ref' name="pmid17305252"></extension><extension extension_name='ref' name="pmid11953888"></extension><extension extension_name='ref' name="pmid22965963"></extension><extension extension_name='ref' name="individual fluorouracil"><template><target>cite journal</target><arg name="author1">Gamelin EC</arg><arg name="author2">Delva R</arg><arg name="author3">Jacob J</arg><arg name="author4">Merrouche Y</arg><arg name="author5">Raoul JL</arg><arg name="author6">Pezet D</arg><arg name="author7">Dorval E</arg><arg name="author8">Piot G</arg><arg name="author9">Morel A</arg><arg name="author10">Boisdron-Celle M</arg><arg name="title"><space/>Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: Results of a multicenter randomized trial of patients with metastatic colorectal cancer</arg><arg name="publisher">J Clin Oncol</arg><arg name="year">2008</arg><arg name="volume">26</arg><arg name="issue">13</arg><arg name="pages">2099–2105</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author1">Saam J</arg><arg name="author2">Critchfield GC</arg><arg name="author3">Hamilton SA</arg><arg name="author4">Roa BB</arg><arg name="author5">Wenstrup RJ</arg><arg name="author6">Kaldate RR</arg><arg name="title">Body Surface Area-based Dosing of 5-Fluorouracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens</arg><arg name="publisher">Clin Colorectal Cancer</arg><arg name="year">2011</arg><arg name="volume">10</arg><arg name="issue">3</arg><arg name="pages">203–206</arg></template></extension><extension extension_name='ref' name="dose adjustment"><template><target>cite journal</target><arg name="author1">Capitain O</arg><arg name="author2">Asevoaia A</arg><arg name="author3">Boisdron-Celle M</arg><arg name="author4">Poirier AL</arg><arg name="author5">Morel A</arg><arg name="author6">Gamelin E</arg><arg name="title">Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study</arg><arg name="publisher">Clin Colorectal Cancer</arg><arg name="year">2012</arg><arg name="volume">11</arg><arg name="issue">4</arg><arg name="pages">263–267</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author1">Kaldate RR</arg><arg name="author2">Haregewoin A</arg><arg name="author3">Grier CE</arg><arg name="author4">Hamilton SA</arg><arg name="author5">McLeod HL</arg><arg name="title">Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6</arg><arg name="publisher">Oncologist, 2012</arg><arg name="volume">17</arg><arg name="issue">3</arg><arg name="pages">296–302</arg></template></extension><space/>For example, in a randomized clinical trial, investigators found 85% of metastatic colorectal cancer patients treated with 5-fluorouracil (5-FU) did not receive the optimal therapeutic dose when dosed by the BSA standard68% were underdosed and 17% were overdosed.<extension extension_name='ref' name="individual fluorouracil"></extension></paragraph><paragraph>There has been recent controversy over the use of BSA to calculate chemotherapy doses for<space/><link><target>obese</target></link><space/>patients.<extension extension_name='ref' name="dosing chemotherapy"><template><target>cite journal</target><arg name="author"><space/>Hunter RJ, Navo MA, Thaker PH, Bodurka DC, Wolf JK, Smith JA<space/></arg><arg name="title"><space/>Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA)<space/></arg><arg name="journal"><space/>Cancer Treatment Reviews<space/></arg><arg name="volume"><space/>35<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>69–78<space/></arg><arg name="date"><space/>Feb 2009<space/></arg><arg name="pmid"><space/>18922643<space/></arg><arg name="doi"><space/>10.1016/j.ctrv.2008.07.005<space/></arg><arg name="publisher"><space/>Cancer Treat Rev<space/></arg></template></extension><space/>Because of their higher BSA, clinicians often arbitrarily reduce the dose prescribed by the BSA formula for fear of<space/><link><target>overdosing</target></link>.<extension extension_name='ref' name="dosing chemotherapy"></extension><space/>In many cases, this can result in sub-optimal treatment.<extension extension_name='ref' name="dosing chemotherapy"></extension></paragraph><paragraph>Several clinical studies have demonstrated that when chemotherapy dosing is individualized to achieve optimal systemic drug exposure, treatment outcomes are improved and toxic side effects are reduced.<extension extension_name='ref' name="individual fluorouracil"></extension><extension extension_name='ref' name="dose adjustment"></extension><space/>In the 5-FU clinical study cited above, patients whose dose was adjusted to achieve a pre-determined target exposure realized an 84% improvement in treatment response rate and a six-month improvement in overall survival (OS) compared with those dosed by BSA.<extension extension_name='ref' name="individual fluorouracil"></extension></paragraph><paragraph><link><target>File:Toxicity.png</target><part>thumb</part><part>180px</part><part>left</part><part>5-FU dose management avoids serious side effects experienced with BSA dosing<extension extension_name='ref' name="individual fluorouracil"></extension></part></link><template><target>multiple image</target><arg name="align"><space/>right
</arg><arg name="direction"><space/>vertical
</arg><arg name="width"><space/>100
</arg><arg name="image1"><space/>Response 1.jpg
</arg><arg name="image2"><space/>Survival 1.png
</arg><arg name="caption2"><space/>5-FU dose management in the FOLFOX regimen increases treatment response significantly & improves survival by 6 months<ref name</arg></template>In the same study, investigators compared the incidence of common 5-FU-associated grade 3/4 toxicities between the dose-adjusted patients and the BSA-dosed patients.<extension extension_name='ref' name="individual fluorouracil"></extension><space/>The incidence of debilitating grades of diarrhea was reduced from 18% in the BSA-dosed group to 4% in the dose-adjusted group of patients and serious hematologic side effects were eliminated.<extension extension_name='ref' name="individual fluorouracil"></extension><space/>Because of the reduced toxicity, dose-adjusted patients were able to be treated for longer periods of time.<extension extension_name='ref' name="individual fluorouracil"></extension><space/>BSA-dosed patients were treated for a total of 680 months while dose-adjusted patients were treated for a total of 791 months.<extension extension_name='ref' name="individual fluorouracil"></extension><space/>Completing the course of treatment is an important factor in achieving better treatment outcomes.</paragraph><paragraph>Similar results were found in a study involving colorectal cancer patients treated with the popular<space/><link><target>FOLFOX</target></link><space/>regimen.<extension extension_name='ref' name="dose adjustment"></extension><space/>The incidence of serious diarrhea was reduced from 12% in the BSA-dosed group of patients to 1.7% in the dose-adjusted group, and the incidence of severe mucositis was reduced from 15% to 0.8%.<extension extension_name='ref' name="dose adjustment"></extension></paragraph><paragraph>The FOLFOX study also demonstrated an improvement in treatment outcomes.<extension extension_name='ref' name="dose adjustment"></extension><space/>Positive response increased from 46% in the BSA-dosed patients to 70% in the dose-adjusted group. Median progression free survival (PFS) and overall survival (OS) both improved by six months in the dose adjusted group.<extension extension_name='ref' name="dose adjustment"></extension></paragraph><paragraph>One approach that can help clinicians individualize chemotherapy dosing is to measure the drug levels in blood plasma over time and adjust dose according to a formula or algorithm to achieve optimal exposure. With an established target exposure for optimized treatment effectiveness with minimized toxicities, dosing can be personalized to achieve target exposure and optimal results for each patient. Such an algorithm was used in the clinical trials cited above and resulted in significantly improved treatment outcomes.</paragraph><paragraph>Oncologists are already individualizing dosing of some cancer drugs based on exposure.<space/><link><target>Carboplatin</target></link><extension extension_name='ref' name="isbn0-521-61816-9">Macbeth, p. 4</extension><space/>and<space/><link><target>busulfan</target></link><extension extension_name='ref'><template><target>cite journal</target><arg name="author1">Buffery, PJ</arg><arg name="author2">Allen, KM</arg><arg name="author3">Chin, PKL</arg><arg name="author4">Moore, GA</arg><arg name="author5">Barclay, ML</arg><arg name="author6">Begg, EJ</arg><arg name="title">Thirteen Years' Experience of Pharmacokinetic Monitoring and Dosing of Busulfan: Can the Strategy Be Improved?</arg><arg name="publisher">Ther Drug Monit</arg><arg name="year">2014</arg><arg name="volume">36</arg><arg name="issue">1</arg><arg name="pages">86–92</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author1">Bartelink IH</arg><arg name="author2">Bredius RG</arg><arg name="author3">Belitser SV</arg><arg name="author4">Suttorp MM</arg><arg name="author5">Bierings M</arg><arg name="author6">Knibbe CA</arg><arg name="author7">Egeler M</arg><arg name="author8">Lankester AC</arg><arg name="author9">Egberts AC</arg><arg name="author10">Zwaveling J</arg><arg name="author11">Boelens JJ</arg><arg name="title">Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation</arg><arg name="publisher">Ther Drug Monit</arg><arg name="volume">36</arg><arg name="issue">1</arg><arg name="pages">93–99</arg></template></extension><space/>dosing rely upon results from blood tests to calculate the optimal dose for each patient. Simple blood tests are also available for dose optimization of<space/><link><target>methotrexate</target></link>,<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://ark-tdm.com/DB_methotrexate.html</arg><arg name="title">ARK™ Methotrexate Assay</arg><arg name="publisher">Ark Diagnostics</arg></template></extension><space/>5-FU,<space/><link><target>paclitaxel</target></link>, and<space/><link><target>docetaxel</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://mycaretests.com</arg><arg name="title">Customizing Chemotherapy for Better Cancer Care</arg><arg name="publisher">My Care Diagnostics</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://bettercancercare.com</arg><arg name="title">A Brief History of BSA Dosing</arg><arg name="publisher">My Care Diagnostics</arg></template></extension></paragraph><heading level='3'>Types</heading><paragraph><link><target>File:Cross-linked DNA by nitrogen mustard.png</target><part>thumb</part><part>left</part><part>Two DNA bases that are cross-linked by a nitrogen mustard. Different nitrogen mustards will have different chemical groups (R). The nitrogen mustards most commonly alkylate the N7 nitrogen of guanine (as shown here) but other atoms can be alkylated.<extension extension_name='ref' name="Siddik"></extension></part></link></paragraph><heading level='4'>Alkylating agents</heading><paragraph><template><target>Main</target><arg>Alkylating antineoplastic agent</arg></template>Alkylating agents are the oldest group of chemotherapeutics in use today. Originally derived from<space/><link><target>mustard gas</target></link><space/>used in<space/><link><target>World War I</target></link>, there are now many types of alkylating agents in use.<extension extension_name='ref' name="Corrie"></extension><space/>They are so named because of their ability to<space/><link><target>alkylation</target><part>alkylate</part></link><space/>many molecules, including<space/><link><target>protein</target><trail>s</trail></link>,<space/><link><target>RNA</target></link><space/>and<space/><link><target>DNA</target></link>. This ability to bind<space/><link><target>covalent bond</target><part>covalently</part></link><space/>to DNA via their<space/><link><target>alkyl group</target></link><space/>is the primary cause for their anti-cancer effects.<extension extension_name='ref' name="lind"><template><target>cite journal</target><arg name="last">Lind M.J.</arg><arg name="title">Principles of cytotoxic chemotherapy</arg><arg name="journal">Medicine</arg><arg name="year">2008</arg><arg name="volume">36</arg><arg name="issue">1</arg><arg name="pages">19–23</arg><arg name="doi">10.1016/j.mpmed.2007.10.003</arg><arg name="first1">M.J.</arg></template></extension><space/>DNA is made of two strands and the molecules may either bind twice to one strand of DNA (intrastrand crosslink) or may bind once to both strands (interstrand crosslink). If the cell tries to replicate crosslinked DNA during<space/><link><target>cell division</target></link>, or tries to repair it, the DNA strands can break. This leads to a form of programmed cell death called<space/><link><target>apoptosis</target></link>.<extension extension_name='ref' name="Siddik"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last">Siddik ZH</arg><arg name="title">Mechanisms of Action of Cancer Chemotherapeutic Agents: DNA-Interactive Alkylating Agents and Antitumour Platinum-Based Drugs</arg><arg name="year">2005</arg><arg name="publisher">John Wiley & Sons, Ltd</arg><arg name="doi">10.1002/0470025077.chap84b</arg></template></extension><extension extension_name='ref' name="pmid19002790"></extension><space/>Alkylating agents will work at any point in the cell cycle and thus are known as cell cycle-independent drugs. For this reason the effect on the cell is dose dependent; the fraction of cells that die is directly proportional to the dose of drug.<extension extension_name='ref' name="pmid14508075"></extension></paragraph><paragraph>The subtypes of alkylating agents are the<space/><link><target>nitrogen mustard</target><trail>s</trail></link>,<space/><link><target>nitrosoureas</target></link>,<space/><link><target>tetrazine</target><trail>s</trail></link>,<space/><link><target>aziridine</target><trail>s</trail></link>,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Giorgi-Renault S., Renault J., Baron M., Gebel-Servolles P., Delic J., Cros S., Paoletti C.<space/></arg><arg name="year"><space/>1988<space/></arg><arg name="title"><space/>Heterocyclic quinones XIII. Dimerization in the series of 5,8-quinazolinediones: Synthesis and anti tumor effects of bis(4-amino-5,8-quinazolinediones)<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Chem. Pharm. Bull.<space/></arg><arg name="volume"><space/>36<space/></arg><arg name="issue"><space/>10</arg><arg name="pages"><space/>3933–3947<space/></arg><arg name="doi">10.1248/cpb.36.3933</arg></template></extension><space/><link><target>cisplatin</target><trail>s</trail></link><space/>and derivatives, and non-classical alkylating agents. Nitrogen mustards include<space/><link><target>mechlorethamine</target></link>,<space/><link><target>cyclophosphamide</target></link>,<space/><link><target>melphalan</target></link>,<space/><link><target>chlorambucil</target></link>,<space/><link><target>ifosfamide</target></link><space/>and<space/><link><target>busulfan</target></link>. Nitrosoureas include<space/><link><target>N-Nitroso-N-methylurea</target></link><space/>(MNU),<space/><link><target>carmustine</target></link><space/>(BCNU),<space/><link><target>lomustine</target></link><space/>(CCNU) and<space/><link><target>semustine</target></link><space/>(MeCCNU),<space/><link><target>fotemustine</target></link><space/>and<space/><link><target>streptozotocin</target></link>. Tetrazines include<space/><link><target>dacarbazine</target></link>,<space/><link><target>mitozolomide</target></link><space/>and<space/><link><target>temozolomide</target></link>. Aziridines include<space/><link><target>thiotepa</target></link>,<space/><link><target>mytomycin</target></link><space/>and diaziquone (AZQ). Cisplatin and derivatives include<space/><link><target>cisplatin</target></link>,<space/><link><target>carboplatin</target></link><space/>and<space/><link><target>oxaliplatin</target></link>.<extension extension_name='ref' name="lind"></extension><extension extension_name='ref' name="pmid19002790"><template><target>cite journal</target><arg name="author"><space/>Damia G, D'Incalci M<space/></arg><arg name="title"><space/>Mechanisms of resistance to alkylating agents<space/></arg><arg name="journal"><space/>Cytotechnology<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>1-3<space/></arg><arg name="pages"><space/>165–73<space/></arg><arg name="date"><space/>Sep 1998<space/></arg><arg name="pmid"><space/>19002790<space/></arg><arg name="pmc"><space/>3449574<space/></arg><arg name="doi"><space/>10.1023/A:1008060720608<space/></arg></template></extension><space/>They impair cell function by forming<space/><link><target>covalent bond</target><trail>s</trail></link><space/>with the<space/><link><target>amino group</target><part>amino</part></link>,<space/><link><target>carboxyl group</target><part>carboxyl</part></link>,<space/><link><target>sulfhydryl group</target><part>sulfhydryl</part></link>, and<space/><link><target>phosphate group</target><trail>s</trail></link><space/>in biologically important molecules.<extension extension_name='ref' name="takimoto">Takimoto CH, Calvo E.<link type='external' href='http://www.cancernetwork.com/cancer-management-11/chapter03/article/10165/1402628'>&quot;Principles of Oncologic Pharmacotherapy&quot;</link><space/>in Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (Eds)<space/><link type='external' href='http://www.cancernetwork.com/cancer-management-11/'>Cancer Management: A Multidisciplinary Approach</link>. 11 ed. 2008.</extension><space/>Non-classical alkylating agents include<space/><link><target>procarbazine</target></link><space/>and hexamethylmelamine.<extension extension_name='ref' name="lind"></extension><extension extension_name='ref' name="pmid19002790"></extension></paragraph><heading level='4'>Antimetabolites</heading><paragraph><link><target>File:Deoxcytidine, Gemcitidine and Decitabine.png</target><part>thumb</part><part>Deoxcytidine (left) and two anti-metabolite drugs (centre and right);<space/><link><target>Gemcitabine</target></link><space/>and<space/><link><target>Decitabine</target></link>. The drugs are very similar but they have subtle differences in their<space/><link><target>chemical group</target><trail>s</trail></link>.</part></link><template><target>Main</target><arg>Antimetabolite</arg></template><link><target>Anti-metabolite</target><trail>s</trail></link><space/>are a group of molecules that impede DNA and RNA synthesis. Many of them have a similar structure to the building blocks of DNA and RNA. The building blocks are<space/><link><target>nucleotide</target><trail>s</trail></link>; a molecule comprising a<space/><link><target>nucleobase</target></link>, a sugar and a<space/><link><target>phosphate group</target></link>. The nucleobases are divided into<space/><link><target>purine</target><trail>s</trail></link><space/>(<link><target>guanine</target></link><space/>and<space/><link><target>adenine</target></link>) and<space/><link><target>pyrimidine</target><trail>s</trail></link><space/>(<link><target>cytosine</target></link>,<space/><link><target>thymine</target></link><space/>and<space/><link><target>uracil</target></link>). Anti-metabolites resemble either nucleobases or nucleosides (a nucleotide without the phosphate group), but have altered<space/><link><target>chemical group</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid19476376"><template><target>cite journal</target><arg name="author"><space/>Parker WB<space/></arg><arg name="title"><space/>Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer<space/></arg><arg name="journal"><space/>Chemical Reviews<space/></arg><arg name="volume"><space/>109<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>2880–93<space/></arg><arg name="date"><space/>Jul 2009<space/></arg><arg name="pmid"><space/>19476376<space/></arg><arg name="pmc"><space/>2827868<space/></arg><arg name="doi"><space/>10.1021/cr900028p<space/></arg></template></extension><space/>These drugs exert their effect by either blocking the enzymes required for DNA synthesis or becoming incorporated into DNA or RNA. By inhibiting the enzymes involved in DNA synthesis, they prevent mitosis because the DNA cannot duplicate itself. Also, after misincorporation of the molecules into DNA,<space/><link><target>DNA damage</target></link><space/>can occur and programmed cell death (<link><target>apoptosis</target></link>) is induced. Unlike alkylating agents, anti-metabolites are cell cycle dependent. This means that they only work during a specific part of the cell cycle, in this case<space/><link><target>S-phase</target></link><space/>(the DNA synthesis phase). For this reason, at a certain dose, the effect plateaus and proportionally no more cell death occurs with increased doses. Subtypes of the anti-metabolites are the<space/><link><target>antifolate</target><part>anti-folates</part></link>, fluoropyrimidines, deoxynucleoside analogues and<space/><link><target>thiopurine</target><trail>s</trail></link>.<extension extension_name='ref' name="lind"></extension><extension extension_name='ref' name="pmid19476376"></extension></paragraph><paragraph>The anti-folates include<space/><link><target>methotrexate</target></link><space/>and<space/><link><target>pemetrexed</target></link>. Methotrexate inhibits<space/><link><target>dihydrofolate reductase</target></link><space/>(DHFR), an enzyme that regenerates<space/><link><target>tetrahydrofolate</target></link><space/>from<space/><link><target>dihydrofolate</target></link>. When the enzyme is inhibited by methotrexate, the cellular levels of folate coenzymes diminish. These are required for<space/><link><target>thymidylate</target></link><space/>and purine production, which are both essential for DNA synthesis and cell division.<extension extension_name='ref' name="isbn0-470-09254-8"></extension><extension extension_name='ref' name="isbn0-443-07101-2">Wood, p. 11</extension><space/>Pemetrexed is another anti-metabolite that affects purine and pyrimidine production, and therefore also inhibits DNA synthesis. It primarily inhibits the enzyme<space/><link><target>thymidylate synthase</target></link>, but also has effects on DHFR, aminoimidazole carboxamide ribonucleotide formyltransferase and<space/><link><target>glycinamide ribonucleotide formyltransferase</target></link>.<extension extension_name='ref' name="pmid15217974"><template><target>cite journal</target><arg name="author"><space/>Adjei AA<space/></arg><arg name="title"><space/>Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent<space/></arg><arg name="journal"><space/>Clinical Cancer Research<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>12 Pt 2<space/></arg><arg name="pages"><space/>4276s–4280s<space/></arg><arg name="date"><space/>Jun 2004<space/></arg><arg name="pmid"><space/>15217974<space/></arg><arg name="doi"><space/>10.1158/1078-0432.CCR-040010<space/></arg></template></extension><space/>The fluoropyrimidines include<space/><link><target>fluorouracil</target></link><space/>and<space/><link><target>capecitabine</target></link>. Fluorouracil is a nucleobase analogue that is metabolised in cells to form at least two active products; 5-fluourouridine monophosphate (FUMP) and 5-fluoro-2'-deoxyuridine 5'-phosphate (fdUMP). FUMP becomes incorporated into RNA and fdUMP inhibits the enzyme thymidylate synthase; both of which lead to cell death.<extension extension_name='ref' name="isbn0-443-07101-2"></extension><space/>Capecitabine is a<space/><link><target>prodrug</target></link><space/>of 5-fluorouracil that is broken down in cells to produce the active drug.<extension extension_name='ref' name="pmid12515569"><template><target>cite journal</target><arg name="author"><space/>Wagstaff AJ, Ibbotson T, Goa KL<space/></arg><arg name="title"><space/>Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>63<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>217–36<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12515569<space/></arg><arg name="doi"><space/>10.2165/00003495-200363020-00009<space/></arg></template></extension><space/>The deoxynucleoside analogues include<space/><link><target>cytarabine</target></link>,<space/><link><target>gemcitabine</target></link>,<space/><link><target>decitabine</target></link>,<space/><link><target>Vidaza</target></link>,<space/><link><target>fludarabine</target></link>,<space/><link><target>nelarabine</target></link>,<space/><link><target>cladribine</target></link>,<space/><link><target>clofarabine</target></link><space/>and<space/><link><target>pentostatin</target></link>. The thiopurines include<space/><link><target>thioguanine</target></link><space/>and<space/><link><target>mercaptopurine</target></link>.<extension extension_name='ref' name="lind"></extension><extension extension_name='ref' name="pmid19476376"></extension></paragraph><heading level='4'>Anti-microtubule agents</heading><paragraph><link><target>File:Microtubules and alkaloids.png</target><part>thumb</part><part>left</part><part>Vinca alkaloids prevent the assembly of microtubules, whereas taxanes prevent their disassembly. Both mechanisms cause defective mitosis.</part></link>Anti-microtubule agents are<space/><link><target>plant</target></link>-derived chemicals that block cell division by preventing<space/><link><target>microtubule</target></link><space/>function. Microtubules are an important cellular structure composed of two proteins;<space/><link><target>-tubulin</target></link><space/>and<space/><link><target>-tubulin</target></link>. They are hollow rod shaped structures that are required for cell division, among other cellular functions.<extension extension_name='ref' name="pmid1687171"><template><target>cite journal</target><arg name="author"><space/>Rowinsky EK, Donehower RC<space/></arg><arg name="title"><space/>The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics<space/></arg><arg name="journal"><space/>Pharmacology & Therapeutics<space/></arg><arg name="volume"><space/>52<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>35–84<space/></arg><arg name="date"><space/>Oct 1991<space/></arg><arg name="pmid"><space/>1687171<space/></arg><arg name="doi"><space/>10.1016/0163-7258(91)90086-2<space/></arg></template></extension><space/>Microtubules are dynamic structures, which means that they are permanently in a state of assembly and disassembly.<space/><link><target>Vinca alkaloid</target><trail>s</trail></link><space/>and<space/><link><target>taxane</target><trail>s</trail></link><space/>are the two main groups of anti-microtubule agents, and although both of these groups of drugs cause microtubule dysfunction, their mechanisms of action are completely opposite. The vinca alkaloids prevent the formation of the microtubules, whereas the taxanes prevent the microtubule disassembly. By doing so, they prevent the cancer cells from completing mitosis. Following this, cell cycle arrest occurs, which induces programmed cell death (<link><target>apoptosis</target></link>).<extension extension_name='ref' name="lind"></extension><extension extension_name='ref' name="pmid20577942"></extension><space/>Also, these drugs can affect blood vessel growth; an essential process that tumours utilise in order to grow and metastasise.<extension extension_name='ref' name="pmid20577942"><template><target>cite journal</target><arg name="author"><space/>Yue QX, Liu X, Guo DA<space/></arg><arg name="title"><space/>Microtubule-binding natural products for cancer therapy<space/></arg><arg name="journal"><space/>Planta Medica<space/></arg><arg name="volume"><space/>76<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1037–43<space/></arg><arg name="date"><space/>Aug 2010<space/></arg><arg name="pmid"><space/>20577942<space/></arg><arg name="doi"><space/>10.1055/s-0030-1250073<space/></arg></template></extension></paragraph><paragraph>Vinca alkaloids are derived from the<space/><link><target>Madagascar periwinkle</target></link>,<space/><italics>Catharanthus roseus</italics><space/>(formerly known as<space/><italics>Vinca rosea</italics>). They bind to specific sites on tubulin, inhibiting the assembly of tubulin into microtubules. The original vinca alkaloids are completely natural chemicals that include<space/><link><target>vincristine</target></link><space/>and<space/><link><target>vinblastine</target></link>. Following the success of these drugs, semi-synthetic vinca alkaloids were produced:<space/><link><target>vinorelbine</target></link>,<space/><link><target>vindesine</target></link>, and<space/><link><target>vinflunine</target></link>.<extension extension_name='ref' name="pmid20577942"></extension><space/>These drugs are<space/><link><target>cell cycle</target></link>-specific. They bind to the tubulin molecules in<space/><link><target>S-phase</target></link><space/>and prevent proper microtubule formation required for<space/><link><target>M-phase</target></link>.<extension extension_name='ref' name="pmid14508075"></extension></paragraph><paragraph>Taxanes are natural and semi-synthetic drugs. The first drug of their class,<space/><link><target>paclitaxel</target></link>, was originally extracted from the<space/><link><target>Pacific Yew</target></link><space/>tree,<space/><italics>Taxus brevifolia</italics>. Now this drug and another in this class,<space/><link><target>docetaxel</target></link>, are produced semi-synthetically from a chemical found in the bark of another Yew tree;<space/><italics><link><target>Taxus baccata</target></link></italics>. These drugs promote microtubule stability, preventing their disassembly. Paclitaxel prevents the cell cycle at the boundary of G2-M, whereas docetaxel exerts its effect during<space/><link><target>S-phase</target></link>. Taxanes present difficulties in formulation as medicines because they are poorly soluble in water.<extension extension_name='ref' name="pmid20577942"></extension></paragraph><paragraph><link><target>Podophyllotoxin</target></link><space/>is an antineoplastic<space/><link><target>lignan</target></link><space/>obtained primarily from the<space/><link><target>American Mayapple</target></link><space/>(<italics>Podophyllum peltatum</italics>) and<space/><link><target>Himalayan Mayapple</target></link><space/>(<italics>Podophyllum hexandrum</italics><space/>or<space/><italics>Podophyllum emodi</italics>). It has anti-microtubule activity, and its mechanism is similar to that of vinca alkaloids in that they bind to tubulin, inhibiting microtubule formation. Podophyllotoxin is used to produce two other drugs with different mechanisms of action:<space/><link><target>etoposide</target></link><space/>and<space/><link><target>teniposide</target></link>.<extension extension_name='ref' name="pmid9562603"><template><target>cite journal</target><arg name="author"><space/>Damayanthi Y, Lown JW<space/></arg><arg name="title"><space/>Podophyllotoxins: current status and recent developments<space/></arg><arg name="journal"><space/>Current Medicinal Chemistry<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>205–52<space/></arg><arg name="date"><space/>Jun 1998<space/></arg><arg name="pmid"><space/>9562603<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Liu YQ, Yang L, Tian X</arg><arg name="title">Podophyllotoxin: current perspectives</arg><arg name="journal">Curr Bioactive Compounds</arg><arg name="year">2007</arg><arg name="volume">3</arg><arg name="issue">1</arg><arg name="pages">37–66</arg><arg name="doi">10.1016/j.jallcom.2006.06.070</arg><arg name="first1">Cong</arg><arg name="last2">Zhang</arg><arg name="first2">Wei</arg><arg name="last3">Qian</arg><arg name="first3">Zhengnan</arg><arg name="last4">Hua</arg><arg name="first4">Zhong</arg><arg name="last5">Zhao</arg><arg name="first5">Qibo</arg><arg name="last6">Sui</arg><arg name="first6">Yu</arg><arg name="last7">Su</arg><arg name="first7">Wenhui</arg><arg name="last8">Zhang</arg><arg name="first8">Ming</arg><arg name="last9">Liu</arg><arg name="first9">Zhuhong</arg><arg name="last10">Liu</arg><arg name="first10">Guodong</arg><arg name="last11">Wu</arg><arg name="first11">Guangheng</arg></template></extension></paragraph><heading level='4'>Topoisomerase inhibitors</heading><paragraph><link><target>File:Topoisomerase Inhibitor.JPG</target><part>thumb</part><part>Topoisomerase I and II Inhibitors</part></link><link><target>Topoisomerase inhibitor</target><trail>s</trail></link><space/>are drugs that affect the activity of two enzymes:<space/><link><target>topoisomerase I</target></link><space/>and<space/><link><target>topoisomerase II</target></link>. When the DNA double-strand helix is unwound, during DNA replication or<space/><link><target>transcription (biology)</target><part>transcription</part></link>, for example, the adjacent unopened DNA winds tighter (supercoils), like opening the middle of a twisted rope. The stress caused by this effect is in part aided by the topoisomerase enzymes. They produce single- or double-strand breaks into DNA, reducing the tension in the DNA strand. This allows the normal unwinding of DNA to occur during<space/><link><target>DNA replication</target><part>replication</part></link><space/>or<space/><link><target>transcription (biology)</target><part>transcription</part></link>. Inhibition of topoisomerase I or II interferes with both of these processes.<extension extension_name='ref'><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last">Lodish H, Berk A, Zipursky SL</arg><arg name="title">Molecular Cell Biology. 4th edition. The Role of Topoisomerases in DNA Replication</arg><arg name="year">2000</arg><arg name="publisher">New York: W. H. Freeman</arg><arg name="url">http://www.ncbi.nlm.nih.gov/books/NBK21703/</arg><arg name="author2">and others</arg><arg name="displayauthors">1</arg></template></extension><extension extension_name='ref' name="pmid12351817"><template><target>cite journal</target><arg name="author"><space/>Goodsell DS<space/></arg><arg name="title"><space/>The molecular perspective: DNA topoisomerases<space/></arg><arg name="journal"><space/>Stem Cells<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>470–1<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12351817<space/></arg><arg name="doi"><space/>10.1634/stemcells.20-5-470<space/></arg></template></extension></paragraph><paragraph>Two topoisomerase I inhibitors,<space/><link><target>irinotecan</target></link><space/>and<space/><link><target>topotecan</target></link>, are semi-synthetically derived from<space/><link><target>camptothecin</target></link>, which is obtained from the Chinese ornamental tree<space/><italics><link><target>Camptotheca acuminata</target></link></italics>.<extension extension_name='ref' name="pmid14508075"></extension><space/>Drugs that target topoisomerase II can be divided into two groups. The topoisomerase II poisons cause increased levels enzymes bound to DNA. This prevents DNA replication and<space/><link><target>transcription (biology)</target><part>transcription</part></link>, causes DNA strand breaks, and leads to programmed cell death (<link><target>apoptosis</target></link>). These agents include<space/><link><target>etoposide</target></link>,<space/><link><target>doxorubicin</target></link>,<space/><link><target>mitoxantrone</target></link><space/>and<space/><link><target>teniposide</target></link>. The second group, catalytic inhibitors, are drugs that block the activity of topoisomerase II, and therefore prevent DNA synthesis and translation because the DNA cannot unwind properly. This group includes<space/><link><target>novobiocin</target></link>, merbarone, and<space/><link><target>aclarubicin</target></link>, which also have other significant mechanisms of action.<extension extension_name='ref' name="pmid19377506"><template><target>cite journal</target><arg name="author"><space/>Nitiss JL<space/></arg><arg name="title"><space/>Targeting DNA topoisomerase II in cancer chemotherapy<space/></arg><arg name="journal"><space/>Nature Reviews. Cancer<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>338–50<space/></arg><arg name="date"><space/>May 2009<space/></arg><arg name="pmid"><space/>19377506<space/></arg><arg name="pmc"><space/>2748742<space/></arg><arg name="doi"><space/>10.1038/nrc2607<space/></arg></template></extension></paragraph><heading level='4'>Cytotoxic antibiotics</heading><paragraph>The cytotoxic antibiotics are a varied group of drugs that have various mechanisms of action. The group includes the<space/><link><target>anthracycline</target><trail>s</trail></link><space/>and other drugs including<space/><link><target>actinomycin</target></link>,<space/><link><target>bleomycin</target></link>,<space/><link><target>plicamycin</target></link>, and<space/><link><target>mitomycin</target></link>.<space/><link><target>Doxorubicin</target></link><space/>and<space/><link><target>daunorubicin</target></link><space/>were the first two anthracyclines, and were obtained from the<space/><link><target>bacterium</target></link><space/><italics><link><target>Streptomyces peucetius</target></link></italics>. Derivatives of these compounds include<space/><link><target>epirubicin</target></link><space/>and<space/><link><target>idarubicin</target></link>. Other clinically used drugs in the anthracyline group are<space/><link><target>pirarubicin</target></link>,<space/><link><target>aclarubicin</target></link>, and<space/><link><target>mitoxantrone</target></link>. The mechanisms of anthracyclines include<space/><link><target>DNA intercalation</target></link><space/>(molecules insert between the two strands of DNA), generation of highly reactive<space/><link><target>free radicals</target></link><space/>that damage intercellular molecules and topoisomerase inhibition.<extension extension_name='ref' name="pmid15169927"><template><target>cite journal</target><arg name="author"><space/>Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L<space/></arg><arg name="title"><space/>Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity<space/></arg><arg name="journal"><space/>Pharmacological Reviews<space/></arg><arg name="volume"><space/>56<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>185–229<space/></arg><arg name="date"><space/>Jun 2004<space/></arg><arg name="pmid"><space/>15169927<space/></arg><arg name="doi"><space/>10.1124/pr.56.2.6<space/></arg></template></extension><space/>Actinomycin is a complex molecule that intercalates DNA and prevents<space/><link><target>RNA synthesis</target></link>.<extension extension_name='ref' name="pmid2410919"><template><target>cite journal</target><arg name="author"><space/>Sobell HM<space/></arg><arg name="title"><space/>Actinomycin and DNA transcription<space/></arg><arg name="journal"><space/>Proceedings of the National Academy of Sciences of the United States of America<space/></arg><arg name="volume"><space/>82<space/></arg><arg name="issue"><space/>16<space/></arg><arg name="pages"><space/>5328–31<space/></arg><arg name="date"><space/>Aug 1985<space/></arg><arg name="pmid"><space/>2410919<space/></arg><arg name="pmc"><space/>390561<space/></arg><arg name="doi"><space/>10.1073/pnas.82.16.5328<space/></arg><arg name="bibcode"><space/>1985PNAS...82.5328S<space/></arg></template></extension><space/>Bleomycin, a<space/><link><target>glycopeptide</target></link><space/>isolated from<space/><italics>Streptomyces verticillus</italics>, also intercalates DNA, but produces<space/><link><target>free radical</target><trail>s</trail></link><space/>that damage DNA. This occurs when bleomycin binds to a<space/><link><target>metal ion</target></link>, becomes<space/><link><target>reduction (chemistry)</target><part>chemically reduced</part></link><space/>and reacts with<space/><link><target>oxygen</target></link>.<extension extension_name='ref' name="pmid1384141"><template><target>cite journal</target><arg name="author"><space/>Dorr RT<space/></arg><arg name="title"><space/>Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics<space/></arg><arg name="journal"><space/>Seminars in Oncology<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>2 Suppl 5<space/></arg><arg name="pages"><space/>3–8<space/></arg><arg name="date"><space/>Apr 1992<space/></arg><arg name="pmid"><space/>1384141<space/></arg><arg name="doi"><space/></arg></template></extension><extension extension_name='ref' name="isbn0-470-09254-8 3">Airley, p. 87</extension><space/>Mitomycin is a cytotoxic antibiotic with the ability to alkylate DNA.<extension extension_name='ref' name="pmid2131038"><template><target>cite journal</target><arg name="author"><space/>Verweij J, Pinedo HM<space/></arg><arg name="title"><space/>Mitomycin C: mechanism of action, usefulness and limitations<space/></arg><arg name="journal"><space/>Anti-Cancer Drugs<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>5–13<space/></arg><arg name="date"><space/>Oct 1990<space/></arg><arg name="pmid"><space/>2131038<space/></arg><arg name="doi"><space/>10.1097/00001813-199010000-00002<space/></arg></template></extension></paragraph><heading level='3'>Delivery</heading><paragraph><link><target>File:Cyclophosphamide iv.jpg</target><part>thumb</part><part>140px</part><part><link><target>Cyclophosphamide</target></link><space/>IV drip</part></link>Most chemotherapy is<space/><link><target>Route of administration</target><part>delivered</part></link><space/><link><target>intravenous therapy</target><part>intravenously</part></link>, although a number of agents can be administered orally (e.g.,<space/><link><target>melphalan</target></link>,<space/><link><target>busulfan</target></link>,<space/><link><target>capecitabine</target></link>).</paragraph><paragraph>There are many intravenous methods of drug delivery, known as vascular access devices. These include the<space/><link><target>Winged infusion set</target><part>winged infusion device</part></link>,<space/><link><target>Intravenous therapy#Peripheral cannula</target><part>peripheral cannula</part></link>, midline catheter,<space/><link><target>peripherally inserted central catheter</target></link><space/>(PICC),<space/><link><target>central venous catheter</target></link><space/>and<space/><link><target>implantable port</target></link>. The devices have different applications regarding duration of chemotherapy treatment, method of delivery and types of chemotherapeutic agent.<extension extension_name='ref' name="isbn0-443-07101-2 3"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="author">Wood, Miriam; David Brighton</arg><arg name="title">The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team<space/></arg><arg name="publisher">Elsevier Churchill Livingstone<space/></arg><arg name="location">St. Louis, Mo<space/></arg><arg name="year">2005</arg><arg name="pages">93–94<space/></arg><arg name="isbn">0-443-07101-2<space/></arg><arg name="oclc"><space/></arg><arg name="doi"><space/></arg><arg name="accessdate"></arg></template></extension></paragraph><paragraph>Depending on the patient, the cancer, the stage of cancer, the type of chemotherapy, and the dosage, intravenous chemotherapy may be given on either an<space/><link><target>inpatient</target></link><space/>or an<space/><link><target>outpatient</target></link><space/>basis. For continuous, frequent or prolonged intravenous chemotherapy administration, various systems may be surgically inserted into the vasculature to maintain access.<extension extension_name='ref' name="isbn0-443-07101-2 5">Wood, pp. 113-118</extension><space/>Commonly used systems are the<space/><link><target>Hickman line</target></link>, the<space/><link><target>Port-a-Cath</target></link>, and the<space/><link><target>PICC line</target></link>. These have a lower infection risk, are much less prone to<space/><link><target>phlebitis</target></link><space/>or<space/><link><target>extravasation</target></link>, and eliminate the need for repeated insertion of peripheral cannulae.<template><target>citation needed</target><arg name="date">August 2013</arg></template></paragraph><paragraph><link><target>Isolated limb perfusion</target></link><space/>(often used in<space/><link><target>melanoma</target></link>),<extension extension_name='ref' name="pmid20348274"><template><target>cite journal</target><arg name="author"><space/>Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, Villegas-Portero R, Nieto-Garcia A<space/></arg><arg name="title"><space/>Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety<space/></arg><arg name="journal"><space/>The Oncologist<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>416–27<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20348274<space/></arg><arg name="pmc"><space/>3227960<space/></arg><arg name="doi"><space/>10.1634/theoncologist.2009-0325<space/></arg></template></extension><space/>or isolated infusion of chemotherapy into the liver<extension extension_name='ref' name="pmid18722924"><template><target>cite journal</target><arg name="author"><space/>Verhoef C, de Wilt JH, ten Hagen TL, Eggermont AM<space/></arg><arg name="title"><space/>Isolated hepatic perfusion for the treatment of liver tumors: sunset or sunrise?<space/></arg><arg name="journal"><space/>Surgical Oncology Clinics of North America<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>877–94, xi<space/></arg><arg name="date"><space/>Oct 2008<space/></arg><arg name="pmid"><space/>18722924<space/></arg><arg name="doi"><space/>10.1016/j.soc.2008.04.007<space/></arg></template></extension><space/>or the lung have been used to treat some tumors. The main purpose of these approaches is to deliver a very high dose of chemotherapy to tumor sites without causing overwhelming systemic damage.<extension extension_name='ref' name="pmid10421507"><template><target>cite journal</target><arg name="author"><space/>Hendriks JM, Van Schil PE<space/></arg><arg name="title"><space/>Isolated lung perfusion for the treatment of pulmonary metastases<space/></arg><arg name="journal"><space/>Surgical Oncology<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>1-2<space/></arg><arg name="pages"><space/>59–63<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="pmid"><space/>10421507<space/></arg><arg name="doi"><space/>10.1016/S0960-7404(98)00028-0<space/></arg></template></extension><space/>These approaches can help control solitary or limited metastases, but they are by definition not systemic, and, therefore, do not treat distributed metastases or<space/><link><target>micrometastasis</target><part>micrometastases</part></link>.</paragraph><paragraph>Topical chemotherapies, such as<space/><link><target>5-fluorouracil</target></link>, are used to treat some cases of<space/><link><target>non-melanoma skin cancer</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Chitwood K, Etzkorn J, Cohen G<space/></arg><arg name="title"><space/>Topical and intralesional treatment of nonmelanoma skin cancer: efficacy and cost comparisons<space/></arg><arg name="journal"><space/>Dermatologic Surgery<space/></arg><arg name="volume"><space/>39<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1306–16<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>23915332<space/></arg><arg name="doi"><space/>10.1111/dsu.12300<space/></arg></template></extension></paragraph><paragraph>If the cancer has<space/><link><target>central nervous system</target></link><space/>involvement, or with meningeal disease,<space/><link><target>intrathecal</target></link><space/>chemotherapy may be administered.<extension extension_name='ref' name="Corrie"></extension></paragraph><heading level='2'>Adverse effects</heading><paragraph><link><target>Chemotherapeutic</target></link><space/>techniques have a range of side-effects that depend on the type of medications used. The most common medications affect mainly the<space/><link><target>fast-dividing cells</target></link><space/>of the body, such as blood cells and the cells lining the mouth, stomach, and intestines. Chemotherapy-related toxicities can occur acutely after administration, within hours or days, or chronically, from weeks to years.<extension extension_name='ref' name="isbn0-470-09254-8 2">Airley, p. 265</extension></paragraph><heading level='3'>Immunosuppression and myelosuppression</heading><paragraph>Virtually all chemotherapeutic regimens can cause depression of the<space/><link><target>immune system</target></link>, often by paralysing the<space/><link><target>bone marrow</target></link><space/>and leading to a decrease of<space/><link><target>white blood cell</target><trail>s</trail></link>,<space/><link><target>red blood cell</target><trail>s</trail></link>, and<space/><link><target>platelet</target><trail>s</trail></link>.<link><target>Anemia</target></link><space/>and<space/><link><target>thrombocytopenia</target></link>, when they occur, are improved with<space/><link><target>blood transfusion</target></link>.<space/><link><target>Neutropenia</target></link><space/>(a decrease of the<space/><link><target>neutrophil granulocyte</target></link><space/>count below 0.5 x 10<xhtml:sup>9</xhtml:sup>/<link><target>litre</target></link>) can be improved with synthetic<space/><link><target>G-CSF</target></link><space/>(<link><target>granulocyte</target></link>-colony-stimulating factor, e.g.,<space/><link><target>filgrastim</target></link>,<space/><link><target>lenograstim</target></link>).</paragraph><paragraph>In very severe<space/><link><target>myelosuppression</target></link>, which occurs in some regimens, almost all the bone marrow<space/><link><target>stem cell</target><trail>s</trail></link><space/>(cells that produce<space/><link><target>white blood cells</target><part>white</part></link><space/>and<space/><link><target>red blood cell</target><trail>s</trail></link>) are destroyed, meaning<space/><italics>allogenic</italics><space/>or<space/><italics><link><target>autologous</target></link></italics><space/><link><target>bone marrow transplant</target><part>bone marrow cell transplants</part></link><space/>are necessary. (In autologous BMTs, cells are removed from the patient before the treatment, multiplied and then re-injected afterward; in<space/><italics>allogenic</italics><space/>BMTs, the source is a donor.) However, some patients still develop diseases because of this interference with bone marrow.</paragraph><paragraph>Although patients are encouraged to wash their hands, avoid sick people, and take other infection-reducing steps, about 85% of infections are due to naturally occurring microorganisms in the patient's own<space/><link><target>gastrointestinal tract</target></link><space/>(including<space/><link><target>oral cavity</target></link>) and skin.<extension extension_name='ref' name="internal_medicine_a05">Huang, p. 130</extension><space/>This may manifest as systemic infections, such as<space/><link><target>sepsis</target></link>, or as localized outbreaks, such as<space/><link><target>Herpes simplex</target></link>,<space/><link><target>shingles</target></link>, or other members of the<space/><link><target>human herpes virus</target><part>Herpesviridea</part></link>.<extension extension_name='ref' name="HSV"><template><target>cite journal</target><arg name="author"><space/>Elad S, Zadik Y, Hewson I, Hovan A, Correa ME, Logan R, Elting LS, Spijkervet FK, Brennan MT<space/></arg><arg name="title"><space/>A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea<space/></arg><arg name="journal"><space/>Supportive Care in Cancer<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>993–1006<space/></arg><arg name="date"><space/>Aug 2010<space/></arg><arg name="pmid"><space/>20544224<space/></arg><arg name="doi"><space/>10.1007/s00520-010-0900-3<space/></arg><arg name="url"><space/>http://www.springerlink.com/content/g476114717852h80/<space/></arg></template></extension><space/>Sometimes, chemotherapy treatments are postponed because the immune system is suppressed to a critically low level.</paragraph><paragraph>In<space/><link><target>Japan</target></link>, the government has approved the use of some<space/><link><target>medicinal mushrooms</target></link><space/>like<space/><italics><link><target>Trametes versicolor</target></link></italics>, to counteract depression of the immune system in patients undergoing chemotherapy.<extension extension_name='ref' name="psk"><template><target>cite web</target><arg name="url">http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Coriolous_Versicolor.asp<space/></arg><arg name="title">Coriolus Versicolor<space/></arg><arg name="publisher">Cancer.org</arg><arg name="date">2008-06-10<space/></arg><arg name="accessdate">7 August 2012</arg></template></extension></paragraph><heading level='3'>Typhlitis</heading><paragraph>Due to immune system suppression,<space/><link><target>typhlitis</target></link><space/>is a &quot;life-threatening gastrointestinal complication of chemotherapy.&quot;<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Davila ML<space/></arg><arg name="title"><space/>Neutropenic enterocolitis<space/></arg><arg name="journal"><space/>Current Opinion in Gastroenterology<space/></arg><arg name="volume"><space/>22<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>44–7<space/></arg><arg name="date"><space/>Jan 2006<space/></arg><arg name="pmid"><space/>16319675<space/></arg></template></extension><space/><link><target>Typhlitis</target></link><space/>is an intestinal infection which may manifest itself through symptoms including<space/><link><target>nausea</target></link>,<space/><link><target>vomiting</target></link>,<space/><link><target>diarrhea</target></link>, a<space/><link><target>distended abdomen</target></link>,<space/><link><target>fever</target></link>,<space/><link><target>chills</target></link>, or<space/><link><target>abdominal pain</target></link><space/>and tenderness.</paragraph><paragraph><link><target>Typhlitis</target></link><space/>is a<space/><link><target>medical emergency</target></link>. It has a very poor<space/><link><target>prognosis</target></link><space/>and is often fatal unless promptly recognized and aggressively treated.<extension extension_name='ref' name="Keidan 1989 2069"><template><target>cite journal</target><arg name="author"><space/>Keidan RD, Fanning J, Gatenby RA, Weese JL<space/></arg><arg name="title"><space/>Recurrent typhlitis. A disease resulting from aggressive chemotherapy<space/></arg><arg name="journal"><space/>Diseases of the Colon and Rectum<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>206–9<space/></arg><arg name="date"><space/>Mar 1989<space/></arg><arg name="pmid"><space/>2920627<space/></arg><arg name="doi"><space/>10.1007/BF02554529<space/></arg></template></extension><space/>Successful treatment hinges on early diagnosis provided by a high index of suspicion and the use of CT scanning, nonoperative treatment for uncomplicated cases, and sometimes elective right<space/><link><target>hemicolectomy</target></link><space/>to prevent recurrence.<extension extension_name='ref' name="Keidan 1989 2069"></extension></paragraph><heading level='3'>Gastrointestinal distress</heading><paragraph><link><target>Nausea</target></link>,<space/><link><target>vomiting</target></link>,<space/><link><target>Anorexia (symptom)</target><part>anorexia</part></link>,<space/><link><target>diarrhoea</target></link>, abdominal cramps, and<space/><link><target>constipation</target></link><space/>are common side-effects of chemotherapeutic medications that kill fast-dividing cells.<extension extension_name='ref' name="pmid"><template><target>cite journal</target><arg name="author"><space/>Gibson RJ, Keefe DM<space/></arg><arg name="title"><space/>Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies<space/></arg><arg name="journal"><space/>Supportive Care in Cancer<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>890–900<space/></arg><arg name="date"><space/>Sep 2006<space/></arg><arg name="pmid"><space/>16604351<space/></arg><arg name="doi"><space/>10.1007/s00520-006-0040-y<space/></arg></template></extension><space/><link><target>Malnutrition</target></link><space/>and<space/><link><target>dehydration</target></link><space/>can result when the patient does not eat or drink enough, or when the patient vomits frequently, because of gastrointestinal damage. This can result in rapid weight loss, or occasionally in weight gain, if the patient eats too much in an effort to allay nausea or heartburn. Weight gain can also be caused by some steroid medications. These side-effects can frequently be reduced or eliminated with<space/><link><target>antiemetic</target></link><space/>drugs. Self-care measures, such as eating frequent small meals and drinking clear liquids or<space/><link><target>Ginger#Medicinal use</target><part>ginger</part></link><space/>tea, are often recommended. In general, this is a temporary effect, and frequently resolves within a week of finishing treatment. However, a high<space/><link><target>index of suspicion</target></link><space/>is appropriate, since<space/><link><target>diarrhea</target></link><space/>and bloating are also symptoms of<space/><link><target>typhlitis</target></link>, a very serious and potentially life-threatening<space/><link><target>medical emergency</target></link><space/>that requires immediate treatment.</paragraph><heading level='3'>Anemia</heading><paragraph><link><target>Anemia</target></link><space/>in cancer patients can be a combined outcome caused by myelosuppressive chemotherapy, and possible cancer-related causes such as<space/><link><target>bleeding</target></link>,<space/><link><target>blood cell</target></link><space/>destruction (<link><target>hemolysis</target></link>), hereditary disease, kidney dysfunction, nutritionaldeficiencies and/or<space/><link><target>anemia of chronic disease</target></link>. Treatments to mitigate anemia include hormones to boost blood production (<link><target>erythropoietin</target></link>),<space/><link><target>iron supplement</target><trail>s</trail></link>, and<space/><link><target>blood transfusion</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid10511589"><template><target>cite journal</target><arg name="author"><space/>Groopman JE, Itri LM<space/></arg><arg name="title"><space/>Chemotherapy-induced anemia in adults: incidence and treatment<space/></arg><arg name="journal"><space/>Journal of the National Cancer Institute<space/></arg><arg name="volume"><space/>91<space/></arg><arg name="issue"><space/>19<space/></arg><arg name="pages"><space/>1616–34<space/></arg><arg name="date"><space/>Oct 1999<space/></arg><arg name="pmid"><space/>10511589<space/></arg><arg name="doi"><space/>10.1093/jnci/91.19.1616<space/></arg></template></extension><extension extension_name='ref' name="pmid16925107"><template><target>cite journal</target><arg name="author"><space/>Henry DH<space/></arg><arg name="title"><space/>The role of intravenous iron in cancer-related anemia<space/></arg><arg name="journal"><space/>Oncology<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>8 Suppl 6<space/></arg><arg name="pages"><space/>21–4<space/></arg><arg name="date"><space/>Jul 2006<space/></arg><arg name="pmid"><space/>16925107<space/></arg><arg name="doi"><space/></arg></template></extension><extension extension_name='ref' name="pmid18597709"><template><target>cite journal</target><arg name="author"><space/>Rodgers GM, Becker PS, Bennett CL, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Djulbegovic B, Garst JL, Gilreath JA, Kraut EH, Lin WC, Matulonis U, Millenson M, Reinke D, Rosenthal J, Sabbatini P, Schwartz RN, Stein RS, Vij R<space/></arg><arg name="title"><space/>Cancer- and chemotherapy-induced anemia<space/></arg><arg name="journal"><space/>Journal of the National Comprehensive Cancer Network<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>536–64<space/></arg><arg name="date"><space/>Jul 2008<space/></arg><arg name="pmid"><space/>18597709<space/></arg><arg name="doi"><space/></arg></template></extension><space/>Myelosuppressive therapy can cause a tendency to bleed easily, leading to anemia. Medications that kill rapidly dividing cells or blood cells can reduce the number of<space/><link><target>platelet</target><trail>s</trail></link><space/>in the blood, which can result in<space/><link><target>Hematoma</target><part>bruises</part></link><space/>and<space/><link><target>Hemorrhage</target><part>bleeding</part></link>. Extremely low platelet counts may be temporarily boosted through<space/><link><target>platelet transfusion</target><trail>s</trail></link><space/>and new drugs to increase platelet counts during chemotherapy are being developed.<extension extension_name='ref' name="pmid19245931"><template><target>cite journal</target><arg name="author"><space/>Vadhan-Raj S<space/></arg><arg name="title"><space/>Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents<space/></arg><arg name="journal"><space/>Seminars in Hematology<space/></arg><arg name="volume"><space/>46<space/></arg><arg name="issue"><space/>1 Suppl 2<space/></arg><arg name="pages"><space/>S26–32<space/></arg><arg name="date"><space/>Jan 2009<space/></arg><arg name="pmid"><space/>19245931<space/></arg><arg name="doi"><space/>10.1053/j.seminhematol.2008.12.007<space/></arg></template></extension><extension extension_name='ref' name="pmid16711312"><template><target>cite journal</target><arg name="author"><space/>Sekhon SS, Roy V<space/></arg><arg name="title"><space/>Thrombocytopenia in adults: A practical approach to evaluation and management<space/></arg><arg name="journal"><space/>Southern Medical Journal<space/></arg><arg name="volume"><space/>99<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>491–8; quiz 499–500, 533<space/></arg><arg name="date"><space/>May 2006<space/></arg><arg name="pmid"><space/>16711312<space/></arg><arg name="doi"><space/>10.1097/01.smj.0000209275.75045.d4<space/></arg></template></extension><space/>Sometimes, chemotherapy treatments are postponed to allow platelet counts to recover.</paragraph><heading level='3'>Fatigue</heading><paragraph><link><target>Cancer-related fatigue</target><part>Fatigue</part></link><space/>may be a consequence of the cancer or its treatment, and can last for months to years after treatment. One physiological cause of fatigue is<space/><link><target>anemia</target></link>, which can be caused by chemotherapy,<space/><link><target>surgery</target></link>,<space/><link><target>radiotherapy</target></link>, primary and metastatic disease and/or nutritional depletion.<extension extension_name='ref' name="pmid20870636"><template><target>cite journal</target><arg name="author"><space/>Berger AM, Abernethy AP, Atkinson A, Barsevick AM, Breitbart WS, Cella D, Cimprich B, Cleeland C, Eisenberger MA, Escalante CP, Jacobsen PB, Kaldor P, Ligibel JA, Murphy BA, O'Connor T, Pirl WF, Rodler E, Rugo HS, Thomas J, Wagner LI<space/></arg><arg name="title"><space/>Cancer-related fatigue<space/></arg><arg name="journal"><space/>Journal of the National Comprehensive Cancer Network<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>904–31<space/></arg><arg name="date"><space/>Aug 2010<space/></arg><arg name="pmid"><space/>20870636<space/></arg><arg name="doi"><space/></arg></template></extension><extension extension_name='ref' name="pmid16500197"><template><target>cite journal</target><arg name="author"><space/>Franklin DJ, Packel L<space/></arg><arg name="title"><space/>Cancer-related fatigue<space/></arg><arg name="journal"><space/>Archives of Physical Medicine and Rehabilitation<space/></arg><arg name="volume"><space/>87<space/></arg><arg name="issue"><space/>3 Suppl 1<space/></arg><arg name="pages"><space/>S91–3; quiz S94–5<space/></arg><arg name="date"><space/>Mar 2006<space/></arg><arg name="pmid"><space/>16500197<space/></arg><arg name="doi"><space/>10.1016/j.apmr.2005.12.015<space/></arg></template></extension><space/><link><target>Anaerobic exercise</target></link><space/>has been found to be beneficial in reducing fatigue in people with<space/><link><target>solid tumour</target><trail>s</trail></link>.<extension extension_name='ref' name="pmid23152233"><template><target>cite journal</target><arg name="author"><space/>Cramp F, Byron-Daniel J<space/></arg><arg name="title"><space/>Exercise for the management of cancer-related fatigue in adults<space/></arg><arg name="journal"><space/>The Cochrane Database of Systematic Reviews<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>CD006145<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>23152233<space/></arg><arg name="doi"><space/>10.1002/14651858.CD006145.pub3<space/></arg><arg name="editor1-last"><space/>Cramp<space/></arg><arg name="editor1-first"><space/>Fiona<space/></arg></template></extension></paragraph><heading level='3'>Nausea and vomiting</heading><paragraph><template><target>Further</target><arg>Chemotherapy-induced nausea and vomiting</arg></template><link><target>Nausea</target></link><space/>and<space/><link><target>vomiting</target></link><space/>are two of the most feared cancer treatment-related side-effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments.<extension extension_name='ref'><template><target>cite journal</target><arg name="url"><space/>http://www.springerlink.com/content/g152223567614560/<space/></arg><arg name="title"><space/>Nausea and Vomiting in the Cancer Patient<space/></arg><arg name="accessdate"><space/>2 September 2011<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="journal"><space/>Oncology<space/></arg><arg name="pages"><space/>1482–1496<space/></arg><arg name="doi"><space/>10.1007/0-387-31056-8_83<space/></arg><arg name="quote"><space/>Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families.<space/></arg><arg name="archiveurl"><space/></arg><arg name="archivedate"><space/></arg><arg name="last1"><space/>Gill<space/></arg><arg name="first1"><space/>Paula<space/></arg><arg name="last2"><space/>Grothey<space/></arg><arg name="first2"><space/>Axel<space/></arg><arg name="last3"><space/>Loprinzi<space/></arg><arg name="first3"><space/>Charles<space/></arg><arg name="isbn"><space/>978-0-387-24291-0<space/></arg></template></extension><space/>Chemotherapy-induced nausea and vomiting (CINV) are common with many treatments and some forms of cancer. Since the 1990s, several novel classes of<space/><link><target>antiemetics</target></link><space/>have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to successfully manage these symptoms in a large portion of patients. Effective mediation of these unpleasant and sometimes-crippling symptoms results in increased quality of life for the patient and more efficient treatment cycles, due to less stoppage of treatment due to better tolerance by the patient, and due to better overall health of the patient.</paragraph><heading level='3'>Hair loss</heading><paragraph><link><target>Alopecia</target><part>Hair loss</part></link><space/>(Alopecia) can be caused by chemotherapy that kills rapidly dividing cells; other medications may cause hair to thin. These are most often temporary effects: hair usually starts to regrow a few weeks after the last treatment, and can sometimes change colour, texture, thickness and style. Sometimes hair has a tendency to curl after regrowth, resulting in &quot;chemo curls.&quot; Severe hair loss occurs most often with drugs such as<space/><link><target>doxorubicin</target></link>,<space/><link><target>daunorubicin</target></link>,<space/><link><target>paclitaxel</target></link>,<space/><link><target>docetaxel</target></link>,<space/><link><target>cyclophosphamide</target></link>,<space/><link><target>ifosfamide</target></link><space/>and<space/><link><target>etoposide</target></link>. Permanent thinning or hair loss can result from some standard chemotherapy regimens.</paragraph><paragraph>Chemotherapy induced hair loss occurs by a non-androgenic mechanism, and can manifests as<space/><link><target>alopecia totalis</target></link>, telogen effluvium, or less often<space/><link><target>alopecia areata</target></link>.<extension extension_name='ref' name="pmid17642856"><template><target>cite journal</target><arg name="author"><space/>Chadha V, Shenoi SD<space/></arg><arg name="title"><space/>Hair loss in cancer chemotherapeutic patients<space/></arg><arg name="journal"><space/>Indian Journal of Dermatology, Venereology and Leprology<space/></arg><arg name="volume"><space/>69<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>131–132<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>17642856<space/></arg></template></extension><space/>It is usually associated with systemic treatment due to the high mitotic rate of hair follicles, and more reversible than androgenic hair loss,<extension extension_name='ref' name="pmid23187775"><template><target>cite journal</target><arg name="author"><space/>Lemieux J<space/></arg><arg name="title"><space/>Reducing chemotherapy-induced alopecia with scalp cooling<space/></arg><arg name="journal"><space/>Clinical Advances in Hematology & Oncology<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>681–682<space/></arg><arg name="date"><space/>Oct 2012<space/></arg><arg name="pmid"><space/>23187775<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Shapiro J, Price VH<space/></arg><arg name="title"><space/>Hair regrowth. Therapeutic agents<space/></arg><arg name="journal"><space/>Dermatologic Clinics<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>341–356<space/></arg><arg name="date"><space/>Apr 1998<space/></arg><arg name="pmid"><space/>9589208<space/></arg><arg name="doi"><space/>10.1016/S0733-8635(05)70017-6<space/></arg></template></extension><space/>although permanent cases can occur.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Al-Mohanna H, Al-Khenaizan S<space/></arg><arg name="title"><space/>Permanent alopecia following cranial irradiation in a child<space/></arg><arg name="journal"><space/>Journal of Cutaneous Medicine and Surgery<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>141–143<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20487675<space/></arg><arg name="doi">10.2310/7750.2010.09014</arg></template></extension><space/>Chemotherapy induces hair loss in women more often than men.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Can G, Demir M, Erol O, Aydiner A<space/></arg><arg name="title"><space/>A comparison of men and women's experiences of chemotherapy-induced alopecia<space/></arg><arg name="journal"><space/>European Journal of Oncology Nursing<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>255–60<space/></arg><arg name="date"><space/>Jun 2013<space/></arg><arg name="pmid"><space/>22901547<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1016/j.ejon.2012.06.003<space/></arg></template></extension></paragraph><paragraph><link><target>Hypothermia cap</target><part>Scalp cooling</part></link><space/>offers a means of preventing both permanent and temporary hair loss; however, concerns about this method have been raised.<extension extension_name='ref' name="pmid19341937"><template><target>cite journal</target><arg name="author"><space/>Trüeb RM<space/></arg><arg name="title"><space/>Chemotherapy-induced alopecia<space/></arg><arg name="journal"><space/>Seminars in Cutaneous Medicine and Surgery<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>11–4<space/></arg><arg name="date"><space/>Mar 2009<space/></arg><arg name="pmid"><space/>19341937<space/></arg><arg name="doi"><space/>10.1016/j.sder.2008.12.001<space/></arg></template></extension><extension extension_name='ref' name="pmid22178150"><template><target>cite journal</target><arg name="author"><space/>Chon SY, Champion RW, Geddes ER, Rashid RM<space/></arg><arg name="title"><space/>Chemotherapy-induced alopecia<space/></arg><arg name="journal"><space/>Journal of the American Academy of Dermatology<space/></arg><arg name="volume"><space/>67<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>e37–47<space/></arg><arg name="date"><space/>Jul 2012<space/></arg><arg name="pmid"><space/>22178150<space/></arg><arg name="doi"><space/>10.1016/j.jaad.2011.02.026<space/></arg></template></extension></paragraph><heading level='3'>Secondary neoplasm</heading><paragraph>Development of secondary neoplasia after successful chemotherapy and/or radiotherapy treatment can occur. The most common<space/><link><target>secondary neoplasm</target></link><space/>is secondary acute myeloid leukemia, which develops primarily after treatment with alkylating agents or topoisomerase inhibitors.<extension extension_name='ref'>U. Rther, C. Nunnensiek, H.-J. Schmoll,<italics>Secondary Neoplasias following Chemotherapy, Radiotherapy, and Immunosuppression</italics>, Contributions to Oncology (Beitrge zur Onkologie); Vol 55, 2000, ISBN 3-8055-7116-X</extension><space/>Survivors of<space/><link><target>childhood cancer</target></link><space/>are more than 13 times as likely to get a<space/><link><target>secondary neoplasm</target></link><space/>during the 30 years after treatment than the general population.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hijiya N, Hudson MM, Lensing S, Zacher M, Onciu M, Behm FG, Razzouk BI, Ribeiro RC, Rubnitz JE, Sandlund JT, Rivera GK, Evans WE, Relling MV, Pui CH<space/></arg><arg name="title"><space/>Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia<space/></arg><arg name="journal"><space/>Jama<space/></arg><arg name="volume"><space/>297<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1207–1215<space/></arg><arg name="date"><space/>Mar 2007<space/></arg><arg name="pmid"><space/>17374815<space/></arg><arg name="doi"><space/>10.1001/jama.297.11.1207<space/></arg></template></extension><space/>Not all of this increase can be attributed to chemotherapy.</paragraph><heading level='3'>Infertility</heading><paragraph>Some types of chemotherapy are gonadotoxic and may cause<space/><link><target>infertility</target></link>.<extension extension_name='ref' name="Brydoy"><template><target>cite journal</target><arg name="author"><space/>Brydøy M, Fosså SD, Dahl O, Bjøro T<space/></arg><arg name="title"><space/>Gonadal dysfunction and fertility problems in cancer survivors<space/></arg><arg name="journal"><space/>Acta Oncologica<space/></arg><arg name="volume"><space/>46<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>480–9<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17497315<space/></arg><arg name="doi"><space/>10.1080/02841860601166958<space/></arg><arg name="url"><space/>http://informahealthcare.com/doi/pdf/10.1080/02841860601166958<space/></arg></template></extension><space/>Chemotherapies with high risk include procarbazine and other alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, melphalan, chlorambucil, and chlormethine.<extension extension_name='ref' name="Brydoy"></extension><space/>Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin.<extension extension_name='ref' name="Brydoy"></extension><space/>On the other hand, therapies with low risk of gonadotoxicity include plant derivatives such as vincristine and vinblastine,<space/><link><target>antibiotics</target></link><space/>such as bleomycin and dactinomycin, and antimetabolites such as methotrexate, mercaptopurine, and 5-fluorouracil.<extension extension_name='ref' name="Brydoy"></extension></paragraph><paragraph><link><target>Female infertility</target></link><space/>by chemotherapy appears to be secondary to<space/><link><target>premature ovarian failure</target></link><space/>by loss of<space/><link><target>primordial follicles</target></link>.<extension extension_name='ref' name="Morgan2012"><template><target>cite journal</target><arg name="author"><space/>Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N<space/></arg><arg name="title"><space/>How do chemotherapeutic agents damage the ovary?<space/></arg><arg name="journal"><space/>Human Reproduction Update<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>525–35<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22647504<space/></arg><arg name="doi"><space/>10.1093/humupd/dms022<space/></arg></template></extension><space/>This loss is not necessarily a direct effect of the chemotherapeutic agents, but could be due to an increased rate of growth initiation to replace damaged developing follicles.<extension extension_name='ref' name="Morgan2012"></extension></paragraph><paragraph>Patients may choose between several methods of<space/><link><target>fertility preservation</target></link><space/>prior to chemotherapy, including<space/><link><target>cryopreservation</target></link><space/>of semen, ovarian tissue, oocytes, or embryos.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gurgan T, Salman C, Demirol A<space/></arg><arg name="title"><space/>Pregnancy and assisted reproduction techniques in men and women after cancer treatment<space/></arg><arg name="journal"><space/>Placenta<space/></arg><arg name="volume"><space/>29 Suppl B<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>152–9<space/></arg><arg name="date"><space/>Oct 2008<space/></arg><arg name="pmid"><space/>18790328<space/></arg><arg name="doi"><space/>10.1016/j.placenta.2008.07.007<space/></arg></template></extension><space/>As more than half of cancer patients are elderly, this adverse effect is only relevant for a minority of patients. A study in France between 1999 and 2011 came to the result that embryo freezing before administration of gonadotoxic agents to females caused a delay of treatment in 34% of cases, and a live birth in 27% of surviving cases who wanted to become pregnant, with the follow-up time varying between 1 and 13 years.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Courbiere B, Decanter C, Bringer-Deutsch S, Rives N, Mirallié S, Pech JC, De Ziegler D, Carré-Pigeon F, May-Panloup P, Sifer C, Amice V, Schweitzer T, Porcu-Buisson G, Poirot C<space/></arg><arg name="title"><space/>Emergency IVF for embryo freezing to preserve female fertility: a French multicentre cohort study<space/></arg><arg name="journal"><space/>Human Reproduction<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>2381–8<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>23832792<space/></arg><arg name="pmc"><space/></arg><arg name="doi"><space/>10.1093/humrep/det268<space/></arg></template></extension></paragraph><paragraph>Potential protective or attenuating agents include<space/><link><target>GnRH analog</target><trail>s</trail></link>, where several studies have shown a protective effect<space/><italics><link><target>in vivo</target></link></italics><space/>in humans, but some studies show no such effect.<space/><link><target>Sphingosine-1-phosphate</target></link><space/>(S1P) has shown similar effect, but its mechanism of inhibiting the<space/><link><target>Sphingomyelin#Apoptosis</target><part>sphingomyelin apoptotic pathway</part></link><space/>may also interfere with the<space/><link><target>apoptosis</target></link><space/>action of chemotherapy drugs.<extension extension_name='ref' name="RonessKalich-Philosoph2014"><template><target>cite journal</target><arg name="author"><space/>Roness H, Kalich-Philosoph L, Meirow D<space/></arg><arg name="title"><space/>Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents<space/></arg><arg name="journal"><space/>Human Reproduction Update<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>759–774<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>24833728<space/></arg><arg name="doi"><space/>10.1093/humupd/dmu019<space/></arg></template></extension></paragraph><paragraph>In chemotherapy as a<space/><link><target>conditioning regimen</target></link><space/>in hematopoietic stem cell transplantation, a study of patients conditioned with cyclophosphamide alone for severe aplastic anemia came to the result that ovarian recovery occurred in all women younger than 26 years at time of transplantation, but only in five of 16 women older than 26 years.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Tichelli A, Rovó A<space/></arg><arg name="title"><space/>Fertility issues following hematopoietic stem cell transplantation<space/></arg><arg name="journal"><space/>Expert Review of Hematology<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>375–388<space/></arg><arg name="date"><space/>Aug 2013<space/></arg><arg name="pmid"><space/>23991924<space/></arg><arg name="doi"><space/>10.1586/17474086.2013.816507<space/></arg><arg name="url"><space/>http://www.medscape.com/viewarticle/810686_2?nlid</arg></template><xhtml:br></xhtml:br>In turn citing:<space/><template><target>cite journal</target><arg name="author"><space/>Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan K, Witherspoon R, Appelbaum FR<space/></arg><arg name="title"><space/>Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation<space/></arg><arg name="journal"><space/>Blood<space/></arg><arg name="volume"><space/>87<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>3045–3052<space/></arg><arg name="date"><space/>Apr 1996<space/></arg><arg name="pmid"><space/>8639928<space/></arg></template></extension></paragraph><heading level='3'>Teratogenicity</heading><paragraph>Chemotherapy is potentially<space/><link><target>teratogenic</target></link><space/>during<space/><link><target>pregnancy</target></link>, especially during the<space/><link><target>first trimester</target></link>, to the extent that<space/><link><target>abortion</target></link><space/>usually is recommended if pregnancy in this period is found during chemotherapy.<extension extension_name='ref' name="arnon2011"><template><target>cite journal</target><arg name="author"><space/>Arnon J, Meirow D, Lewis-Roness H, Ornoy A<space/></arg><arg name="title"><space/>Genetic and teratogenic effects of cancer treatments on gametes and embryos<space/></arg><arg name="journal"><space/>Human Reproduction Update<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>394–403<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="pmid"><space/>11476352<space/></arg><arg name="doi"><space/>10.1093/humupd/7.4.394<space/></arg></template><space/><link type='external' href='http://humupd.oxfordjournals.org/content/7/4/394.full.pdf'></link></extension><space/>Second- and third-trimester exposure does not usually increase the teratogenic risk and adverse effects on cognitive development, but it may increase the risk of various<space/><link><target>complications of pregnancy</target></link><space/>and fetal myelosuppression.<extension extension_name='ref' name="arnon2011"></extension></paragraph><paragraph>In males previously having undergone chemotherapy or radiotherapy, there appears to be no increase in genetic defects or congenital malformations in their children conceived after therapy.<extension extension_name='ref' name="arnon2011"></extension><space/>The use of<space/><link><target>assisted reproductive technologies</target></link><space/>and<space/><link><target>micromanipulation technique</target><trail>s</trail></link><space/>might increase this risk.<extension extension_name='ref' name="arnon2011"></extension><space/>In females previously having undergone chemotherapy, miscarriage and congenital malformations are not increased in subsequent conceptions.<extension extension_name='ref' name="arnon2011"></extension><space/>However, when<space/><link><target>in vitro fertilization</target></link><space/>and<space/><link><target>embryo cryopreservation</target><trail>is</trail></link><space/>practised between or shortly after treatment, possible genetic risks to the growing oocytes exist, and hence it has been recommended that the babies be screened.<extension extension_name='ref' name="arnon2011"></extension></paragraph><heading level='3'>Peripheral neuropathy</heading><paragraph><template><target>further</target><arg>Chemotherapy-induced peripheral neuropathy</arg></template>Between 30 and 40 percent of patients undergoing chemotherapy experience<space/><link><target>chemotherapy-induced peripheral neuropathy</target></link><space/>(CIPN), a progressive, enduring, and often irreversible condition, causing pain, tingling, numbness and sensitivity to cold, beginning in the hands and feet and sometimes progressing to the arms and legs.<extension extension_name='ref' name="NCI"><template><target>vcite journal</target><arg name="author"><space/>del Pino BM<space/></arg><arg name="date"><space/>Feb 23, 2010<space/></arg><arg name="journal"><space/>NCI Cancer Bulletin<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="page"><space/>6<space/></arg><arg name="title"><space/>Chemotherapy-induced Peripheral Neuropathy<space/></arg><arg name="url"><space/>http://www.cancer.gov/cancertopics/research/chemotherapy-induced-peripheral-neuropathy</arg></template></extension><space/>Chemotherapy drugs associated with CIPN include<space/><link><target>thalidomide</target></link>,<space/><link><target>epothilone</target><trail>s</trail></link>,<space/><link><target>vinca alkaloid</target><trail>s</trail></link>,<space/><link><target>taxane</target><trail>s</trail></link>,<space/><link><target>proteasome inhibitor</target><trail>s</trail></link>, and the platinum-based drugs.<extension extension_name='ref' name="NCI"></extension><extension extension_name='ref'><template><target>vcite journal</target><arg name="url">http://www.kup.at/kup/pdf/10376.pdf</arg><arg name="author">Grisold W, Oberndorfer S, Windebank AJ</arg><arg name="journal">European Association of Neurooncology Magazine</arg><arg name="title">Chemotherapy and polyneuropathies</arg><arg name="year">2012</arg><arg name="volume">12</arg><arg name="issue">1</arg></template></extension><extension extension_name='ref'>http://www.ehealthme.com/ds/herceptin/peripheral%20sensory%20neuropathy</extension><space/>Whether CIPN arises, and to what degree, is determined by the choice of drug, duration of use, the total amount consumed and whether the patient already has<space/><link><target>peripheral neuropathy</target></link>. Though the symptoms are mainly sensory, in some cases<space/><link><target>motor nerve</target><trail>s</trail></link><space/>and the<space/><link><target>autonomic nervous system</target></link><space/>are affected.<extension extension_name='ref' name="Beijers"><template><target>vcite journal</target><arg name="author"><space/>Beijers AJM, Jongen, JLM & Vreugdenhil1 G<space/></arg><arg name="date"><space/>January 2012<space/></arg><arg name="journal"><space/>The Netherlands journal of medicine<space/></arg><arg name="volume"><space/>70<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pmid"><space/>22271810<space/></arg><arg name="url"><space/>http://www.njmonline.nl/getpdf.php?id</arg></template></extension><space/>CIPN often follows the first chemotherapy dose and increases in severity as treatment continues, but this progression usually levels off at completion of treatment. The platinum-based drugs are the exception; with these drugs, sensation may continue to deteriorate for several months after the end of treatment.<extension extension_name='ref' name="Windebank"><template><target>vcite journal</target><arg name="author"><space/>Windebank AJ & Grisold W<space/></arg><arg name="title"><space/>Chemotherapy-induced neuropathy<space/></arg><arg name="journal"><space/>Journal of the Peripheral Nervous System<space/></arg><arg name="date"><space/>2008 Mar<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>27–46<space/></arg><arg name="pmid"><space/>18346229<space/></arg><arg name="doi">10.1111/j.1529-8027.2008.00156.x</arg></template></extension><space/>Some CIPN appears to be irreversible.<extension extension_name='ref' name="Windebank"></extension><space/>Pain can often be managed with drug or other treatment but the numbness is usually resistant to treatment.<extension extension_name='ref' name="Savage"><template><target>vcite journal</target><arg name="journal"><space/>Journal of the National Cancer Institute</arg><arg name="title"><space/>Chemotherapy-induced pain puzzles scientists<space/></arg><arg name="volume"><space/>99<space/></arg><arg name="issue"><space/>14<space/></arg><arg name="author"><space/>Savage L<space/></arg><arg name="date"><space/>2007<space/></arg><arg name="url"><space/>http://jnci.oxfordjournals.org/content/99/14/1070.long<space/></arg><arg name="pages"><space/>1070–1071<space/></arg><arg name="doi">10.1093/jnci/djm072</arg></template></extension></paragraph><heading level='3'>Cognitive impairment</heading><paragraph>Some patients report fatigue or non-specific neurocognitive problems, such as an inability to concentrate; this is sometimes called<space/><link><target>post-chemotherapy cognitive impairment</target></link>, referred to as &quot;chemo brain&quot; by patients' groups.<extension extension_name='ref' name="pmid15169812"><template><target>cite journal</target><arg name="author"><space/>Tannock IF, Ahles TA, Ganz PA, Van Dam FS<space/></arg><arg name="title"><space/>Cognitive impairment associated with chemotherapy for cancer: report of a workshop<space/></arg><arg name="journal"><space/>Journal of Clinical Oncology<space/></arg><arg name="volume"><space/>22<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>2233–9<space/></arg><arg name="date"><space/>Jun 2004<space/></arg><arg name="pmid"><space/>15169812<space/></arg><arg name="doi"><space/>10.1200/JCO.2004.08.094<space/></arg><arg name="url"><space/>http://www.jco.org/cgi/pmidlookup?view</arg></template></extension></paragraph><heading level='3'>Tumor lysis syndrome</heading><paragraph>In particularly large tumors and cancers with high<space/><link><target>white cell count</target><trail>s</trail></link>, such as<space/><link><target>lymphoma</target><trail>s</trail></link>,<space/><link><target>teratoma</target><trail>s</trail></link>, and some<space/><link><target>leukemia</target><trail>s</trail></link>, some patients develop<space/><link><target>tumor lysis syndrome</target></link>. The rapid breakdown of cancer cells causes the release of chemicals from the inside of the cells. Following this, high levels of<space/><link><target>hyperuricemia</target><part>uric acid</part></link>,<space/><link><target>hyperkalemia</target><part>potassium</part></link><space/>and<space/><link><target>hyperphosphatemia</target><part>phosphate</part></link><space/>are found in the blood. High levels of phosphate induce secondary hypoparathyroidism, resulting in low levels of calcium in the blood. This causes kidney damage and the high levels of potassium can cause<space/><link><target>Cardiac dysrhythmia</target><part>cardiac arrhythmia</part></link>. Although prophylaxis is available and is often initiated in patients with large tumors, this is a dangerous side-effect that can lead to death if left untreated.<extension extension_name='ref' name="isbn0-443-07101-2 4">Wood, p. 202</extension></paragraph><heading level='3'>Organ damage</heading><paragraph><link><target>Cardiotoxicity</target></link><space/>(heart damage) is especially prominent with the use of<space/><link><target>anthracycline</target></link><space/>drugs (<link><target>doxorubicin</target></link>,<space/><link><target>epirubicin</target></link>,<space/><link><target>idarubicin</target></link>, and<space/><link><target>liposomal doxorubicin</target></link>). The cause of this is most likely due to the production of<space/><link><target>free radical</target><trail>s</trail></link><space/>in the cell and subsequent<space/><link><target>DNA damage</target></link>. Other chemotherapeutic agents that cause cardiotoxicity, but at a lower incidence, are<space/><link><target>cyclophosphamide</target></link>,<space/><link><target>docetaxel</target></link><space/>and<space/><link><target>clofarabine</target></link>.<extension extension_name='ref' name="pmid22382639"><template><target>cite journal</target><arg name="author"><space/>Shaikh AY, Shih JA<space/></arg><arg name="title"><space/>Chemotherapy-induced cardiotoxicity<space/></arg><arg name="journal"><space/>Current Heart Failure Reports<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>117–27<space/></arg><arg name="date"><space/>Jun 2012<space/></arg><arg name="pmid"><space/>22382639<space/></arg><arg name="doi"><space/>10.1007/s11897-012-0083-y<space/></arg></template></extension></paragraph><paragraph><link><target>Hepatotoxicity</target></link><space/>(liver damage) can be caused by many cytotoxic drugs. The susceptibility of an individual to liver damage can be altered by other factors such as the cancer itself,<space/><link><target>viral hepatitis</target></link>,<space/><link><target>immunosuppression</target></link><space/>and<space/><link><target>nutritional deficiency</target></link>. The liver damage can consist of damage to liver cells,<space/><link><target>Hepatic veno-occlusive disease</target><part>hepatic sinusoidal syndrome</part></link><space/>(obstruction of the veins in the liver),<space/><link><target>cholestasis</target></link><space/>(where bile does not flow from the liver to the intestine) and<space/><link><target>liver fibrosis</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Thatishetty AV, Agresti N, O'Brien CB<space/></arg><arg name="title"><space/>Chemotherapy-induced hepatotoxicity<space/></arg><arg name="journal"><space/>Clinics in Liver Disease<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>671–86, ix–x<space/></arg><arg name="date"><space/>Nov 2013<space/></arg><arg name="pmid"><space/>24099024<space/></arg><arg name="doi"><space/>10.1016/j.cld.2013.07.010<space/></arg><arg name="url"><space/>http://dx.doi.org/10.1016/j.cld.2013.07.010<space/></arg></template></extension><extension extension_name='ref' name="pmid11306728"><template><target>cite journal</target><arg name="author"><space/>King PD, Perry MC<space/></arg><arg name="title"><space/>Hepatotoxicity of chemotherapy<space/></arg><arg name="journal"><space/>The Oncologist<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>162–76<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="pmid"><space/>11306728<space/></arg><arg name="doi"><space/>10.1634/theoncologist.6-2-162<space/></arg></template></extension></paragraph><paragraph><link><target>Nephrotoxicity</target></link><space/>(kidney damage) can be caused by<space/><link><target>tumor lysis syndrome</target></link><space/>and also due direct effects of drug clearance by the kidneys. Different drugs will affect different parts of the kidney and the toxicity may be<space/><link><target>asymptomatic</target></link><space/>(only seen on blood or urine tests) or may cause<space/><link><target>acute renal failure</target></link>.<extension extension_name='ref' name="pmid16473645"><template><target>cite journal</target><arg name="author"><space/>de Jonge MJ, Verweij J<space/></arg><arg name="title"><space/>Renal toxicities of chemotherapy<space/></arg><arg name="journal"><space/>Seminars in Oncology<space/></arg><arg name="volume"><space/>33<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>68–73<space/></arg><arg name="date"><space/>Feb 2006<space/></arg><arg name="pmid"><space/>16473645<space/></arg><arg name="doi"><space/>10.1053/j.seminoncol.2005.11.011<space/></arg></template></extension><extension extension_name='ref' name="pmid15574506"><template><target>cite journal</target><arg name="author"><space/>Humphreys BD, Soiffer RJ, Magee CC<space/></arg><arg name="title"><space/>Renal failure associated with cancer and its treatment: an update<space/></arg><arg name="journal"><space/>Journal of the American Society of Nephrology<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>151–61<space/></arg><arg name="date"><space/>Jan 2005<space/></arg><arg name="pmid"><space/>15574506<space/></arg><arg name="doi"><space/>10.1681/ASN.2004100843<space/></arg></template></extension></paragraph><paragraph><link><target>Ototoxicity</target></link><space/>(damage to the inner ear) is a common side effect of platinum based drugs that can produce symptoms such as dizziness and<space/><link><target>Vertigo (medical)</target><part>vertigo</part></link>.<extension extension_name='ref' name="pmid22547603"><template><target>cite journal</target><arg name="author"><space/>Brock PR, Knight KR, Freyer DR, Campbell KC, Steyger PS, Blakley BW, Rassekh SR, Chang KW, Fligor BJ, Rajput K, Sullivan M, Neuwelt EA<space/></arg><arg name="title"><space/>Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale<space/></arg><arg name="journal"><space/>Journal of Clinical Oncology<space/></arg><arg name="volume"><space/>30<space/></arg><arg name="issue"><space/>19<space/></arg><arg name="pages"><space/>2408–17<space/></arg><arg name="date"><space/>Jul 2012<space/></arg><arg name="pmid"><space/>22547603<space/></arg><arg name="pmc"><space/>3675696<space/></arg><arg name="doi"><space/>10.1200/JCO.2011.39.1110<space/></arg></template></extension><extension extension_name='ref' name="pmid19851045"><template><target>cite journal</target><arg name="author"><space/>Rybak LP, Mukherjea D, Jajoo S, Ramkumar V<space/></arg><arg name="title"><space/>Cisplatin ototoxicity and protection: clinical and experimental studies<space/></arg><arg name="journal"><space/>The Tohoku Journal of Experimental Medicine<space/></arg><arg name="volume"><space/>219<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>177–86<space/></arg><arg name="date"><space/>Nov 2009<space/></arg><arg name="pmid"><space/>19851045<space/></arg><arg name="pmc"><space/>2927105<space/></arg><arg name="doi"><space/>10.1620/tjem.219.177<space/></arg></template></extension></paragraph><heading level='3'>Other side-effects</heading><paragraph>Less common side-effects include red skin (<link><target>erythema</target></link>), dry skin, damaged fingernails, a dry mouth (<link><target>xerostomia</target></link>),<space/><link><target>Water retention (medicine)</target><part>water retention</part></link>, and<space/><link><target>sexual impotence</target></link>. Some medications can trigger<space/><link><target>allergic</target></link><space/>or<space/><link><target>pseudoallergic</target></link><space/>reactions.</paragraph><paragraph>Specific chemotherapeutic agents are associated with organ-specific toxicities, including<space/><link><target>cardiovascular disease</target></link><space/>(e.g.,<space/><link><target>doxorubicin</target></link>),<space/><link><target>interstitial lung disease</target></link><space/>(e.g.,<space/><link><target>bleomycin</target></link>) and occasionally<space/><link><target>secondary neoplasm</target></link><space/>(e.g.,<space/><link><target>MOPP (medicine)</target><part>MOPP</part></link><space/>therapy for Hodgkin's disease).</paragraph><heading level='2'>Limitations</heading><paragraph>Chemotherapy does not always work, and even when it is useful, it may not completely destroy the cancer. Patients frequently fail to understand its limitations. In one study of patients who had been newly diagnosed with incurable,<space/><link><target>Stage-4 cancer</target><part>stage 4 cancer</part></link>, more than two-thirds of patients with lung cancer and more than four-fifths of patients with colorectal cancer still believed that chemotherapy was likely to cure their cancer.<extension extension_name='ref' name="Weeks"><template><target>cite journal</target><arg name="author"><space/>Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, Schrag D<space/></arg><arg name="title"><space/>Patients' expectations about effects of chemotherapy for advanced cancer<space/></arg><arg name="journal"><space/>The New England Journal of Medicine<space/></arg><arg name="volume"><space/>367<space/></arg><arg name="issue"><space/>17<space/></arg><arg name="pages"><space/>1616–25<space/></arg><arg name="date"><space/>Oct 2012<space/></arg><arg name="pmid"><space/>23094723<space/></arg><arg name="pmc"><space/>3613151<space/></arg><arg name="doi"><space/>10.1056/NEJMoa1204410<space/></arg></template></extension></paragraph><paragraph>The<space/><link><target>bloodbrain barrier</target></link><space/>poses a difficult obstacle to pass to deliver chemotherapy to the<space/><link><target>brain</target></link>. This is because the brain has an extensive system in place to protect it from harmful chemicals. Drug transporters can pump out drugs from the brain and brain's blood vessel cells into the<space/><link><target>cerebrospinal fluid</target></link><space/>and blood circulation. These transporters pump out most chemotherapy drugs, which reduces their efficacy for treatment of brain tumors. Only small<space/><link><target>lipophilic</target></link><space/><link><target>alkylating agents</target></link><space/>such as<space/><link><target>lomustine</target></link><space/>or<space/><link><target>temozolomide</target></link><space/>are able to cross this bloodbrain barrier.<extension extension_name='ref' name="pmid17363519"><template><target>cite journal</target><arg name="author"><space/>Deeken JF, Löscher W<space/></arg><arg name="title"><space/>The blood-brain barrier and cancer: transporters, treatment, and Trojan horses<space/></arg><arg name="journal"><space/>Clinical Cancer Research<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1663–74<space/></arg><arg name="date"><space/>Mar 2007<space/></arg><arg name="pmid"><space/>17363519<space/></arg><arg name="doi"><space/>10.1158/1078-0432.CCR-06-2854<space/></arg></template></extension><extension extension_name='ref' name="pmid10794805"><template><target>cite journal</target><arg name="author"><space/>Agarwala SS, Kirkwood JM<space/></arg><arg name="title"><space/>Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma<space/></arg><arg name="journal"><space/>The Oncologist<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>144–51<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="pmid"><space/>10794805<space/></arg><arg name="doi"><space/>10.1634/theoncologist.5-2-144<space/></arg></template></extension><extension extension_name='ref' name="pmid17538177"><template><target>cite journal</target><arg name="author"><space/>Gerstner ER, Fine RL<space/></arg><arg name="title"><space/>Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm<space/></arg><arg name="journal"><space/>Journal of Clinical Oncology<space/></arg><arg name="volume"><space/>25<space/></arg><arg name="issue"><space/>16<space/></arg><arg name="pages"><space/>2306–12<space/></arg><arg name="date"><space/>Jun 2007<space/></arg><arg name="pmid"><space/>17538177<space/></arg><arg name="doi"><space/>10.1200/JCO.2006.10.0677<space/></arg></template></extension></paragraph><paragraph><link><target>Blood vessel</target><trail>s</trail></link><space/>in tumors are very different from those seen in normal tissues. As a tumor grows, tumor cells furthest away from the blood vessels become low in oxygen (<link><target>Tumor hypoxia</target><part>hypoxic</part></link>). To counteract this they then signal for new blood vessels to grow. The newly formed tumor vasculature is poorly formed and does not deliver an adequate blood supply to all areas of the tumor. This leads to issues with drug delivery because many drugs will be delivered to the tumor by the<space/><link><target>circulatory system</target></link>.<extension extension_name='ref' name="pmid16862189"><template><target>cite journal</target><arg name="author"><space/>Minchinton AI, Tannock IF<space/></arg><arg name="title"><space/>Drug penetration in solid tumours<space/></arg><arg name="journal"><space/>Nature Reviews. Cancer<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>583–92<space/></arg><arg name="date"><space/>Aug 2006<space/></arg><arg name="pmid"><space/>16862189<space/></arg><arg name="doi"><space/>10.1038/nrc1893<space/></arg></template></extension></paragraph><heading level='2'>Resistance</heading><paragraph><link><target>Drug resistance</target><part>Resistance</part></link><space/>is a major cause of treatment failure in chemotherapeutic drugs. There are a few possible causes of resistance in cancer, one of which is the presence of small pumps on the surface of cancer cells that actively move chemotherapy from inside the cell to the outside. Cancer cells produce high amounts of these pumps, known as<space/><link><target>p-glycoprotein</target></link>, in order to protect themselves from chemotherapeutics. Research on<space/><link><target>p-glycoprotein</target></link><space/>and other such chemotherapy efflux pumps is currently ongoing. Medications to inhibit the function of<space/><link><target>p-glycoprotein</target></link><space/>are undergoing investigation, but due to toxicities and interactions with anti-cancer drugs their development has been difficult.<extension extension_name='ref' name="pmid12591977"><template><target>cite journal</target><arg name="author"><space/>Goldman B<space/></arg><arg name="title"><space/>Multidrug resistance: can new drugs help chemotherapy score against cancer?<space/></arg><arg name="journal"><space/>Journal of the National Cancer Institute<space/></arg><arg name="volume"><space/>95<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>255–7<space/></arg><arg name="date"><space/>Feb 2003<space/></arg><arg name="pmid"><space/>12591977<space/></arg><arg name="doi"><space/>10.1093/jnci/95.4.255<space/></arg></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last">E. Crowley, CA. McDevitt, R. Callaghan</arg><arg name="title">Multidrug Resistance in Cancer. Generating Inhibitors of P-Glycoprotein: Where to, Now?</arg><arg name="year">2009</arg><arg name="publisher">Springer Protocols</arg><arg name="pages">405–432</arg></template></extension><space/>Another mechanism of resistance is<space/><link><target>gene duplication</target><part>gene amplification</part></link>, a process in which multiple copies of a gene are produced by cancer cells. This overcomes the effect of drugs that reduce the expression of genes involved in replication. With more copies of the gene, the drug can not prevent all expression of the gene and therefore the cell can restore its proliferative ability. Cancer cells can also cause defects in the cellular pathways of<space/><link><target>apoptosis</target></link><space/>(programmed cell death). As most chemotherapy drugs kill cancer cells in this manner, defective apoptosis allows survival of these cells, making them resistant. Many chemotherapy drugs also cause DNA damage, which can be repaired by<space/><link><target>enzyme</target><trail>s</trail></link><space/>in the cell that carry out<space/><link><target>DNA repair</target></link>. Upregulation of these genes can overcome the DNA damage and prevent the induction of apoptosis. Mutations in genes that produce drug target proteins, such as<space/><link><target>tubulin</target></link>, can occur which prevent the drugs from binding to the protein, leading to resistance to these types of drugs.<extension extension_name='ref' name="pmid16103712"><template><target>cite journal</target><arg name="author"><space/>Luqmani YA<space/></arg><arg name="title"><space/>Mechanisms of drug resistance in cancer chemotherapy<space/></arg><arg name="journal"><space/>Medical Principles and Practice<space/></arg><arg name="volume"><space/>14 Suppl 1<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>35–48<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16103712<space/></arg><arg name="doi"><space/>10.1159/000086183<space/></arg></template></extension></paragraph><heading level='2'>Cytotoxics and targeted therapies</heading><paragraph><link><target>Targeted therapy</target><part>Targeted therapies</part></link><space/>are a relatively new class of cancer drugs that can overcome many of the issues seen with the use of cytotoxics. They are divided into two groups: small molecule and antibodies. The massive toxicity seen with the use of cytotoxics is due to the lack of cell specificity of the drugs. They will kill any rapidly dividing cell, tumor or normal. Targeted therapies are designed to affect cellular proteins or processes that are utilised by the cancer cells. This allows a high dose to cancer tissues with a relatively low dose to other tissues. As different proteins are utilised by different cancer types, the targeted therapy drugs are used on a cancer type specific, or even on a patient specific basis. Although the<space/><link><target>adverse effects</target><part>side effects</part></link><space/>are often less severe than that seen of cytotoxic chemotherapeutics, life-threatening effects can occur. Initially, the targeted therapeutics were supposed to be solely selective for one protein. Now it is clear that there is often a range of protein targets that the drug can bind. An example target for targeted therapy is the protein produced by the<space/><link><target>Philadelphia chromosome</target></link>, a genetic lesion found commonly in<space/><link><target>chronic myelomonocytic leukemia</target></link>. This fusion protein has enzyme activity that can be inhibited by<space/><link><target>imatinib</target></link>, a<space/><link><target>small molecule</target></link><space/>drug.<extension extension_name='ref' name="pmid18297955"><template><target>cite journal</target><arg name="author"><space/>Gerber DE<space/></arg><arg name="title"><space/>Targeted therapies: a new generation of cancer treatments<space/></arg><arg name="journal"><space/>American Family Physician<space/></arg><arg name="volume"><space/>77<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>311–9<space/></arg><arg name="date"><space/>Feb 2008<space/></arg><arg name="pmid"><space/>18297955<space/></arg><arg name="doi"><space/></arg></template></extension><extension extension_name='ref' name="pmid12360278"><template><target>cite journal</target><arg name="author"><space/>Allen TM<space/></arg><arg name="title"><space/>Ligand-targeted therapeutics in anticancer therapy<space/></arg><arg name="journal"><space/>Nature Reviews. Cancer<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>750–63<space/></arg><arg name="date"><space/>Oct 2002<space/></arg><arg name="pmid"><space/>12360278<space/></arg><arg name="doi"><space/>10.1038/nrc903<space/></arg></template></extension><extension extension_name='ref' name="pmid19581909"><template><target>cite journal</target><arg name="author"><space/>Chen HX, Cleck JN<space/></arg><arg name="title"><space/>Adverse effects of anticancer agents that target the VEGF pathway<space/></arg><arg name="journal"><space/>Nature Reviews. Clinical Oncology<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>465–77<space/></arg><arg name="date"><space/>Aug 2009<space/></arg><arg name="pmid"><space/>19581909<space/></arg><arg name="doi"><space/>10.1038/nrclinonc.2009.94<space/></arg></template></extension><extension extension_name='ref' name="pmid19104514"><template><target>cite journal</target><arg name="author"><space/>Zhang J, Yang PL, Gray NS<space/></arg><arg name="title"><space/>Targeting cancer with small molecule kinase inhibitors<space/></arg><arg name="journal"><space/>Nature Reviews. Cancer<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>28–39<space/></arg><arg name="date"><space/>Jan 2009<space/></arg><arg name="pmid"><space/>19104514<space/></arg><arg name="doi"><space/>10.1038/nrc2559<space/></arg></template></extension></paragraph><heading level='2'>Mechanism of action</heading><paragraph><link><target>File:Cell cycle simple.png</target><part>thumb</part><part>The four phases of the cell cycle. G1 the initial growth phase. S the phase in which DNA is synthesised. G2 the second growth phase in preparation for cell division. M mitosis; where the cell divides to produce two daughter cells that continue the cell cycle.</part></link><link><target>Cancer</target></link><space/>is the uncontrolled growth of<space/><link><target>cell (biology)</target><part>cells</part></link><space/>coupled with<space/><link><target>malignant</target></link><space/>behaviour: invasion and<space/><link><target>metastasis</target></link><space/>(among other features).<extension extension_name='ref' name="pmid10647931"><template><target>cite journal</target><arg name="author"><space/>Hanahan D, Weinberg RA<space/></arg><arg name="title"><space/>The hallmarks of cancer<space/></arg><arg name="journal"><space/>Cell<space/></arg><arg name="volume"><space/>100<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>57–70<space/></arg><arg name="date"><space/>Jan 2000<space/></arg><arg name="pmid"><space/>10647931<space/></arg><arg name="doi"><space/>10.1016/S0092-8674(00)81683-9<space/></arg></template></extension><space/>It is caused by the interaction between<space/><link><target>gene</target><trail>tic</trail></link><space/>susceptibility and environmental factors.<extension extension_name='ref' name="pmid18196605"><template><target>cite journal</target><arg name="author"><space/>Hodgson S<space/></arg><arg name="title"><space/>Mechanisms of inherited cancer susceptibility<space/></arg><arg name="journal"><space/>Journal of Zhejiang University. Science. B<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>1–4<space/></arg><arg name="date"><space/>Jan 2008<space/></arg><arg name="pmid"><space/>18196605<space/></arg><arg name="pmc"><space/>2170461<space/></arg><arg name="doi"><space/>10.1631/jzus.B073001<space/></arg></template></extension><extension extension_name='ref' name="pmid9353182"><template><target>cite journal</target><arg name="author"><space/>Perera FP<space/></arg><arg name="title"><space/>Environment and cancer: who are susceptible?<space/></arg><arg name="journal"><space/>Science<space/></arg><arg name="volume"><space/>278<space/></arg><arg name="issue"><space/>5340<space/></arg><arg name="pages"><space/>1068–73<space/></arg><arg name="date"><space/>Nov 1997<space/></arg><arg name="pmid"><space/>9353182<space/></arg><arg name="doi"><space/>10.1126/science.278.5340.1068<space/></arg><arg name="bibcode"><space/>1997Sci...278.1068P<space/></arg></template></extension><space/>These factors lead to accumulations of<space/><link><target>genetic mutation</target><trail>s</trail></link><space/>in<space/><link><target>oncogene</target><trail>s</trail></link><space/>(genes that control the growth rate of cells) and<space/><link><target>tumor suppressor gene</target><trail>s</trail></link><space/>(genes that help to prevent cancer), which gives cancer cells their malignant characteristics, such as uncontrolled growth.<extension extension_name='ref'>Randall, pp, 93-94</extension></paragraph><paragraph>In the broad sense, most chemotherapeutic drugs work by impairing<space/><link><target>mitosis</target></link><space/>(<link><target>cell division</target></link>), effectively targeting<space/><link><target>fast-dividing cells</target></link>. As these drugs cause damage to cells, they are termed<space/><italics>cytotoxic</italics>. They prevent mitosis by various mechanisms including damaging DNA and inhibition of the cellular machinery involved in cell division.<extension extension_name='ref' name="pmid14508075"><template><target>cite journal</target><arg name="author"><space/>Malhotra V, Perry MC<space/></arg><arg name="title"><space/>Classical chemotherapy: mechanisms, toxicities and the therapeutic window<space/></arg><arg name="journal"><space/>Cancer Biology & Therapy<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/>4 Suppl 1<space/></arg><arg name="pages"><space/>S2–4<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14508075<space/></arg><arg name="doi">10.4161/cbt.199</arg></template></extension><extension extension_name='ref' name="pmid19651324"><template><target>cite journal</target><arg name="author"><space/>Kehe K, Balszuweit F, Steinritz D, Thiermann H<space/></arg><arg name="title"><space/>Molecular toxicology of sulfur mustard-induced cutaneous inflammation and blistering<space/></arg><arg name="journal"><space/>Toxicology<space/></arg><arg name="volume"><space/>263<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>12–9<space/></arg><arg name="date"><space/>Sep 2009<space/></arg><arg name="pmid"><space/>19651324<space/></arg><arg name="doi"><space/>10.1016/j.tox.2009.01.019<space/></arg></template></extension><space/>One theory as to why these drugs kill cancer cells is that they induce a programmed form of cell death known as<space/><link><target>apoptosis</target></link>.<extension extension_name='ref' name="pmid10928287"><template><target>cite journal</target><arg name="author"><space/>Makin G, Hickman JA<space/></arg><arg name="title"><space/>Apoptosis and cancer chemotherapy<space/></arg><arg name="journal"><space/>Cell and Tissue Research<space/></arg><arg name="volume"><space/>301<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>143–52<space/></arg><arg name="date"><space/>Jul 2000<space/></arg><arg name="pmid"><space/>10928287<space/></arg><arg name="doi"><space/>10.1007/s004419900160<space/></arg><arg name="bibcode"><space/>1994RSPTB.345..319H<space/></arg></template></extension></paragraph><paragraph>As chemotherapy affects cell division, tumors with high<space/><link><target>proliferative index</target><part>growth rates</part></link><space/>(such as<space/><link><target>acute myelogenous leukemia</target></link><space/>and the aggressive<space/><link><target>lymphoma</target><trail>s</trail></link>, including<space/><link><target>Hodgkin's disease</target></link>) are more sensitive to chemotherapy, as a larger proportion of the targeted cells are undergoing<space/><link><target>cell division</target></link><space/>at any time. Malignancies with slower growth rates, such as<space/><link><target>Indolent condition</target><part>indolent</part></link><space/>lymphomas, tend to respond to chemotherapy much more modestly.<extension extension_name='ref' name="Corrie"><template><target>cite journal</target><arg name="last">Corrie PG</arg><arg name="title">Cytotoxic chemotherapy: clinical aspects</arg><arg name="journal">Medicine</arg><arg name="year">2008</arg><arg name="volume">36</arg><arg name="issue">1</arg><arg name="pages">24–28</arg><arg name="doi">10.1016/j.mpmed.2007.10.012</arg><arg name="first1">Pippa G.</arg></template></extension><space/><link><target>Tumour heterogeneity</target><part>Heterogeneic tumours</part></link><space/>may also display varying sensitivities to chemotherapy agents, depending on the subclonal populations within the tumor.</paragraph><heading level='2'>Other uses</heading><paragraph>Some chemotherapy drugs are used in diseases other than cancer, such as in autoimmune disorders,<extension extension_name='ref' name="pmid15100330"></extension><space/>and noncancerous<space/><link><target>plasma cell dyscrasia</target></link>. In some cases they are often used at lower doses, which means that the side effects are minimized.<extension extension_name='ref' name="pmid15100330"><template><target>cite journal</target><arg name="author"><space/>Ben-Ari ET<space/></arg><arg name="title"><space/>Dual purpose: some cancer therapies used to treat autoimmune diseases<space/></arg><arg name="journal"><space/>Journal of the National Cancer Institute<space/></arg><arg name="volume"><space/>96<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>577–9<space/></arg><arg name="date"><space/>Apr 2004<space/></arg><arg name="pmid"><space/>15100330<space/></arg><arg name="doi"><space/>10.1093/jnci/96.8.577<space/></arg></template></extension><space/><link><target>Methotrexate</target></link><space/>is used in the treatment of<space/><link><target>rheumatoid arthritis</target></link><space/>(RA),<extension extension_name='ref' name="pmid11454634"><template><target>cite journal</target><arg name="author"><space/>Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH<space/></arg><arg name="title"><space/>Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis<space/></arg><arg name="journal"><space/>Annals of the Rheumatic Diseases<space/></arg><arg name="volume"><space/>60<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>729–35<space/></arg><arg name="date"><space/>Aug 2001<space/></arg><arg name="pmid"><space/>11454634<space/></arg><arg name="pmc"><space/>1753808<space/></arg><arg name="doi"><space/>10.1136/ard.60.8.729<space/></arg></template></extension><space/><link><target>psoriasis</target></link>,<extension extension_name='ref' name="pmid21388454"><template><target>cite journal</target><arg name="author"><space/>Montaudié H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Maître M, Misery L, Richard MA, Ortonne JP<space/></arg><arg name="title"><space/>Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity<space/></arg><arg name="journal"><space/>Journal of the European Academy of Dermatology and Venereology<space/></arg><arg name="volume"><space/>25 Suppl 2<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>12–8<space/></arg><arg name="date"><space/>May 2011<space/></arg><arg name="pmid"><space/>21388454<space/></arg><arg name="doi"><space/>10.1111/j.1468-3083.2011.03991.x<space/></arg></template></extension><space/><link><target>ankylosing spondylitis</target></link><extension extension_name='ref' name="pmid23450553"><template><target>cite journal</target><arg name="author"><space/>Chen J, Veras MM, Liu C, Lin J<space/></arg><arg name="title"><space/>Methotrexate for ankylosing spondylitis<space/></arg><arg name="journal"><space/>The Cochrane Database of Systematic Reviews<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>CD004524<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="pmid"><space/>23450553<space/></arg><arg name="doi"><space/>10.1002/14651858.CD004524.pub4<space/></arg><arg name="editor1-last"><space/>Chen<space/></arg><arg name="editor1-first"><space/>Junmin<space/></arg></template></extension><space/>and<space/><link><target>multiple sclerosis</target></link>.<extension extension_name='ref' name="pmid15106195"></extension><extension extension_name='ref' name="pmid16900766"></extension><space/>The anti-inflammatory response seen in RA is thought to be due to increases in<space/><link><target>adenosine</target></link>, which causes<space/><link><target>immunosuppression</target></link>; effects on immuno-regulatory<space/><link><target>cyclooxygenase</target></link>-2 enzyme pathways; reduction in pro-inflammatory<space/><link><target>cytokine</target><trail>s</trail></link>; and anti-proliferative properties.<extension extension_name='ref' name="pmid11454634"></extension><space/>Although methotrexate is used to treat both multiple sclerosis and ankylosing spondylitis, its efficacy in these diseases is still uncertain.<extension extension_name='ref' name="pmid23450553"></extension><extension extension_name='ref' name="pmid15106195"><template><target>cite journal</target><arg name="author"><space/>Gray O, McDonnell GV, Forbes RB<space/></arg><arg name="title"><space/>Methotrexate for multiple sclerosis<space/></arg><arg name="journal"><space/>The Cochrane Database of Systematic Reviews<space/></arg><arg name="volume"><space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>CD003208<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15106195<space/></arg><arg name="doi"><space/>10.1002/14651858.CD003208.pub2<space/></arg><arg name="editor1-last"><space/>Gray<space/></arg><arg name="editor1-first"><space/>Orla<space/></arg></template></extension><extension extension_name='ref' name="pmid16900766"><template><target>cite journal</target><arg name="author"><space/>Gray OM, McDonnell GV, Forbes RB<space/></arg><arg name="title"><space/>A systematic review of oral methotrexate for multiple sclerosis<space/></arg><arg name="journal"><space/>Multiple Sclerosis<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>507–10<space/></arg><arg name="date"><space/>Aug 2006<space/></arg><arg name="pmid"><space/>16900766<space/></arg><arg name="doi"><space/>10.1191/1352458506ms1299oa<space/></arg></template></extension><space/><link><target>Cyclophosphamide</target></link><space/>is sometimes used to treat<space/><link><target>lupus nephritis</target></link>, a common symptom of<space/><link><target>systemic lupus erythematosus</target></link>.<extension extension_name='ref' name="pmid20107927"><template><target>cite journal</target><arg name="author"><space/>Ntali S, Bertsias G, Boumpas DT<space/></arg><arg name="title"><space/>Cyclophosphamide and lupus nephritis: when, how, for how long?<space/></arg><arg name="journal"><space/>Clinical Reviews in Allergy & Immunology<space/></arg><arg name="volume"><space/>40<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>181–91<space/></arg><arg name="date"><space/>Jun 2011<space/></arg><arg name="pmid"><space/>20107927<space/></arg><arg name="doi"><space/>10.1007/s12016-009-8196-0<space/></arg></template></extension><space/><link><target>Dexamethasone</target></link><space/>along with either<space/><link><target>bortezomib</target></link><space/>or<space/><link><target>melphalan</target></link><space/>is commonly used as a treatment for<space/><link><target>AL amyloidosis</target></link>. Recently, bortezomid in combination with<space/><link><target>cyclophosphamide</target></link><space/>and dexamethasone has also shown promise as a treatment for AL amyloidosis. Other drugs used to treat<space/><link><target>myeloma</target></link><space/>such as<space/><link><target>lenalidomide</target></link><space/>have shown promise in treating AL amyloidosis.<extension extension_name='ref'><template><target>cite web</target><arg name="title">NCCN Guidelines: Systemic Light Chain Amyloidosis</arg><arg name="url">http://williams.medicine.wisc.edu/amyloidosis.pdf</arg><arg name="publisher">National Comprehensive Cancer Network</arg></template></extension></paragraph><paragraph>Chemotherapy drugs are also used in<space/><link><target>conditioning regimen</target><trail>s</trail></link><space/>prior to bone marow transplant (<link><target>hematopoietic stem cell transplant</target></link>). Conditioning regimens are used to suppress the recipient's immune system in order to allow a transplant to engraft. Cyclophosphamide is a common cytotoxic drug used in this manner, and is often used in conjunction with<space/><link><target>total body irradiation</target></link>. Chemotherapeutic drugs may be used at high doses to permanently remove the recipient's bone marrow cells (myeloablative conditioning) or at lower doses that will prevent permanent bone marrow loss (non-myeloablative and reduced intensity conditioning).<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, Horowitz M<space/></arg><arg name="title"><space/>Defining the intensity of conditioning regimens: working definitions<space/></arg><arg name="journal"><space/>Biology of Blood and Marrow Transplantation<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1628–33<space/></arg><arg name="date"><space/>Dec 2009<space/></arg><arg name="pmid"><space/>19896087<space/></arg><arg name="pmc"><space/>2861656<space/></arg><arg name="doi"><space/>10.1016/j.bbmt.2009.07.004<space/></arg></template></extension><space/>When used in non-cancer setting, the treatment is still called Chemotherapy, and is often done in the same treatment center as cancer patients.</paragraph><heading level='2'>Occupational precautions</heading><paragraph>Healthcare workers exposed to antineoplastic agents take precautions to keep their exposure to a minimum. There is a limitation in cytotoxics dissolution in Australia and the United States to 20 dissolutions per pharmacist/nurse,<template><target>Citation needed</target><arg name="date">August 2013</arg></template><space/>since pharmacists who prepare these drugs or nurses who may prepare or administer them are the two occupational groups with the highest potential exposure to antineoplastic agents. In addition, physicians and operating room personnel may also be exposed through the treatment of patients. Hospital staff, such as shipping and receiving personnel, custodial workers, laundry workers, and waste handlers, all have potential exposure to these drugs during the course of their work. The increased use of antineoplastic agents in veterinary oncology also puts these workers at risk for exposure to these drugs.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.cdc.gov/niosh/topics/antineoplastic/</arg><arg name="title">NIOSH Occupational Exposure to Antineoplastic Agents<space/></arg><arg name="accessdate">10 October 2007<space/></arg><arg name="publisher">United States National Institute for Occupational Safety and Health</arg></template></extension><extension extension_name='ref' name=":0"><template><target>Cite web</target><arg name="url"><space/>http://www.medscape.com/viewarticle/738076</arg><arg name="title"><space/>Hazardous Drugs in Healthcare</arg><arg name="date"><space/>March 7, 2011</arg><arg name="accessdate"><space/></arg><arg name="website"><space/>NIOSH: Workplace Safety and Health</arg><arg name="publisher"><space/>Medscape & NIOSH</arg><arg name="last"><space/>Connor</arg><arg name="first"><space/>Thomas H.</arg></template></extension><space/>Routes of entry into the worker's body are skin absorption,<space/><link><target>inhalation</target></link>, and<space/><link><target>ingestion</target></link><space/>via hand-to-mouth.<extension extension_name='ref' name=":0"></extension><space/>The long-term effects of exposure include<space/><link><target>chromosomal abnormality</target><part>chromosomal abnormalities</part></link><space/>and<space/><link><target>infertility</target></link>.<extension extension_name='ref' name="isbn0-443-07101-2 2">Wood, p. 38.</extension></paragraph><heading level='2'>Comparison of available agents</heading><table class="wikitable collapsible collapsed" style="width:100%"><tablerow><tablehead colspan="8">Antineoplastic agents</tablehead></tablerow><tablerow><tablehead><link><target>International Nonproprietary Name</target><part>INN</part></link></tablehead><tablehead>Reviews</tablehead><tablehead width="80px">Chemical classification</tablehead><tablehead width="60px">Preg. cat.</tablehead><tablehead>Route<extension extension_name='ref' name="AMH"></extension></tablehead><tablehead>Mechanism of action<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="BNF"></extension><extension extension_name='ref' name="GG"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="editor1-last">Brunton<space/></arg><arg name="editor1-first">L. L.<space/></arg><arg name="editor2-last">Chabner<space/></arg><arg name="editor2-first">Bruce<space/></arg><arg name="editor3-last">Knollmann<space/></arg><arg name="editor3-first">Björn C.<space/></arg><arg name="title">[[Goodman & Gilman's The Pharmacological Basis of Therapeutics]]<space/></arg><arg name="edition">12th<space/></arg><arg name="location">New York<space/></arg><arg name="publisher">McGraw-Hill<space/></arg><arg name="year">2011<space/></arg><arg name="isbn">978-0-07-162442-8</arg></template></extension><extension extension_name='ref' name="AT"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="author"><space/>Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, Williams BR<space/></arg><arg name="title"><space/>Applied therapeutics: the clinical use of drugs.<space/></arg><arg name="date"><space/>February 2012<space/></arg><arg name="isbn"><space/>978-1-60913-713-7<space/></arg><arg name="series"><space/>Koda Kimble and Youngs Applied Therapeutics<space/></arg><arg name="edition"><space/>10th<space/></arg><arg name="oclc"><space/></arg><arg name="editor2-link"><space/></arg><arg name="location"><space/>Baltimore, MD<space/></arg><arg name="publisher"><space/>Lippincott Williams & Wilkins<space/></arg></template></extension></tablehead><tablehead>Indications<extension extension_name='ref' name="AMH"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="title"><space/>Australian Medicines Handbook<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="publisher"><space/>The Australian Medicines Handbook Unit Trust<space/></arg><arg name="isbn"><space/>978-0-9805790-9-3<space/></arg><arg name="edition"><space/>2013<space/></arg><arg name="place"><space/>Adelaide<space/></arg><arg name="editor"><space/>Rossi, S<space/></arg></template></extension><extension extension_name='ref' name="BNF"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1"><space/>Joint Formulary Committee<space/></arg><arg name="title"><space/>British National Formulary (BNF)<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="isbn"><space/>978-0-85711-084-8<space/></arg><arg name="editor1-last"><space/></arg><arg name="edition"><space/>65<space/></arg><arg name="location"><space/>London, UK<space/></arg><arg name="publisher"><space/>Pharmaceutical Press<space/></arg></template></extension><extension extension_name='ref' name="AT"></extension></tablehead><tablehead>Major toxicities<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="BNF"></extension><extension extension_name='ref' name="AT"></extension><extension extension_name='ref' name="MD"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="title">Martindale: The Complete Drug Reference</arg><arg name="publisher">Pharmaceutical Press</arg><arg name="accessdate">8 February 2014</arg><arg name="url">http://www.medicinescomplete.com/mc/martindale/current/</arg><arg name="editor">Sweetman, S</arg><arg name="place">London, UK</arg></template></extension></tablehead></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:span style="font-size:125%;">1. Cytotoxic antineoplastics</xhtml:span></bold></tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.01 Nucleoside analogues</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Azacitidine</target></link></tablecell><tablecell><extension extension_name='ref' name="Epi"><template><target>cite journal</target><arg name="author"><space/>Momparler RL<space/></arg><arg name="title"><space/>A Perspective on the Comparative Antileukemic Activity of 5-Aza-2'-deoxycytidine (Decitabine) and 5-Azacytidine (Vidaza)<space/></arg><arg name="journal"><space/>Pharmaceuticals<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>875–881<space/></arg><arg name="date"><space/>August 2012<space/></arg><arg name="pmid"><space/>24280679<space/></arg><arg name="pmc"><space/>3763670<space/></arg><arg name="doi"><space/>10.3390/ph5080875<space/></arg></template></extension><extension extension_name='ref' name="Epi2"><template><target>cite journal</target><arg name="author"><space/>Estey EH<space/></arg><arg name="title"><space/>Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia<space/></arg><arg name="journal"><space/>Leukemia<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1803–1812<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>23757301<space/></arg><arg name="doi"><space/>10.1038/leu.2013.173<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kim YJ, Jang JH, Kwak JY, Lee JH, Kim HJ<space/></arg><arg name="title"><space/>Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations<space/></arg><arg name="journal"><space/>Blood Research<space/></arg><arg name="volume"><space/>48<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>87–98<space/></arg><arg name="date"><space/>Jun 2013<space/></arg><arg name="pmid"><space/>23826577<space/></arg><arg name="pmc"><space/>3698413<space/></arg><arg name="doi"><space/>10.5045/br.2013.48.2.87<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Platzbecker U, Germing U<space/></arg><arg name="title"><space/>Combination of azacitidine and lenalidomide in myelodysplastic syndromes or acute myeloid leukemia-a wise liaison?<space/></arg><arg name="journal"><space/>Leukemia<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1813–9<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>23644421<space/></arg><arg name="doi"><space/>10.1038/leu.2013.140<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ritchie EK<space/></arg><arg name="title"><space/>Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome<space/></arg><arg name="journal"><space/>Clinical Interventions in Aging<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="pages"><space/>165–73<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22791989<space/></arg><arg name="pmc"><space/>3393359<space/></arg><arg name="doi"><space/>10.2147/CIA.S24659<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Keating GM<space/></arg><arg name="title"><space/>Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>72<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1111–36<space/></arg><arg name="date"><space/>May 2012<space/></arg><arg name="pmid"><space/>22571445<space/></arg><arg name="doi"><space/>10.2165/11209430-000000000-00000<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Martínez-Francés A<space/></arg><arg name="title"><space/>Adverse effects of azacitidine: onset, duration, and treatment<space/></arg><arg name="journal"><space/>Advances in Therapy<space/></arg><arg name="volume"><space/>28 Suppl 4<space/></arg><arg name="pages"><space/>1–5<space/></arg><arg name="date"><space/>Jun 2011<space/></arg><arg name="pmid"><space/>21688206<space/></arg><arg name="doi"><space/>10.1007/s12325-011-0021-5<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Font P<space/></arg><arg name="title"><space/>Azacitidine for the treatment of patients with acute myeloid leukemia with 20%-30% blasts and multilineage dysplasia<space/></arg><arg name="journal"><space/>Advances in Therapy<space/></arg><arg name="volume"><space/>28 Suppl 3<space/></arg><arg name="pages"><space/>1–9<space/></arg><arg name="date"><space/>Mar 2011<space/></arg><arg name="pmid"><space/>21431628<space/></arg><arg name="doi"><space/>10.1007/s12325-011-0002-8<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Vigil CE, Martin-Santos T, Garcia-Manero G<space/></arg><arg name="title"><space/>Safety and efficacy of azacitidine in myelodysplastic syndromes<space/></arg><arg name="journal"><space/>Drug Design, Development and Therapy<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="pages"><space/>221–9<space/></arg><arg name="date"><space/>24 September 2010<space/></arg><arg name="pmid"><space/>20957213<space/></arg><arg name="pmc"><space/>2948932<space/></arg><arg name="doi"><space/>10.2147/DDDT.S3143<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McCormack SE, Warlick ED<space/></arg><arg name="title"><space/>Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine<space/></arg><arg name="journal"><space/>OncoTargets and Therapy<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="pages"><space/>157–65<space/></arg><arg name="date"><space/>7 September 2010<space/></arg><arg name="pmid"><space/>20856790<space/></arg><arg name="pmc"><space/>2939768<space/></arg><arg name="doi"><space/>10.2147/OTT.S5852<space/></arg></template></extension></tablecell><tablecell><link><target>Cytidine</target></link><space/>analogue</tablecell><tablecell>X (Au)</tablecell><tablecell>SC, IV</tablecell><tablecell><link><target>DNA methyltransferase</target></link><space/>inhibitor and incorporates itself into RNA, hence inhibiting gene expression.<extension extension_name='ref'><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="title">Small molecules in oncology</arg><arg name="year">2010</arg><arg name="publisher">Springer</arg><arg name="location">Heidelberg</arg><arg name="isbn">978-3-642-01222-8</arg><arg name="pages">159–170</arg><arg name="url">http://link.springer.com/book/10.1007/978-3-642-01222-8</arg><arg name="editor">Martens, UM</arg><arg name="chapter">11 5-Azacytidine/Azacitidine</arg><arg name="doi">10.1007/978-3-642-01222-8</arg><arg name="volume">184</arg><arg name="series">Recent Results in Cancer Research</arg></template></extension></tablecell><tablecell><link><target>Myelodysplastic syndromes</target></link>,<space/><link><target>acute myeloid leukaemia</target></link><space/>and<space/><link><target>chronic myeloid leukaemia</target></link></tablecell><tablecell><link><target>Myelosuppression</target></link>,<space/><link><target>kidney failure</target></link><space/>(uncommon/rare),<space/><link><target>renal tubular acidosis</target></link><space/>and<space/><link><target>hypokalaemia</target></link>.</tablecell></tablerow><tablerow><tablecell><link><target>Capecitabine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Chintala</arg><arg name="first">L</arg><arg name="author2">Vaka, S<space/></arg><arg name="author3">Baranda, J<space/></arg><arg name="author4"><space/>Williamson, SK<space/></arg><arg name="title">Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?</arg><arg name="journal">Oncology Reviews</arg><arg name="date">9 April 2011</arg><arg name="volume">5</arg><arg name="issue">2</arg><arg name="pages">129–140</arg><arg name="doi">10.1007/s12156-011-0074-3</arg><arg name="url">http://link.springer.com/content/pdf/10.1007%2Fs12156-011-0074-3.pdf</arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bang YJ<space/></arg><arg name="title"><space/>Capecitabine in gastric cancer<space/></arg><arg name="journal"><space/>Expert Review of Anticancer Therapy<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1791–1806<space/></arg><arg name="date"><space/>Dec 2011<space/></arg><arg name="pmid"><space/>22117147<space/></arg><arg name="doi"><space/>10.1586/era.11.172<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hirsch BR, Zafar SY<space/></arg><arg name="title"><space/>Capecitabine in the management of colorectal cancer<space/></arg><arg name="journal"><space/>Cancer Management and Research<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="pages"><space/>79–89<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>21629830<space/></arg><arg name="pmc"><space/>3097797<space/></arg><arg name="doi"><space/>10.2147/CMR.S11250<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Quidde J, Arnold D, Stein A<space/></arg><arg name="title"><space/>Clinical management of localized colon cancer with capecitabine<space/></arg><arg name="journal"><space/>Clinical Medicine Insights. Oncology<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="pages"><space/>363–73<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>23170068<space/></arg><arg name="pmc"><space/>3498969<space/></arg><arg name="doi"><space/>10.4137/CMO.S8194<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fernández-Martos C, Nogué M, Cejas P, Moreno-García V, Machancoses AH, Feliu J<space/></arg><arg name="title"><space/>The role of capecitabine in locally advanced rectal cancer treatment: an update<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>72<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1057–1073<space/></arg><arg name="date"><space/>May 2012<space/></arg><arg name="pmid"><space/>22621694<space/></arg><arg name="doi"><space/>10.2165/11633870-000000000-00000<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ma Y, Tang L, Wang HX, Xu YC, Ma Y, Zhang FC<space/></arg><arg name="title"><space/>Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity<space/></arg><arg name="journal"><space/>Journal of Clinical Pharmacy and Therapeutics<space/></arg><arg name="volume"><space/>37<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>266–275<space/></arg><arg name="date"><space/>Jun 2012<space/></arg><arg name="pmid"><space/>21950464<space/></arg><arg name="doi"><space/>10.1111/j.1365-2710.2011.01289.x<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>O'Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, Harbeck N<space/></arg><arg name="title"><space/>Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer<space/></arg><arg name="journal"><space/>The Oncologist<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>476–84<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22418569<space/></arg><arg name="pmc"><space/>3336834<space/></arg><arg name="doi"><space/>10.1634/theoncologist.2011-0281<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Petrelli F, Cabiddu M, Barni S<space/></arg><arg name="title"><space/>5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials<space/></arg><arg name="journal"><space/>Medical Oncology<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>1020–1029<space/></arg><arg name="date"><space/>Jun 2012<space/></arg><arg name="pmid"><space/>21516482<space/></arg><arg name="doi"><space/>10.1007/s12032-011-9958-0<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Barrios</arg><arg name="first">CH</arg><arg name="title">The Role of Capecitabine in Early Stage Breast Cancer</arg><arg name="journal">Current Breast Cancer Reports</arg><arg name="date">26 January 2012</arg><arg name="volume">4</arg><arg name="issue">1</arg><arg name="pages">22–29</arg><arg name="doi">10.1007/s12609-011-0067-z</arg></template></extension></tablecell><tablecell><link><target>Uracil</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>Fluorouracil</target><trail>prodrug</trail></link></tablecell><tablecell><link><target>Breast cancer</target><part>Breast</part></link>,<space/><link><target>Colorectal cancer</target><part>colorectal</part></link>,<space/><link><target>Stomach cancer</target><part>gastric</part></link><space/>and<space/><link><target>oesophageal cancer</target></link></tablecell><tablecell>Myelosuppression, cardiotoxicity,<space/><link><target>hypertriglyceridaemia</target></link>, GI haemorrhage (uncommon), cerebellar syndrome (uncommon), encephalopathy (uncommon) and diarrhoea.</tablecell></tablerow><tablerow><tablecell><link><target>Carmofur</target></link></tablecell><tablecell>N/A</tablecell><tablecell><link><target>Uracil</target></link><space/>analogue</tablecell><tablecell>N/A</tablecell><tablecell>PO</tablecell><tablecell><link><target>Fluorouracil</target></link><space/>prodrug</tablecell><tablecell>Colorectal, breast and ovarian cancer</tablecell><tablecell>Myelosuppression, neurotoxicity and diarrhoea.</tablecell></tablerow><tablerow><tablecell><link><target>Cladribine</target></link></tablecell><tablecell><bold>MS:</bold><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Comi G, Hartung HP, Kurukulasuriya NC, Greenberg SJ, Scaramozza M<space/></arg><arg name="title"><space/>Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>123–36<space/></arg><arg name="date"><space/>Jan 2013<space/></arg><arg name="pmid"><space/>23256518<space/></arg><arg name="doi"><space/>10.1517/14656566.2013.754012<space/></arg></template></extension><extension extension_name='ref' name="Spurgeon 116981"><template><target>cite journal</target><arg name="author"><space/>Spurgeon S, Yu M, Phillips JD, Epner EM<space/></arg><arg name="title"><space/>Cladribine: not just another purine analogue?<space/></arg><arg name="journal"><space/>Expert Opinion on Investigational Drugs<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1169–81<space/></arg><arg name="date"><space/>Aug 2009<space/></arg><arg name="pmid"><space/>19604118<space/></arg><arg name="doi"><space/>10.1517/13543780903071038<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Bagnato</arg><arg name="first">F</arg><arg name="author2">Pirko, I</arg><arg name="title">Novel Agents and Emerging Treatment Strategies in Multiple Sclerosis. What Role for Cladribine?</arg><arg name="journal">Clinical Medicine Insights: Therapeutics</arg><arg name="date">October 2011</arg><arg name="pages">425</arg><arg name="doi">10.4137/CMT.S6456</arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Leist TP, Weissert R<space/></arg><arg name="title"><space/>Cladribine: mode of action and implications for treatment of multiple sclerosis<space/></arg><arg name="journal"><space/>Clinical Neuropharmacology<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>28–35<space/></arg><arg name="date"><space/>January–February 2011<space/></arg><arg name="pmid"><space/>21242742<space/></arg><arg name="doi"><space/>10.1097/WNF.0b013e318204cd90<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC<space/></arg><arg name="title"><space/>Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine<space/></arg><arg name="journal"><space/>Drug Design, Development and Therapy<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="pages"><space/>117–26<space/></arg><arg name="date"><space/>21 July 2010<space/></arg><arg name="pmid"><space/>20689698<space/></arg><arg name="pmc"><space/>2915536<space/></arg><arg name="doi"><space/>10.2147/DDDT.S6627<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sigal DS, Miller HJ, Schram ED, Saven A<space/></arg><arg name="title"><space/>Beyond hairy cell: the activity of cladribine in other hematologic malignancies<space/></arg><arg name="journal"><space/>Blood<space/></arg><arg name="volume"><space/>116<space/></arg><arg name="issue"><space/>16<space/></arg><arg name="pages"><space/>2884–96<space/></arg><arg name="date"><space/>Oct 2010<space/></arg><arg name="pmid"><space/>20634380<space/></arg><arg name="doi"><space/>10.1182/blood-2010-02-246140<space/></arg><arg name="url"><space/>http://bloodjournal.hematologylibrary.org/content/116/16/2884.full.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sipe JC<space/></arg><arg name="title"><space/>Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis<space/></arg><arg name="journal"><space/>Expert Review of Neurotherapeutics<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>365–75<space/></arg><arg name="date"><space/>Mar 2010<space/></arg><arg name="pmid"><space/>20187859<space/></arg><arg name="doi"><space/>10.1586/ern.10.12<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC<space/></arg><arg name="title"><space/>Development of oral cladribine for the treatment of multiple sclerosis<space/></arg><arg name="journal"><space/>Journal of Neurology<space/></arg><arg name="volume"><space/>257<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>163–70<space/></arg><arg name="date"><space/>Feb 2010<space/></arg><arg name="pmid"><space/>19921304<space/></arg><arg name="doi"><space/>10.1007/s00415-009-5359-0<space/></arg></template></extension><extension extension_name='ref' name="Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP 6875"><template><target>cite journal</target><arg name="author"><space/>Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP<space/></arg><arg name="title"><space/>Cladribine as a therapeutic option in multiple sclerosis<space/></arg><arg name="journal"><space/>Clinical Immunology<space/></arg><arg name="volume"><space/>142<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>68–75<space/></arg><arg name="date"><space/>Jan 2012<space/></arg><arg name="pmid"><space/>21733757<space/></arg><arg name="doi"><space/>10.1016/j.clim.2011.05.009<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Warnke C, Wiendl H, Hartung HP, Stüve O, Kieseier BC<space/></arg><arg name="title"><space/>Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine<space/></arg><arg name="journal"><space/>Drug Design, Development and Therapy<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="pages"><space/>117–126<space/></arg><arg name="date"><space/>21 July 2010<space/></arg><arg name="pmid"><space/>20689698<space/></arg><arg name="pmc"><space/>2915536<space/></arg><arg name="doi"><space/>10.2147/DDDT.S6627<space/></arg></template></extension><xhtml:br></xhtml:br><bold>Cancer:</bold><xhtml:br></xhtml:br><extension extension_name='ref' name="Spurgeon 116981"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bryson HM, Sorkin EM<space/></arg><arg name="title"><space/>Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>46<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>872–894<space/></arg><arg name="date"><space/>Nov 1993<space/></arg><arg name="pmid"><space/>7507037<space/></arg><arg name="doi"><space/>10.2165/00003495-199346050-00007<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Robak T, Korycka A, Robak E<space/></arg><arg name="title"><space/>Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies<space/></arg><arg name="journal"><space/>Recent Patents on Anti-Cancer Drug Discovery<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>23–38<space/></arg><arg name="date"><space/>Jan 2006<space/></arg><arg name="pmid"><space/>18221024<space/></arg><arg name="doi"><space/>10.2174/157489206775246467<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hentosh P, Peffley DM<space/></arg><arg name="title"><space/>The cladribine conundrum: deciphering the drug's mechanism of action<space/></arg><arg name="journal"><space/>Expert Opinion on Drug Metabolism & Toxicology<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>75–81<space/></arg><arg name="date"><space/>Jan 2010<space/></arg><arg name="pmid"><space/>19968576<space/></arg><arg name="doi"><space/>10.1517/17425250903393745<space/></arg></template></extension></tablecell><tablecell><link><target>Adenosine</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO, SC, IV</tablecell><tablecell><link><target>DNA methyltransferase</target><trail>inhibitor</trail></link>, metabolites incorporate themselves into DNA.<extension extension_name='ref' name="Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP 6875"></extension></tablecell><tablecell><link><target>Hairy cell leukaemia</target></link>,<space/><link><target>chronic lymphocytic leukaemia</target></link>,<space/><link><target>Waldenstrom macroglobulinaemia</target></link><space/>and<space/><link><target>multiple sclerosis</target></link>.</tablecell><tablecell>Myelosuppression,<space/><link><target>haemolytic anaemia</target></link><space/>(uncommon), neurotoxicity (rare), renal impairment (rare), pulmonary interstitial infiltrates (rare),<space/><link><target>Stevens-Johnson syndrome</target></link><space/>(rare) and<space/><link><target>toxic epidermal necrolysis</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Clofarabine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S<space/></arg><arg name="title"><space/>Clofarabine: past, present, and future<space/></arg><arg name="journal"><space/>Leukemia & Lymphoma<space/></arg><arg name="volume"><space/>48<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>1922–30<space/></arg><arg name="date"><space/>Oct 2007<space/></arg><arg name="pmid"><space/>17852710<space/></arg><arg name="doi"><space/>10.1080/10428190701545644<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Harned TM, Gaynon PS<space/></arg><arg name="title"><space/>Treating refractory leukemias in childhood, role of clofarabine<space/></arg><arg name="journal"><space/>Therapeutics and Clinical Risk Management<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>327–36<space/></arg><arg name="date"><space/>Apr 2008<space/></arg><arg name="pmid"><space/>18728851<space/></arg><arg name="pmc"><space/>2504075<space/></arg><arg name="doi"><space/>10.2147/TCRM.S2941<space/></arg><arg name="doi_brokendate"><space/>2015-04-14<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Thomas X, Raffoux E, Elhamri M, Lobe I, Cannas G, Dombret H<space/></arg><arg name="title"><space/>Clofarabine for the treatment of adult acute myeloid leukemia<space/></arg><arg name="journal"><space/>Future Oncology<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1197–210<space/></arg><arg name="date"><space/>Oct 2009<space/></arg><arg name="pmid"><space/>19852733<space/></arg><arg name="doi"><space/>10.2217/fon.09.105<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lech-Maranda E, Korycka A, Robak T<space/></arg><arg name="title"><space/>Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity<space/></arg><arg name="journal"><space/>Mini Reviews in Medicinal Chemistry<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>805–812<space/></arg><arg name="date"><space/>Jun 2009<space/></arg><arg name="pmid"><space/>19519505<space/></arg><arg name="doi"><space/>10.2174/138955709788452586<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Jeha S<space/></arg><arg name="title"><space/>Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine<space/></arg><arg name="journal"><space/>Hematology/Oncology Clinics of North America<space/></arg><arg name="volume"><space/>23<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>1137–44, viii<space/></arg><arg name="date"><space/>Oct 2009<space/></arg><arg name="pmid"><space/>19825457<space/></arg><arg name="doi"><space/>10.1016/j.hoc.2009.07.011<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sampat K, Kantarjian H, Borthakur G<space/></arg><arg name="title"><space/>Clofarabine: emerging role in leukemias<space/></arg><arg name="journal"><space/>Expert Opinion on Investigational Drugs<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>1559–1564<space/></arg><arg name="date"><space/>Oct 2009<space/></arg><arg name="pmid"><space/>19715446<space/></arg><arg name="doi"><space/>10.1517/13543780903173222<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Larson ML, Venugopal P<space/></arg><arg name="title"><space/>Clofarabine: a new treatment option for patients with acute myeloid leukemia<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1353–1357<space/></arg><arg name="date"><space/>Jun 2009<space/></arg><arg name="pmid"><space/>19463072<space/></arg><arg name="doi"><space/>10.1517/14656560902997990<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ghanem H, Jabbour E, Faderl S, Ghandhi V, Plunkett W, Kantarjian H<space/></arg><arg name="title"><space/>Clofarabine in leukemia<space/></arg><arg name="journal"><space/>Expert Review of Hematology<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>15–22<space/></arg><arg name="date"><space/>Feb 2010<space/></arg><arg name="pmid"><space/>21082931<space/></arg><arg name="doi"><space/>10.1586/ehm.09.70<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ghanem H, Kantarjian H, Ohanian M, Jabbour E<space/></arg><arg name="title"><space/>The role of clofarabine in acute myeloid leukemia<space/></arg><arg name="journal"><space/>Leukemia & Lymphoma<space/></arg><arg name="volume"><space/>54<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>688–698<space/></arg><arg name="date"><space/>Apr 2013<space/></arg><arg name="pmid"><space/>22957815<space/></arg><arg name="doi"><space/>10.3109/10428194.2012.726722<space/></arg><arg name="isbn"><space/>978-0-12-374340-4<space/></arg></template></extension></tablecell><tablecell><link><target>Deoxyadenosine</target><trail>analogue</trail></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>Ribonucleotide reductase</target></link><space/>and<space/><link><target>DNA polymerase</target></link><space/>inhibitor.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ghanem H, Kantarjian H, Ohanian M, Jabbour E<space/></arg><arg name="title"><space/>The role of clofarabine in acute myeloid leukemia<space/></arg><arg name="journal"><space/>Leukemia & Lymphoma<space/></arg><arg name="volume"><space/>54<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>688–698<space/></arg><arg name="date"><space/>Apr 2013<space/></arg><arg name="pmid"><space/>22957815<space/></arg><arg name="doi"><space/>10.3109/10428194.2012.726722<space/></arg></template></extension></tablecell><tablecell><link><target>Acute lymphoblastic leukaemia</target></link><space/>and<space/><link><target>acute myeloid leukaemia</target></link></tablecell><tablecell>Myelosuppression,<space/><link><target>hypokalaemia</target></link>,<space/><link><target>cytokine release syndrome</target></link>,<space/><link><target>Stevens-Johnson syndrome</target></link>(uncommon),<space/><link><target>toxic epidermal necrolysis</target></link><space/>(uncommon) and<space/><link><target>pancreatitis</target></link><space/>(uncommon)</tablecell></tablerow><tablerow><tablecell><link><target>Cytarabine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hamada A, Kawaguchi T, Nakano M<space/></arg><arg name="title"><space/>Clinical pharmacokinetics of cytarabine formulations<space/></arg><arg name="journal"><space/>Clinical Pharmacokinetics<space/></arg><arg name="volume"><space/>41<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>705–718<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12162758<space/></arg><arg name="doi"><space/>10.2165/00003088-200241100-00002<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Cros E, Jordheim L, Dumontet C, Galmarini CM<space/></arg><arg name="title"><space/>Problems related to resistance to cytarabine in acute myeloid leukemia<space/></arg><arg name="journal"><space/>Leukemia & Lymphoma<space/></arg><arg name="volume"><space/>45<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1123–1132<space/></arg><arg name="date"><space/>Jun 2004<space/></arg><arg name="pmid"><space/>15359991<space/></arg><arg name="doi"><space/>10.1080/1042819032000159861<space/></arg></template></extension><extension extension_name='ref'><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="title">Profiles of drug substances, excipients and related methodology</arg><arg name="year">2009</arg><arg name="publisher">Academic</arg><arg name="location">London</arg><arg name="isbn">978-0-12-374340-4</arg><arg name="url">https://www.researchgate.net/publication/229062076_Cytarabine_Comprehensive_Profile/file/9fcfd4ffdce4e302f4.pdf</arg><arg name="editor-last">Brittain<space/></arg><arg name="editor-first">HG</arg><arg name="chapter">2 Cytarabine</arg><arg name="doi">10.1016/S0099-5428(08)00002-6</arg><arg name="issn">0099-5428</arg><arg name="pages">37–113</arg><arg name="format">PDF</arg><arg name="last1">El-Subbagh</arg><arg name="first1">HI</arg><arg name="last2">Al-Badr</arg><arg name="first2"><space/>AA</arg></template></extension></tablecell><tablecell><link><target>Cytidine</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>SC, IM, IV, IT</tablecell><tablecell><link><target>DNA polymerase</target></link><space/>inhibitor, S-phase specific. Incorporates its metabolites into DNA.</tablecell><tablecell><link><target>Acute myeloid leukaemia</target></link>,<space/><link><target>acute lymphoblastic leukaemia</target></link>,<space/><link><target>chronic myeloid leukaemia</target></link>,<space/><link><target>lymphomas</target></link>,<space/><link><target>progressive multifocal leucoencephalopathy</target></link><space/>and meningeal leukaemia</tablecell><tablecell>Myelosuppression, GI bleeds,<space/><link><target>pancreatitis</target></link><space/>(uncommon/rare),<space/><link><target>anaphylaxis</target></link><space/>(uncommon/rare),<space/><link><target>pericarditis</target></link><space/>(uncommon/rare) and<space/><link><target>conjunctivitis</target></link><space/>(uncommon/rare).<space/><bold>High dose:</bold><space/>cerebral and cerebellar dysfunction, ocular toxicity, pulmonary toxicity, severe GI ulceration and<space/><link><target>peripheral neuropathy</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Decitabine</target></link></tablecell><tablecell><extension extension_name='ref' name="Epi"></extension><extension extension_name='ref' name="Epi2"></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">Dacogen (decitabine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">10 February 2014</arg><arg name="url">http://reference.medscape.com/drug/dacogen-decitabine-342091#showall</arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G<space/></arg><arg name="title"><space/>A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation<space/></arg><arg name="journal"><space/>Transplantation<space/></arg><arg name="volume"><space/>59<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>1472–1481<space/></arg><arg name="date"><space/>Mar 1995<space/></arg><arg name="pmid"><space/>7701577<space/></arg><arg name="doi"><space/>10.1080/10428190701471981<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Oki Y, Aoki E, Issa JP<space/></arg><arg name="title"><space/>Decitabine--bedside to bench<space/></arg><arg name="journal"><space/>Critical Reviews in Oncology/Hematology<space/></arg><arg name="volume"><space/>61<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>140–152<space/></arg><arg name="date"><space/>Feb 2007<space/></arg><arg name="pmid"><space/>17023173<space/></arg><arg name="doi"><space/>10.1016/j.critrevonc.2006.07.010<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H<space/></arg><arg name="title"><space/>Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies<space/></arg><arg name="journal"><space/>Cancer<space/></arg><arg name="volume"><space/>112<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>2341–51<space/></arg><arg name="date"><space/>Jun 2008<space/></arg><arg name="pmid"><space/>18398832<space/></arg><arg name="doi"><space/>10.1002/cncr.23463<space/></arg><arg name="url"><space/>http://onlinelibrary.wiley.com/doi/10.1002/cncr.23463/pdf<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F<space/></arg><arg name="title"><space/>Decitabine in the treatment of myelodysplastic syndromes<space/></arg><arg name="journal"><space/>Expert Review of Anticancer Therapy<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>9–22<space/></arg><arg name="date"><space/>Jan 2010<space/></arg><arg name="pmid"><space/>20014881<space/></arg><arg name="pmc"><space/>2376088<space/></arg><arg name="doi"><space/>10.1586/era.09.164<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Daskalakis M, Blagitko-Dorfs N, Hackanson B<space/></arg><arg name="title"><space/>Decitabine<space/></arg><arg name="journal"><space/>Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer<space/></arg><arg name="volume"><space/>184<space/></arg><arg name="pages"><space/>131–57<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20072836<space/></arg><arg name="doi"><space/>10.1007/978-3-642-01222-8_10<space/></arg><arg name="isbn"><space/>978-3-642-01221-1<space/></arg><arg name="series"><space/>Recent Results in Cancer Research<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Marks PW<space/></arg><arg name="title"><space/>Decitabine for acute myeloid leukemia<space/></arg><arg name="journal"><space/>Expert Review of Anticancer Therapy<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>299–305<space/></arg><arg name="date"><space/>Mar 2012<space/></arg><arg name="pmid"><space/>22369322<space/></arg><arg name="doi"><space/>10.1586/era.11.207<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Garcia JS, Jain N, Godley LA<space/></arg><arg name="title"><space/>An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes<space/></arg><arg name="journal"><space/>OncoTargets and Therapy<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="pages"><space/>1–13<space/></arg><arg name="date"><space/>June 2010<space/></arg><arg name="pmid"><space/>20616953<space/></arg><arg name="pmc"><space/>2895778<space/></arg><arg name="doi"><space/>10.2147/OTT.S7222<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Curran MP<space/></arg><arg name="title"><space/>Decitabine: a review of its use in older patients with acute myeloid leukaemia<space/></arg><arg name="journal"><space/>Drugs & Aging<space/></arg><arg name="volume"><space/>30<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>447–458<space/></arg><arg name="date"><space/>Jun 2013<space/></arg><arg name="pmid"><space/>23580320<space/></arg><arg name="doi"><space/>10.1007/s40266-013-0084-x<space/></arg></template></extension></tablecell><tablecell><link><target>Cytidine</target></link><space/>analogue.</tablecell><tablecell>D (US)</tablecell><tablecell>IV</tablecell><tablecell>DNA methyltransferase inhibitor.</tablecell><tablecell>Myelodysplastic syndrome,<space/><link><target>sickle cell anaemia</target></link><space/>(orphan), acute myeloid leukaemia and chronic myeloid leukaemia.</tablecell><tablecell>Myelosuppression, hyperglycaemia, hypoalbuminaemia, hypomagnesaemia, hypokalaemia, hyperkalaemia and<space/><link><target>thrombocythaemia</target></link>.</tablecell></tablerow><tablerow><tablecell><link><target>Floxuridine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">FUDR (floxuridine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">10 February 2014</arg><arg name="url">http://reference.medscape.com/drug/fudr-floxuridine-342093#showall</arg></template></extension></tablecell><tablecell><link><target>Uracil</target></link><space/>analogue</tablecell><tablecell>D (US)</tablecell><tablecell>IA</tablecell><tablecell><link><target>Fluorouracil</target></link><space/>analogue.</tablecell><tablecell>Metastatic GI adenocarcinoma and stomach cancer</tablecell><tablecell>Myelosuppression.</tablecell></tablerow><tablerow><tablecell><link><target>Fludarabine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Montillo M, Ricci F, Tedeschi A<space/></arg><arg name="title"><space/>Role of fludarabine in hematological malignancies<space/></arg><arg name="journal"><space/>Expert Review of Anticancer Therapy<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1141–61<space/></arg><arg name="date"><space/>Sep 2006<space/></arg><arg name="pmid"><space/>17020450<space/></arg><arg name="doi"><space/>10.1586/14737140.6.9.1141<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Anderson VR, Perry CM<space/></arg><arg name="title"><space/>Fludarabine: a review of its use in non-Hodgkin's lymphoma<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>67<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1633–55<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17661532<space/></arg><arg name="doi"><space/>10.2165/00003495-200767110-00008<space/></arg></template></extension><extension extension_name='ref' name="Ricci 187207"><template><target>cite journal</target><arg name="author"><space/>Ricci F, Tedeschi A, Morra E, Montillo M<space/></arg><arg name="title"><space/>Fludarabine in the treatment of chronic lymphocytic leukemia: a review<space/></arg><arg name="journal"><space/>Therapeutics and Clinical Risk Management<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>187–207<space/></arg><arg name="date"><space/>Feb 2009<space/></arg><arg name="pmid"><space/>19436622<space/></arg><arg name="pmc"><space/>2697528<space/></arg><arg name="doi"><space/>10.2147/TCRM.S3688<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref' name="Ricci 187207"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Souchet-Compain L, Nguyen S, Choquet S, Leblond V<space/></arg><arg name="title"><space/>Fludarabine in Waldenstrom's macroglobulinemia<space/></arg><arg name="journal"><space/>Expert Review of Hematology<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>229–37<space/></arg><arg name="date"><space/>Jun 2013<space/></arg><arg name="pmid"><space/>23782076<space/></arg><arg name="doi"><space/>10.1586/ehm.13.17<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Plosker GL, Figgitt DP<space/></arg><arg name="title"><space/>Oral fludarabine<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>63<space/></arg><arg name="issue"><space/>21<space/></arg><arg name="pages"><space/>2317–23<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14524733<space/></arg><arg name="doi"><space/>10.2165/00003495-200363210-00004<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lukenbill J, Kalaycio M<space/></arg><arg name="title"><space/>Fludarabine: a review of the clear benefits and potential harms<space/></arg><arg name="journal"><space/>Leukemia Research<space/></arg><arg name="volume"><space/>37<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>986–94<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>23787174<space/></arg><arg name="doi"><space/>10.1016/j.leukres.2013.05.004<space/></arg></template></extension></tablecell><tablecell><link><target>Adenosine</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO, IV</tablecell><tablecell><link><target>DNA polymerase</target></link><space/>and<space/><link><target>ribonucleotide reductase</target></link><space/>inhibitor.</tablecell><tablecell><link><target>Acute myeloid leukaemia</target></link>,<space/><link><target>chronic lymphocytic leukaemia</target></link>,<space/><link><target>non-Hodgkin lymphoma</target></link><space/>and<space/><link><target>Waldenstrom macroglobulinaemia</target></link>.</tablecell><tablecell>Myelosuppression,<space/><link><target>hyperglycaemia</target></link>, GI bleeds (uncommon),<space/><link><target>pneumonitis</target></link><space/>(uncommon),<space/><link><target>haemolytic anaemia</target></link><space/>(uncommon), severe neurotoxicity (rare),<space/><link><target>haemorrhagic cystitis</target></link><space/>(rare),<space/><link><target>Stevens-Johnson syndrome</target></link><space/>(rare) and<space/><link><target>Toxic Epidermal Necrolysis</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Fluorouracil</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Grem JL<space/></arg><arg name="title"><space/>5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development<space/></arg><arg name="journal"><space/>Investigational New Drugs<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>299–313<space/></arg><arg name="date"><space/>Nov 2000<space/></arg><arg name="pmid"><space/>11081567<space/></arg><arg name="doi"><space/>10.1023/A:1006416410198<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Abraham LM, Selva D, Casson R, Leibovitch I<space/></arg><arg name="title"><space/>The clinical applications of fluorouracil in ophthalmic practice<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>67<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>237–55<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17284086<space/></arg><arg name="doi"><space/>10.2165/00003495-200767020-00005<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Patel PA<space/></arg><arg name="title"><space/>Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer<space/></arg><arg name="journal"><space/>Anti-Cancer Drugs<space/></arg><arg name="volume"><space/>22<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>311–6<space/></arg><arg name="date"><space/>Apr 2011<space/></arg><arg name="pmid"><space/>21301320<space/></arg><arg name="doi"><space/>10.1097/CAD.0b013e3283441a63<space/></arg></template></extension></tablecell><tablecell><link><target>Uracil</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>Thymidylate synthase</target></link><space/>inhibitor.</tablecell><tablecell><link><target>Anal cancer</target><part>Anal</part></link>,<space/><link><target>Breast cancer</target><part>breast</part></link>,<space/><link><target>Colorectal cancer</target><part>colorectal</part></link>,<space/><link><target>Gastric cancer</target><part>gastric</part></link>,<space/><link><target>Head and neck cancer</target><part>head and neck</part></link>,<space/><link><target>Oesophageal cancer</target><part>oesophageal</part></link><space/>and<space/><link><target>pancreatic cancer</target></link>.<space/><link><target>Bowen's disease</target></link><space/>and<space/><link><target>actinic keratoses</target></link>.</tablecell><tablecell>Myelosuppression, diarrhoea, cardiotoxicity, GI ulceration and bleeding (uncommon), cerebellar syndrome (uncommon), encephalopathy (uncommon) and<space/><link><target>anaphylaxis</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Gemcitabine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Noble S, Goa KL<space/></arg><arg name="title"><space/>Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>54<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>447–472<space/></arg><arg name="date"><space/>Sep 1997<space/></arg><arg name="pmid"><space/>9279506<space/></arg><arg name="doi"><space/>10.2165/00003495-199754030-00009<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Aapro MS, Martin C, Hatty S<space/></arg><arg name="title"><space/>Gemcitabine--a safety review<space/></arg><arg name="journal"><space/>Anti-Cancer Drugs<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>191–201<space/></arg><arg name="date"><space/>Mar 1998<space/></arg><arg name="pmid"><space/>9625429<space/></arg><arg name="doi"><space/>10.1097/00001813-199803000-00001<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ryan CW, Vogelzang NJ<space/></arg><arg name="title"><space/>Gemcitabine in the treatment of bladder cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>547–553<space/></arg><arg name="date"><space/>Mar 2000<space/></arg><arg name="pmid"><space/>11249537<space/></arg><arg name="doi"><space/>10.1517/14656566.1.3.547<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Manegold C, Zatloukal P, Krejcy K, Blatter J<space/></arg><arg name="title"><space/>Gemcitabine in non-small cell lung cancer (NSCLC)<space/></arg><arg name="journal"><space/>Investigational New Drugs<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>29–42<space/></arg><arg name="date"><space/>Feb 2000<space/></arg><arg name="pmid"><space/>10830139<space/></arg><arg name="doi"><space/>10.1023/A:1006327729228<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Oettle H, Arnold D, Hempel C, Riess H<space/></arg><arg name="title"><space/>The role of gemcitabine alone and in combination in the treatment of pancreatic cancer<space/></arg><arg name="journal"><space/>Anti-Cancer Drugs<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>771–86<space/></arg><arg name="date"><space/>Nov 2000<space/></arg><arg name="pmid"><space/>11142685<space/></arg><arg name="doi"><space/>10.1097/00001813-200011000-00001<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Crinò L, Cappuzzo F<space/></arg><arg name="title"><space/>Gemcitabine in non-small cell lung cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>745–753<space/></arg><arg name="date"><space/>Jun 2002<space/></arg><arg name="pmid"><space/>12036414<space/></arg><arg name="doi"><space/>10.1517/14656566.3.6.745<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Wong A, Soo RA, Yong WP, Innocenti F<space/></arg><arg name="title"><space/>Clinical pharmacology and pharmacogenetics of gemcitabine<space/></arg><arg name="journal"><space/>Drug Metabolism Reviews<space/></arg><arg name="volume"><space/>41<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>77–88<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19514966<space/></arg><arg name="doi"><space/>10.1080/03602530902741828<space/></arg></template></extension></tablecell><tablecell><link><target>Deoxycytidine</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>DNA synthesis inhibitor, induces apoptosis specifically in S-phase.</tablecell><tablecell><link><target>bladder cancer</target><part>Bladder</part></link>,<space/><link><target>breast cancer</target><part>breast</part></link>,<space/><link><target>nasopharyngeal cancer</target><part>nasopharyngeal</part></link>,<space/><link><target>Non-small cell lung cancer</target><part>non-small cell lung</part></link>,<space/><link><target>ovarian cancer</target><part>ovarian</part></link><space/>and<space/><link><target>pancreatic cancer</target></link>,<space/><link><target>lymphomas</target></link><space/>and<space/><link><target>inflammatory bowel disease</target></link>.</tablecell><tablecell>Myelosuppression, pulmonary toxicity,<space/><link><target>kidney failure</target></link><space/>(rare),<space/><link><target>haemolytic uraemic syndrome</target></link>(rare),<space/><link><target>thrombotic thrombocytopenic purpura</target></link><space/>(rare), anaphylactoid reaction (rare), reversible posterior leucoencephalopathy syndrome (rare),<space/><link><target>myocardial infarction</target></link><space/>(rare) and heart failure (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Mercaptopurine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lennard L<space/></arg><arg name="title"><space/>The clinical pharmacology of 6-mercaptopurine<space/></arg><arg name="journal"><space/>European Journal of Clinical Pharmacology<space/></arg><arg name="volume"><space/>43<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>329–339<space/></arg><arg name="date"><space/>October 1992<space/></arg><arg name="pmid"><space/>1451710<space/></arg><arg name="doi"><space/>10.1007/BF02220605<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bradford K, Shih DQ<space/></arg><arg name="title"><space/>Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease<space/></arg><arg name="journal"><space/>World Journal of Gastroenterology<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>37<space/></arg><arg name="pages"><space/>4166–73<space/></arg><arg name="date"><space/>Oct 2011<space/></arg><arg name="pmid"><space/>22072847<space/></arg><arg name="pmc"><space/>3208360<space/></arg><arg name="doi"><space/>10.3748/wjg.v17.i37.4166<space/></arg></template></extension></tablecell><tablecell><link><target>Hypoxanthine</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Purine synthesis inhibitor.</tablecell><tablecell><link><target>Acute lymphoblastic leukaemia</target></link>,<space/><link><target>acute promyelocytic leukaemia</target></link>,<space/><link><target>lymphoblastic lymphoma</target></link><space/>and<space/><link><target>inflammatory bowel disease</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK<space/></arg><arg name="title"><space/>Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis<space/></arg><arg name="journal"><space/>The Cochrane Database of Systematic Reviews<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="pages"><space/>CD000478<space/></arg><arg name="date"><space/>12 September 2012<space/></arg><arg name="pmid"><space/>22972046<space/></arg><arg name="doi"><space/>10.1002/14651858.CD000478.pub3<space/></arg><arg name="url"><space/>http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000478.pub3/pdf<space/></arg></template></extension></tablecell><tablecell>Myelosuppression, hepatotoxicity, GI ulceration (rare), pancreatitis (rare) and secondary leukaemia (rare) or myelodysplasia (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Nelarabine</target></link><extension extension_name='ref'><template><target>cite web</target><arg name="title">Arranon (nelarabine) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">11 February 2014</arg><arg name="url">http://reference.medscape.com/drug/arranon-nelarabine-342090#showall</arg></template></extension></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Reilly KM, Kisor DF<space/></arg><arg name="title"><space/>Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia<space/></arg><arg name="journal"><space/>OncoTargets and Therapy<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="pages"><space/>219–28<space/></arg><arg name="date"><space/>February 2009<space/></arg><arg name="pmid"><space/>20616909<space/></arg><arg name="pmc"><space/>2886323<space/></arg><arg name="doi">10.2147/ott.s4770</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>DeAngelo DJ<space/></arg><arg name="title"><space/>Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma<space/></arg><arg name="journal"><space/>Hematology/Oncology Clinics of North America<space/></arg><arg name="volume"><space/>23<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>1121–35, vii–viii<space/></arg><arg name="date"><space/>Oct 2009<space/></arg><arg name="pmid"><space/>19825456<space/></arg><arg name="doi"><space/>10.1016/j.hoc.2009.07.008<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Roecker AM, Stockert A, Kisor DF<space/></arg><arg name="title"><space/>Nelarabine in the treatment of refractory T-cell malignancies<space/></arg><arg name="journal"><space/>Clinical Medicine Insights. Oncology<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="pages"><space/>133–41<space/></arg><arg name="date"><space/>December 2010<space/></arg><arg name="pmid"><space/>21151585<space/></arg><arg name="pmc"><space/>2999959<space/></arg><arg name="doi"><space/>10.4137/CMO.S4364<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sanford M, Lyseng-Williamson KA<space/></arg><arg name="title"><space/>Nelarabine<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>68<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>439–47<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18318562<space/></arg><arg name="doi"><space/>10.2165/00003495-200868040-00004<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gandhi V, Plunkett W<space/></arg><arg name="title"><space/>Clofarabine and nelarabine: two new purine nucleoside analogs<space/></arg><arg name="journal"><space/>Current Opinion in Oncology<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>584–90<space/></arg><arg name="date"><space/>Nov 2006<space/></arg><arg name="pmid"><space/>16988579<space/></arg><arg name="doi"><space/>10.1097/01.cco.0000245326.65152.af<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Curbo S, Karlsson A<space/></arg><arg name="title"><space/>Nelarabine: a new purine analog in the treatment of hematologic malignancies<space/></arg><arg name="journal"><space/>Reviews on Recent Clinical Trials<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>185–92<space/></arg><arg name="date"><space/>Sep 2006<space/></arg><arg name="pmid"><space/>18473971<space/></arg><arg name="doi"><space/>10.2174/157488706778250104<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kline J, Larson RA<space/></arg><arg name="title"><space/>Nelarabine in the treatment of refractory T-cell malignant diseases<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>13<space/></arg><arg name="pages"><space/>1791–9<space/></arg><arg name="date"><space/>Sep 2006<space/></arg><arg name="pmid"><space/>16925505<space/></arg><arg name="doi"><space/>10.1517/14656566.7.13.1791<space/></arg></template></extension></tablecell><tablecell><link><target>Adenosine</target></link><space/>analogue</tablecell><tablecell>D (US)</tablecell><tablecell>IV</tablecell><tablecell>Purine synthesis inhibitor.</tablecell><tablecell><link><target>Acute lymphoblastic leukaemia</target></link><space/>and<space/><link><target>chronic lymphocytic leukaemia</target></link>.</tablecell><tablecell>Myelosuppression, pleural effusion, seizures, tumour lysis syndrome and a condition similar to<space/><link><target>Guillain-Barr syndrome</target></link>.</tablecell></tablerow><tablerow><tablecell><link><target>Pentostatin</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Grever MR, Doan CA, Kraut EH<space/></arg><arg name="title"><space/>Pentostatin in the treatment of hairy-cell leukemia<space/></arg><arg name="journal"><space/>Best Practice & Research. Clinical Haematology<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>91–9<space/></arg><arg name="date"><space/>Mar 2003<space/></arg><arg name="pmid"><space/>12670468<space/></arg><arg name="doi"><space/>10.1016/S1521-6926(03)00002-1<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Higman M, Vogelsang GB, Chen A<space/></arg><arg name="title"><space/>Pentostatin – pharmacology, immunology, and clinical effects in graft-versus-host disease<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>2605–2613<space/></arg><arg name="date"><space/>Dec 2004<space/></arg><arg name="pmid"><space/>15571477<space/></arg><arg name="doi"><space/>10.1517/14656566.5.12.2605<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ho AD, Hensel M<space/></arg><arg name="title"><space/>Pentostatin for the treatment of indolent lymphoproliferative disorders<space/></arg><arg name="journal"><space/>Seminars in Hematology<space/></arg><arg name="volume"><space/>43<space/></arg><arg name="issue"><space/>2 Suppl 2<space/></arg><arg name="pages"><space/>S2–10<space/></arg><arg name="date"><space/>Apr 2006<space/></arg><arg name="pmid"><space/>16549110<space/></arg><arg name="doi"><space/>10.1053/j.seminhematol.2005.12.005<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Grever MR<space/></arg><arg name="title"><space/>Pentostatin: impact on outcome in hairy cell leukemia<space/></arg><arg name="journal"><space/>Hematology/Oncology Clinics of North America<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>1099–1108<space/></arg><arg name="date"><space/>Oct 2006<space/></arg><arg name="pmid"><space/>16990110<space/></arg><arg name="doi"><space/>10.1016/j.hoc.2006.06.001<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sauter C, Lamanna N, Weiss MA<space/></arg><arg name="title"><space/>Pentostatin in chronic lymphocytic leukemia<space/></arg><arg name="journal"><space/>Expert Opinion on Drug Metabolism & Toxicology<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1217–22<space/></arg><arg name="date"><space/>Sep 2008<space/></arg><arg name="pmid"><space/>18721115<space/></arg><arg name="doi"><space/>10.1517/17425255.4.9.1217<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lamanna N, Kay NE<space/></arg><arg name="title"><space/>Pentostatin treatment combinations in chronic lymphocytic leukemia<space/></arg><arg name="journal"><space/>Clinical Advances in Hematology & Oncology<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>386–392<space/></arg><arg name="date"><space/>Jun 2009<space/></arg><arg name="pmid"><space/>19606074<space/></arg></template></extension></tablecell><tablecell><link><target>Adenosine</target></link><space/>analogue</tablecell><tablecell>D (US)</tablecell><tablecell>IV</tablecell><tablecell><link><target>Adenosine deaminase</target></link><space/>inhibitor.</tablecell><tablecell><link><target>Hairy cell leukaemia</target></link>, peripheral T-cell lymphoma (orphan), cutaneous T cell lymphoma (orphan) and chronic lymphocytic leukaemia (orphan).</tablecell><tablecell>Myelosuppression, neurotoxicity, immune hypersensitivity, hyponatraemia, thrombotic thrombocytopenic purpura and microangiopathic hemolytic anaemia.</tablecell></tablerow><tablerow><tablecell><link><target>Tegafur</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Wellington K, Goa KL<space/></arg><arg name="title"><space/>Oral tegafur/uracil<space/></arg><arg name="journal"><space/>Drugs & Aging<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>935–48; discussion 949–50<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="pmid"><space/>11888348<space/></arg><arg name="doi"><space/>10.2165/00002512-200118120-00005<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Takiuchi H, Ajani JA<space/></arg><arg name="title"><space/>Uracil-tegafur in gastric carcinoma: a comprehensive review<space/></arg><arg name="journal"><space/>Journal of Clinical Oncology<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>2877–85<space/></arg><arg name="date"><space/>Aug 1998<space/></arg><arg name="pmid"><space/>9704742<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ward SE, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT<space/></arg><arg name="title"><space/>The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer<space/></arg><arg name="journal"><space/>British Journal of Cancer<space/></arg><arg name="volume"><space/>95<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>27–34<space/></arg><arg name="date"><space/>Jul 2006<space/></arg><arg name="pmid"><space/>16804526<space/></arg><arg name="pmc"><space/>2360498<space/></arg><arg name="doi"><space/>10.1038/sj.bjc.6603215<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Casado E, Pfeiffer P, Feliu J, González-Barón M, Vestermark L, Jensen HA<space/></arg><arg name="title"><space/>UFT (tegafur-uracil) in rectal cancer<space/></arg><arg name="journal"><space/>Annals of Oncology<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1371–8<space/></arg><arg name="date"><space/>Aug 2008<space/></arg><arg name="pmid"><space/>18381370<space/></arg><arg name="doi"><space/>10.1093/annonc/mdn067<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ishikawa T<space/></arg><arg name="title"><space/>Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma<space/></arg><arg name="journal"><space/>World Journal of Gastroenterology<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>18<space/></arg><arg name="pages"><space/>2797–801<space/></arg><arg name="date"><space/>May 2008<space/></arg><arg name="pmid"><space/>18473401<space/></arg><arg name="pmc"><space/>2710718<space/></arg><arg name="doi"><space/>10.3748/wjg.14.2797<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Oba K<space/></arg><arg name="title"><space/>Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis<space/></arg><arg name="journal"><space/>International Journal of Clinical Oncology<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>85–9<space/></arg><arg name="date"><space/>Apr 2009<space/></arg><arg name="pmid"><space/>19390937<space/></arg><arg name="doi"><space/>10.1007/s10147-009-0877-4<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J, Abadie E, Pignatti F<space/></arg><arg name="title"><space/>The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP)<space/></arg><arg name="journal"><space/>The Oncologist<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>1451–7<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>21963999<space/></arg><arg name="pmc"><space/>3228070<space/></arg><arg name="doi"><space/>10.1634/theoncologist.2011-0224<space/></arg></template></extension></tablecell><tablecell><link><target>Fluorouracil</target><trail>analogue</trail></link></tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>Thymidylate</target></link><space/>synthase inhibitor.</tablecell><tablecell>Breast, colorectal cancer, gallbladder, gastrointestinal tract, head and neck, liver and pancreas cancer.</tablecell><tablecell>Myelosuppression, diarrhoea, neurotoxicity and hepatitis (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Tioguanine</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Estlin EJ<space/></arg><arg name="title"><space/>Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine<space/></arg><arg name="journal"><space/>Cancer Treatment Reviews<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>351–63<space/></arg><arg name="date"><space/>Dec 2001<space/></arg><arg name="pmid"><space/>11908928<space/></arg><arg name="doi"><space/>10.1053/ctrv.2002.0245<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Elgemeie GH<space/></arg><arg name="title"><space/>Thioguanine, mercaptopurine: their analogs and nucleosides as antimetabolites<space/></arg><arg name="journal"><space/>Current Pharmaceutical Design<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>31<space/></arg><arg name="pages"><space/>2627–42<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14529546<space/></arg><arg name="doi"><space/>10.2174/1381612033453677<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Duley JA, Florin TH<space/></arg><arg name="title"><space/>Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides<space/></arg><arg name="journal"><space/>Therapeutic Drug Monitoring<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>647–654<space/></arg><arg name="date"><space/>Oct 2005<space/></arg><arg name="pmid"><space/>16175140<space/></arg><arg name="doi"><space/>10.1097/01.ftd.0000169061.52715.3e<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>De Bruyne R, Portmann B, Samyn M, Bansal S, Knisely A, Mieli-Vergani G, Dhawan A<space/></arg><arg name="title"><space/>Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia<space/></arg><arg name="journal"><space/>Journal of Hepatology<space/></arg><arg name="volume"><space/>44<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>407–10<space/></arg><arg name="date"><space/>Feb 2006<space/></arg><arg name="pmid"><space/>16226335<space/></arg><arg name="doi"><space/>10.1016/j.jhep.2005.06.020<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Seinen ML, van Asseldonk DP, Mulder CJ, de Boer NK<space/></arg><arg name="title"><space/>Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice<space/></arg><arg name="journal"><space/>Journal of Gastrointestinal and Liver Diseases<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>291–4<space/></arg><arg name="date"><space/>Sep 2010<space/></arg><arg name="pmid"><space/>20922194<space/></arg><arg name="url"><space/>http://www.jgld.ro/2010/3/12.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension></tablecell><tablecell><link><target>Guanine</target></link><space/>analogue.</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Purine synthesis inhibitor.</tablecell><tablecell><link><target>Acute lymphoblastic leukaemia</target></link><space/>and<space/><link><target>acute myeloid leukaemia</target></link></tablecell><tablecell>Myelosuppression, hepatotoxicity, peripheral neuropathy (uncommon), intestinal necrosis (rare) and perforation (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.02 Antifolates</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Methotrexate</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Tung JP, Maibach HI<space/></arg><arg name="title"><space/>The practical use of methotrexate in psoriasis<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>40<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>697–712<space/></arg><arg name="date"><space/>Nov 1990<space/></arg><arg name="pmid"><space/>2292232<space/></arg><arg name="doi"><space/>10.2165/00003495-199040050-00005<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bannwarth B, Labat L, Moride Y, Schaeverbeke T<space/></arg><arg name="title"><space/>Methotrexate in rheumatoid arthritis. An update<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>47<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>25–50<space/></arg><arg name="date"><space/>Jan 1994<space/></arg><arg name="pmid"><space/>7510620<space/></arg><arg name="doi"><space/>10.2165/00003495-199447010-00003<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Barnhart K, Coutifaris C, Esposito M<space/></arg><arg name="title"><space/>The pharmacology of methotrexate<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>409–17<space/></arg><arg name="date"><space/>Mar 2001<space/></arg><arg name="pmid"><space/>11336595<space/></arg><arg name="doi"><space/>10.1517/14656566.2.3.409<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Khan ZA, Tripathi R, Mishra B<space/></arg><arg name="title"><space/>Methotrexate: a detailed review on drug delivery and clinical aspects<space/></arg><arg name="journal"><space/>Expert Opinion on Drug Delivery<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>151–69<space/></arg><arg name="date"><space/>Feb 2012<space/></arg><arg name="pmid"><space/>22251428<space/></arg><arg name="doi"><space/>10.1517/17425247.2012.642362<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Graber JJ, Omuro A<space/></arg><arg name="title"><space/>Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?<space/></arg><arg name="journal"><space/>CNS Drugs<space/></arg><arg name="volume"><space/>25<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>447–57<space/></arg><arg name="date"><space/>Jun 2011<space/></arg><arg name="pmid"><space/>21649446<space/></arg><arg name="doi"><space/>10.2165/11589030-000000000-00000<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Dogra S, Mahajan R<space/></arg><arg name="title"><space/>Systemic methotrexate therapy for psoriasis: past, present and future<space/></arg><arg name="journal"><space/>Clinical and Experimental Dermatology<space/></arg><arg name="volume"><space/>38<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>573–588<space/></arg><arg name="date"><space/>Aug 2013<space/></arg><arg name="pmid"><space/>23837932<space/></arg><arg name="doi"><space/>10.1111/ced.12062<space/></arg></template></extension></tablecell><tablecell>Folate analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>SC, IM, IV, IT, PO</tablecell><tablecell><link><target>Dihydrofolate reductase</target></link><space/>inhibitor.</tablecell><tablecell><link><target>bladder cancer</target><part>Bladder</part></link><space/>and<space/><link><target>breast cancer</target></link>.<space/><link><target>Head and neck cancer</target><part>squamous cell carcinoma of head and neck</part></link>, gestational trophoblastic disease, acute leukaemias,<space/><link><target>non-Hodgkin lymphoma</target></link>,<space/><link><target>osteosarcoma</target></link>, brain tumours,<space/><link><target>graft-versus-host disease</target></link><space/>and<space/><link><target>systemic sclerosis</target></link>.</tablecell><tablecell>Myelosuppression, pulmonary toxicity, hepatotoxicity, neurotoxicity (high dose or intrathecal administration), anaphylactic reactions (rare), Stevens-Johnson syndrome (rare), Toxic Epidermal Necrolysis (rare), kidney failure (rare),<space/><link><target>osteoporosis</target></link><space/>(rare), skin and bone necrosis (rare) and<space/><link><target>macrocytic anaemia</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Pemetrexed</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Curtin NJ, Hughes AN<space/></arg><arg name="title"><space/>Pemetrexed disodium, a novel antifolate with multiple targets<space/></arg><arg name="journal"><space/>The Lancet. Oncology<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>298–306<space/></arg><arg name="date"><space/>May 2001<space/></arg><arg name="pmid"><space/>11905785<space/></arg><arg name="doi"><space/>10.1016/S1470-2045(00)00325-9<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gatzemeier U<space/></arg><arg name="title"><space/>Pemetrexed in malignant pleural mesothelioma<space/></arg><arg name="journal"><space/>Oncology<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>13 Suppl 8<space/></arg><arg name="pages"><space/>26–31<space/></arg><arg name="date"><space/>Nov 2004<space/></arg><arg name="pmid"><space/>15655933<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sobrero A, Caprioni F, Fornarini G, Mammoliti S, Comandini D, Baldo S, Decian F<space/></arg><arg name="title"><space/>Pemetrexed in gastric cancer<space/></arg><arg name="journal"><space/>Oncology<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>13 Suppl 8<space/></arg><arg name="pages"><space/>51–5<space/></arg><arg name="date"><space/>Nov 2004<space/></arg><arg name="pmid"><space/>15655938<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R<space/></arg><arg name="title"><space/>Pemetrexed in malignant pleural mesothelioma<space/></arg><arg name="journal"><space/>Clinical Cancer Research<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>982–92<space/></arg><arg name="date"><space/>Feb 2005<space/></arg><arg name="pmid"><space/>15709163<space/></arg><arg name="url"><space/>http://clincancerres.aacrjournals.org/content/11/3/982.full.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Puto K, Garey JS<space/></arg><arg name="title"><space/>Pemetrexed therapy for malignant pleural mesothelioma<space/></arg><arg name="journal"><space/>The Annals of Pharmacotherapy<space/></arg><arg name="volume"><space/>39<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>678–83<space/></arg><arg name="date"><space/>Apr 2005<space/></arg><arg name="pmid"><space/>15755794<space/></arg><arg name="doi"><space/>10.1345/aph.1E329<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Villela LR, Stanford BL, Shah SR<space/></arg><arg name="title"><space/>Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy<space/></arg><arg name="journal"><space/>Pharmacotherapy<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>641–54<space/></arg><arg name="date"><space/>May 2006<space/></arg><arg name="pmid"><space/>16637794<space/></arg><arg name="doi"><space/>10.1592/phco.26.5.641<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Goeminne H, van Meerbeeck JP<space/></arg><arg name="title"><space/>Pemetrexed in thoracic cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>917–28<space/></arg><arg name="date"><space/>May 2006<space/></arg><arg name="pmid"><space/>16634714<space/></arg><arg name="doi"><space/>10.1517/14656566.7.7.917<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Monnerat C, Le Chevalier T<space/></arg><arg name="title"><space/>Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer<space/></arg><arg name="journal"><space/>Annals of Oncology<space/></arg><arg name="volume"><space/>17 Suppl 5<space/></arg><arg name="pages"><space/>v86–90<space/></arg><arg name="date"><space/>May 2006<space/></arg><arg name="pmid"><space/>16807472<space/></arg><arg name="doi"><space/>10.1093/annonc/mdj958<space/></arg><arg name="url"><space/>http://annonc.oxfordjournals.org/content/17/suppl_5/v86.full.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Longo-Sorbello GS, Chen B, Budak-Alpdogan T, Bertino JR<space/></arg><arg name="title"><space/>Role of pemetrexed in non-small cell lung cancer<space/></arg><arg name="journal"><space/>Cancer Investigation<space/></arg><arg name="volume"><space/>25<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>59–66<space/></arg><arg name="date"><space/>Feb 2007<space/></arg><arg name="pmid"><space/>17364559<space/></arg><arg name="doi"><space/>10.1080/07357900601130748<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Chattopadhyay S, Moran RG, Goldman ID<space/></arg><arg name="title"><space/>Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications<space/></arg><arg name="journal"><space/>Molecular Cancer Therapeutics<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>404–417<space/></arg><arg name="date"><space/>Feb 2007<space/></arg><arg name="pmid"><space/>17308042<space/></arg><arg name="doi"><space/>10.1158/1535-7163.MCT-06-0343<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Meriggi F, Di Biasi B, Caliolo C, Zaniboni A<space/></arg><arg name="title"><space/>The potential role of pemetrexed in gastrointestinal cancer<space/></arg><arg name="journal"><space/>Chemotherapy<space/></arg><arg name="volume"><space/>54<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>1–8<space/></arg><arg name="date"><space/>December 2007<space/></arg><arg name="pmid"><space/>18063861<space/></arg><arg name="doi"><space/>10.1159/000112311<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref' name="Kulkarni 6470"><template><target>cite journal</target><arg name="author"><space/>Kulkarni PM, Chen R, Anand T, Monberg MJ, Obasaju CK<space/></arg><arg name="title"><space/>Efficacy and safety of pemetrexed in elderly cancer patients: results of an integrated analysis<space/></arg><arg name="journal"><space/>Critical Reviews in Oncology/Hematology<space/></arg><arg name="volume"><space/>67<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>64–70<space/></arg><arg name="date"><space/>Jul 2008<space/></arg><arg name="pmid"><space/>18358737<space/></arg><arg name="doi"><space/>10.1016/j.critrevonc.2008.01.011<space/></arg></template></extension><extension extension_name='ref' name="Kulkarni 6470"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Felip E, Rosell R<space/></arg><arg name="title"><space/>Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)<space/></arg><arg name="journal"><space/>Therapeutics and Clinical Risk Management<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>579–85<space/></arg><arg name="date"><space/>Jun 2008<space/></arg><arg name="pmid"><space/>18827853<space/></arg><arg name="pmc"><space/>2500250<space/></arg><arg name="doi"><space/>10.2147/TCRM.S2248<space/></arg><arg name="doi_brokendate"><space/>2015-04-14<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hsu JY, Wakelee H<space/></arg><arg name="title"><space/>Pemetrexed disodium for the treatment of NSCLC: an update<space/></arg><arg name="journal"><space/>Drugs of Today<space/></arg><arg name="volume"><space/>44<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>669–78<space/></arg><arg name="date"><space/>Sep 2008<space/></arg><arg name="pmid"><space/>19137122<space/></arg><arg name="doi"><space/>10.1358/dot.2008.44.9.1250412<space/></arg><arg name="doi_brokendate"><space/>2015-04-14<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Peake</arg><arg name="first">MD</arg><arg name="title">Pemetrexed in the treatment of malignant pleural mesothelioma</arg><arg name="journal">Therapy</arg><arg name="date">July 2009</arg><arg name="volume">6</arg><arg name="issue">4</arg><arg name="pages">569–575</arg><arg name="doi">10.2217/thy.09.30</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Manegold C, Schmid-Bindert G, Pilz LR<space/></arg><arg name="title"><space/>Pemetrexed for the treatment of non-small-cell lung cancer<space/></arg><arg name="journal"><space/>Expert Review of Anticancer Therapy<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1195–209<space/></arg><arg name="date"><space/>Sep 2009<space/></arg><arg name="pmid"><space/>19761423<space/></arg><arg name="doi"><space/>10.1586/ERA.09.97<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Tomao F, Panici PB, Frati L, Tomao S<space/></arg><arg name="title"><space/>Emerging role of pemetrexed in ovarian cancer<space/></arg><arg name="journal"><space/>Expert Review of Anticancer Therapy<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1727–35<space/></arg><arg name="date"><space/>Dec 2009<space/></arg><arg name="pmid"><space/>19954283<space/></arg><arg name="doi"><space/>10.1586/ERA.09.141<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fleeman N, Bagust A, McLeod C, Greenhalgh J, Boland A, Dundar Y, Dickson R, Tudur Smith C, Davis H, Green J, Pearson M<space/></arg><arg name="title"><space/>Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer<space/></arg><arg name="journal"><space/>Health Technology Assessment<space/></arg><arg name="volume"><space/>14 Suppl 1<space/></arg><arg name="pages"><space/>47–53<space/></arg><arg name="date"><space/>May 2010<space/></arg><arg name="pmid"><space/>20507803<space/></arg><arg name="doi"><space/>10.3310/hta14Suppl1/07<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fuld AD, Dragnev KH, Rigas JR<space/></arg><arg name="title"><space/>Pemetrexed in advanced non-small-cell lung cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1387–402<space/></arg><arg name="date"><space/>Jun 2010<space/></arg><arg name="pmid"><space/>20446853<space/></arg><arg name="doi"><space/>10.1517/14656566.2010.482560<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Somer</arg><arg name="first">R</arg><arg name="title">Maintenance therapy for metastatic non-small-cell lung cancer – the role of pemetrexed</arg><arg name="journal">Lung Cancer: Targets and Therapy</arg><arg name="date">April 2010</arg><arg name="volume">1</arg><arg name="pages">1–7</arg><arg name="doi">10.2147/LCTT.S7105</arg><arg name="url">https://www.dovepress.com/getfile.php?fileID</arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M<space/></arg><arg name="title"><space/>Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer<space/></arg><arg name="journal"><space/>Health Technology Assessment<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>Suppl. 2<space/></arg><arg name="pages"><space/>33–39<space/></arg><arg name="date"><space/>Oct 2010<space/></arg><arg name="pmid"><space/>21047489<space/></arg><arg name="doi"><space/>10.3310/hta14suppl2/05<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gridelli C, Maione P, Rossi A, Bareschino MA, Schettino C, Sacco PC, Zeppa R<space/></arg><arg name="title"><space/>Pemetrexed in advanced non-small cell lung cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Drug Safety<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>311–7<space/></arg><arg name="date"><space/>Mar 2011<space/></arg><arg name="pmid"><space/>21261558<space/></arg><arg name="doi"><space/>10.1517/14740338.2011.553281<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, Ferrero S<space/></arg><arg name="title"><space/>Pemetrexed disodium in ovarian cancer treatment<space/></arg><arg name="journal"><space/>Expert Opinion on Investigational Drugs<space/></arg><arg name="volume"><space/>21<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>437–49<space/></arg><arg name="date"><space/>Apr 2012<space/></arg><arg name="pmid"><space/>22324304<space/></arg><arg name="doi"><space/>10.1517/13543784.2012.661714<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK<space/></arg><arg name="title"><space/>Pemetrexed in head and neck cancer: a systematic review<space/></arg><arg name="journal"><space/>Oral Oncology<space/></arg><arg name="volume"><space/>49<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>492–501<space/></arg><arg name="date"><space/>Jun 2013<space/></arg><arg name="pmid"><space/>23466170<space/></arg><arg name="doi"><space/>10.1016/j.oraloncology.2013.01.007<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Boons CC, VAN Tulder MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG<space/></arg><arg name="title"><space/>The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review<space/></arg><arg name="journal"><space/>Anticancer Research<space/></arg><arg name="volume"><space/>33<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>3553–61<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>24023280<space/></arg></template></extension></tablecell><tablecell>Folate analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>Dihydrofolate reductase</target></link>,<space/><link><target>thymidylate synthase</target></link><space/>and<space/><link><target>glycinamide ribonucleotide formyltransferase</target></link><space/>inhibitors.</tablecell><tablecell><link><target>Malignant mesothelioma</target></link><space/>and non-squamous non-small cell lung cancer.</tablecell><tablecell>Myelosuppression, renal impairment,<space/><link><target>peripheral neuropathy</target></link>,<space/><link><target>Supraventricular tachycardia</target></link><space/>(uncommon), hepatitis (rare), colitis (rare), pneumonitis (rare), radiation recall (rare), Stevens-Johnson syndrome (rare) and toxic epidermal necrolysis (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Raltitrexed</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gunasekara NS, Faulds D<space/></arg><arg name="title"><space/>Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>55<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>423–35<space/></arg><arg name="date"><space/>Mar 1998<space/></arg><arg name="pmid"><space/>9530547<space/></arg><arg name="doi"><space/>10.2165/00003495-199855030-00012<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Clarke SJ, Beale PJ, Rivory LP<space/></arg><arg name="title"><space/>Clinical and preclinical pharmacokinetics of raltitrexed<space/></arg><arg name="journal"><space/>Clinical Pharmacokinetics<space/></arg><arg name="volume"><space/>39<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>429–443<space/></arg><arg name="date"><space/>Dec 2000<space/></arg><arg name="pmid"><space/>11192475<space/></arg><arg name="doi"><space/>10.1517/13543784.7.5.823<space/></arg></template></extension><extension extension_name='ref' name="Caponigro F, Avallone A, Budillon A, Comella P, Comella G 48997"><template><target>cite journal</target><arg name="author"><space/>Caponigro F, Avallone A, Budillon A, Comella P, Comella G<space/></arg><arg name="title"><space/>Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy<space/></arg><arg name="journal"><space/>Anti-Cancer Drugs<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>489–97<space/></arg><arg name="date"><space/>Jul 2001<space/></arg><arg name="pmid"><space/>11459994<space/></arg><arg name="doi"><space/>10.1097/00001813-200107000-00001<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref' name="Caponigro F, Avallone A, Budillon A, Comella P, Comella G 48997"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Cunningham D, Zalcberg J, Maroun J, James R, Clarke S, Maughan TS, Vincent M, Schulz J, González Barón M, Facchini T<space/></arg><arg name="title"><space/>Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials<space/></arg><arg name="journal"><space/>European Journal of Cancer<space/></arg><arg name="volume"><space/>38<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>478–486<space/></arg><arg name="date"><space/>Mar 2002<space/></arg><arg name="pmid"><space/>11872339<space/></arg><arg name="doi"><space/>10.1016/S0959-8049(01)00413-0<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Van Cutsem E, Cunningham D, Maroun J, Cervantes A, Glimelius B<space/></arg><arg name="title"><space/>Raltitrexed: current clinical status and future directions<space/></arg><arg name="journal"><space/>Annals of Oncology<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>513–522<space/></arg><arg name="date"><space/>Apr 2002<space/></arg><arg name="pmid"><space/>12056700<space/></arg><arg name="doi"><space/>10.1093/annonc/mdf054<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Cao S, Bhattacharya A, Durrani FA, Fakih M<space/></arg><arg name="title"><space/>Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>687–703<space/></arg><arg name="date"><space/>Apr 2006<space/></arg><arg name="pmid"><space/>16556086<space/></arg><arg name="doi"><space/>10.1517/14656566.7.6.687<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Wilson KS, Malfair Taylor SC<space/></arg><arg name="title"><space/>Raltitrexed: optimism and reality<space/></arg><arg name="journal"><space/>Expert Opinion on Drug Metabolism & Toxicology<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1447–1454<space/></arg><arg name="date"><space/>Nov 2009<space/></arg><arg name="pmid"><space/>19863453<space/></arg><arg name="doi"><space/>10.1517/17425250903307455<space/></arg></template></extension></tablecell><tablecell><link><target>Quinazolinone</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>Dihydrofolate reductase</target></link><space/>and<space/><link><target>thymidylate synthase</target></link><space/>inhibitor.</tablecell><tablecell><link><target>Colorectal cancer</target></link></tablecell><tablecell>Myelosuppression</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.03 Other antimetabolites</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Hydroxycarbamide</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Mulaku M, Opiyo N, Karumbi J, Kitonyi G, Thoithi G, English M<space/></arg><arg name="title"><space/>Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries<space/></arg><arg name="journal"><space/>Archives of Disease in Childhood<space/></arg><arg name="volume"><space/>98<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>908–14<space/></arg><arg name="date"><space/>Nov 2013<space/></arg><arg name="pmid"><space/>23995076<space/></arg><arg name="pmc"><space/>3812872<space/></arg><arg name="doi"><space/>10.1136/archdischild-2012-302387<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Navarra P, Preziosi P<space/></arg><arg name="title"><space/>Hydroxyurea: new insights on an old drug<space/></arg><arg name="journal"><space/>Critical Reviews in Oncology/Hematology<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>249–55<space/></arg><arg name="date"><space/>Feb 1999<space/></arg><arg name="pmid"><space/>10226728<space/></arg><arg name="doi"><space/>10.1016/S1040-8428(98)00032-8<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Romanelli F, Pomeroy C, Smith KM<space/></arg><arg name="title"><space/>Hydroxyurea to inhibit human immunodeficiency virus-1 replication<space/></arg><arg name="journal"><space/>Pharmacotherapy<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>196–204<space/></arg><arg name="date"><space/>Feb 1999<space/></arg><arg name="pmid"><space/>10030769<space/></arg><arg name="doi"><space/>10.1592/phco.19.3.196.30913<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Vichinsky EP<space/></arg><arg name="title"><space/>Hydroxyurea in children: present and future<space/></arg><arg name="journal"><space/>Seminars in Hematology<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>3 Suppl 3<space/></arg><arg name="pages"><space/>22–9<space/></arg><arg name="date"><space/>Jul 1997<space/></arg><arg name="pmid"><space/>9317198<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Gwilt PR, Tracewell WG<space/></arg><arg name="title"><space/>Pharmacokinetics and pharmacodynamics of hydroxyurea<space/></arg><arg name="journal"><space/>Clinical Pharmacokinetics<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>347–358<space/></arg><arg name="date"><space/>May 1998<space/></arg><arg name="pmid"><space/>9592619<space/></arg><arg name="doi"><space/>10.2165/00003088-199834050-00002<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ravot E, Lisziewicz J, Lori F<space/></arg><arg name="title"><space/>New uses for old drugs in HIV infection: the role of hydroxyurea, cyclosporin and thalidomide<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>58<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>953–963<space/></arg><arg name="date"><space/>Dec 1999<space/></arg><arg name="pmid"><space/>10651384<space/></arg><arg name="doi"><space/>10.2165/00003495-199958060-00001<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="title">Hydroxyurea</arg><arg name="year">2000</arg><arg name="volume">76</arg><arg name="url">http://monographs.iarc.fr/ENG/Monographs/vol76/mono76-14.pdf</arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Banan M<space/></arg><arg name="title"><space/>Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?<space/></arg><arg name="journal"><space/>Annals of Hematology<space/></arg><arg name="volume"><space/>92<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>289–99<space/></arg><arg name="date"><space/>Mar 2013<space/></arg><arg name="pmid"><space/>23318979<space/></arg><arg name="doi"><space/>10.1007/s00277-012-1671-3<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Dingli D, Tefferi A<space/></arg><arg name="title"><space/>Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia<space/></arg><arg name="journal"><space/>Current Hematologic Malignancy Reports<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>69–74<space/></arg><arg name="date"><space/>Jun 2006<space/></arg><arg name="pmid"><space/>20425334<space/></arg><arg name="doi"><space/>10.1007/s11899-006-0025-4<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lisziewicz J, Foli A, Wainberg M, Lori F<space/></arg><arg name="title"><space/>Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns<space/></arg><arg name="journal"><space/>Drug Safety<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>605–24<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12814330<space/></arg><arg name="doi"><space/>10.2165/00002018-200326090-00002<space/></arg></template></extension></tablecell><tablecell><link><target>Urea</target></link><space/>analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Inhibits DNA synthesis by inhibiting the enzyme<space/><link><target>ribonucleotide reductase</target></link>.</tablecell><tablecell><link><target>Chronic myeloid leukaemia</target></link>,<space/><link><target>essential thrombocytosis</target></link>,<space/><link><target>polycythaemia vera</target></link>,<space/><link><target>myelofibrosis</target></link>,<space/><link><target>acute myeloid leukaemia</target></link><space/>and<space/><link><target>sickle cell anaemia</target></link></tablecell><tablecell>Myelosuppression, skin cancer (rare), oedema (rare), hallucinations (rare), seizures (rare) and pulmonary toxicity (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.04 Topoisomerase I inhibitor</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Irinotecan</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Camptothecin</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Inhibits<space/><link><target>topoisomerase I</target></link>.</tablecell><tablecell>Colorectal cancer</tablecell><tablecell>Diarrhoea, myelosuppression, pulmonary infiltrates (uncommon), bradycardia (uncommon), ileus (rare) and colitis (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Topotecan</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Camptothecin</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Inhibits<space/><link><target>topoisomerase I</target></link>.</tablecell><tablecell>Small cell lung cancer, ovarian cancer and cervical cancer</tablecell><tablecell>Diarrhoea, myelosuppression, interstitial lung disease and allergy.</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.05 Anthracyclines</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Daunorubicin</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Anthracycline</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Inhibits DNA and RNA synthesis by intercalating DNA base pairs. Inhibits DNA repair by inhibiting<space/><link><target>topoisomerase II</target></link>.</tablecell><tablecell>Acute leukaemias</tablecell><tablecell>Myelosuppression, cardiotoxicity, anaphylaxis (rare), secondary malignancies (particularly<space/><link><target>acute myeloid leukaemia</target></link><space/>and<space/><link><target>myelodysplastic syndrome</target></link>) and radiation recall.</tablecell></tablerow><tablerow><tablecell><link><target>Doxorubicin</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Anthracycline</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Breast cancer, lymphomas, sarcomas, bladder cancer, acute lymphoblastic leukaemia,<space/><link><target>Wilms' tumour</target></link>, AIDS-related<space/><link><target>Kaposi's sarcoma</target></link>,<space/><link><target>neuroblastoma</target></link><space/>and<space/><link><target>multiple myeloma</target></link></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Epirubicin</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Anthracycline</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Breast cancer, gastric cancer and bladder cancer</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Idarubicin</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Anthracycline</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV, PO</tablecell><tablecell>As above.</tablecell><tablecell>Acute leukaemias.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Mitoxantrone</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Anthracenedione</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell><link><target>Non-Hodgkin lymphoma</target></link>,<space/><link><target>acute myeloid leukaemia</target></link>,<space/><link><target>prostate cancer</target></link><space/>and<space/><link><target>multiple sclerosis</target></link></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell><link><target>Valrubicin</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Anthracycline</target></link></tablecell><tablecell>C (US)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Bladder cancer.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.06 Podophyllotoxins</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Etoposide</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Podophyllotoxin</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV, PO</tablecell><tablecell><link><target>Topoisomerase II</target></link><space/>inhibitor.</tablecell><tablecell>Testicular cancer, ovarian cancer, lung cancer, acute myeloid leukaemia, lymphomas and sarcomas</tablecell><tablecell>Myelosuppression, hypersensitivity reactions, Stevens-Johnson syndrome (rare), peripheral neuropathy (uncommon) and secondary malignancies (especially<space/><link><target>acute myeloid leukaemia</target></link>).</tablecell></tablerow><tablerow><tablecell><link><target>Teniposide</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Podophyllotoxin</target></link></tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>Topoisomerase II</target></link><space/>inhibitor.</tablecell><tablecell>Lymphomas, acute lymphoblastic leukaemia and<space/><link><target>neuroblastoma</target></link></tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.07 Taxanes</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Cabazitaxel</target></link></tablecell><tablecell></tablecell><tablecell>Taxane</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Microtubule disassembly inhibitor. Arrests cells in late G2 phase and M phase.</tablecell><tablecell><link><target>Prostate cancer</target></link></tablecell><tablecell>Myelosuppression, diarrhoea, kidney failure, hypersensitivity, severe GI reactions (including perforation, ileus, colitis, etc.; all rare) and peripheral neuropathy</tablecell></tablerow><tablerow><tablecell><link><target>Docetaxel</target></link></tablecell><tablecell></tablecell><tablecell>Taxane</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Breast cancer, non-small cell lung cancer, ovarian cancer, prostate cancer, squamous cell head and neck cancer and gastric cancer.</tablecell><tablecell>Myelosuppression, peripheral neuropathy, hypersensitivity, fluid retention, heart failure (uncommon), pulmonary toxicity (rare), radiation recall (rare), scleroderma-like skin changes (rare), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), seizures (rare) and encephalopathy (rare)</tablecell></tablerow><tablerow><tablecell><link><target>Paclitaxel</target></link></tablecell><tablecell></tablecell><tablecell>Taxane</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Ovarian cancer, breast cancer, non-small cell lung cancer, AIDS-related Kaposi's sarcoma, cervical cancer, germ cell cancer and<space/><link><target>endometrial cancer</target></link></tablecell><tablecell>Hypersensitivity, myelosuppression, peripheral neuropathy, myocardial infarction (uncommon), arrhythmias (uncommon), pulmonary toxicity (rare), radiation recall (rare), scleroderma-like skin changes (rare), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), seizures (rare) and encephalopathy (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.08 Vinca alkaloids</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Vinblastine</target></link></tablecell><tablecell></tablecell><tablecell>Vinca alkaloid</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Microtubule assembly inhibitor. Arrests cells in M phase.</tablecell><tablecell>Hodgkin lymphoma, germ cell tumours, non-small cell lung cancer, bladder cancer and primary immune thrombocytopenia</tablecell><tablecell>Neurotoxicity, myelosuppression, myocardial ischaemia (rare) and myocardial infarction (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Vincristine</target></link></tablecell><tablecell></tablecell><tablecell>Vinca alkaloid</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Lymphomas, acute lymphoblastic leukaemia, multiple myeloma, sarcoma, brain tumours, Wilms' tumour, neuroblastoma and primary immune thrombocytopenia</tablecell><tablecell>Neurotoxicity, anaphylaxis (rare), myocardial ischaemia (rare) and myocardial infarction (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Vindesine</target></link></tablecell><tablecell></tablecell><tablecell>Vinka alkaloid</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Refractory metastatic melanoma, childhood acute lymphoblastic leukaemia, chronic myeloid leukaemia in blast crises, neuroblastoma, non-small cell lung cancer and breast cancer.</tablecell><tablecell>Myelosuppression, neurotoxicity and paralytic ileus.</tablecell></tablerow><tablerow><tablecell><link><target>Vinflunine</target></link></tablecell><tablecell></tablecell><tablecell>Vinca alkaloid</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Bladder cancer</tablecell><tablecell>As per vinblastine.</tablecell></tablerow><tablerow><tablecell><link><target>Vinorelbine</target></link></tablecell><tablecell></tablecell><tablecell>Vinca alkaloid</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Breast cancer and non-small cell lung cancer.</tablecell><tablecell>As above.</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.09 Alkylating agents</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Bendamustine</target></link></tablecell><tablecell></tablecell><tablecell>Nitrogen mustard</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell><link><target>Chronic lymphocytic leukaemia</target></link>,<space/><link><target>mantle cell lymphoma</target></link><space/>and non-Hodgkin's lymphoma.</tablecell><tablecell>Myelosuppression,<space/><link><target>hypokalaemia</target></link><space/>and tachycardia.</tablecell></tablerow><tablerow><tablecell><link><target>Busulfan</target></link></tablecell><tablecell></tablecell><tablecell>Dialkylsulfonate</tablecell><tablecell>D (Au)</tablecell><tablecell>IV, PO</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Conditioning treatment before<space/><link><target>haematopoietic stem cell transplantation</target></link><space/>(high dose, IV),<space/><link><target>chronic myeloid leukaemia</target></link>,<space/><link><target>myelofibrosis</target></link>,<space/><link><target>polycythaemia vera</target></link><space/>and<space/><link><target>essential thrombocytosis</target></link></tablecell><tablecell>Myelosuppression, seizures (high dose), tachycardia (high dose), hepatic sinusoidal obstruction syndrome (high dose), Addison-like syndrome (rare), pulmonary fibrosis (rare), cataracts (rare) and hepatitis (rare). Secondary malignancies.<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="sec"><template><target>cite web</target><arg name="title">Secondary Malignancies: Therapy-Related t-MDS/AML</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="year">2008</arg><arg name="accessdate">7 February 2014</arg><arg name="url">http://www.medscape.org/viewarticle/581683_2</arg><arg name="author">Bhatia, S</arg></template></extension></tablecell></tablerow><tablerow><tablecell><link><target>Carmustine</target></link></tablecell><tablecell></tablecell><tablecell>Nitrosourea</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell><link><target>Anaplastic astrocytoma</target></link>,<space/><link><target>glioblastoma multiforme</target></link><space/>and<space/><link><target>mycosis fungoides</target></link><space/>(topical)</tablecell><tablecell>Myelosuppression, pulmonary fibrosis, pulmonary infiltrates, seizure, brain oedema, cerebrospinal leaks, subdural fluid collection, intracranial infection, hypotension (uncommon), tachycardia (uncommon), decrease in kidney size (reversible), uraemia (uncommon), kidney failure (uncommon), severe hepatic toxicity (rare),<space/><link><target>thrombosis</target></link><space/>(rare) and neuroretinitis (rare). Secondary malignancies.<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Chlorambucil</target></link></tablecell><tablecell></tablecell><tablecell>Nitrogen mustard</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell><link><target>Lymphoma</target></link>,<space/><link><target>chronic lymphocytic leukaemia</target></link><space/>and<space/><link><target>Waldenstrm's macroglobulinaemia</target></link></tablecell><tablecell>Myelosuppression, hallucinations (rare), seizures (rare), sterile cystitis (rare), hepatotoxicity (rare), severe pneumonitis (rare), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare) and drug fever (rare). Secondary malignancies.<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Chlormethine</target></link></tablecell><tablecell></tablecell><tablecell>Nitrogen mustard</tablecell><tablecell>D (Au)</tablecell><tablecell>IV, topical</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Cutaneous T-Cell Lymphoma, metastatic carcinoma, leukaemias, lymphomas, polycythemia vera and bronchogenic carcinoma</tablecell><tablecell>Thrombosis, myelosuppression (common), hyperuricaemia, erythema multiforme,<space/><link><target>haemolytic anaemia</target></link>, nausea and vomiting (severe) and secondary malignancies.<extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Cyclophosphamide</target></link></tablecell><tablecell></tablecell><tablecell>Nitrogen mustard</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Breast cancer, lymphoma, acute lymphoblastic leukaemia, chronic lymphocytic leukaemia, sarcoma,<space/><link><target>multiple myeloma</target></link>,<space/><link><target>Waldenstrm's macroglobulinaemia</target></link>,<space/><link><target>systemic lupus erythematosus</target></link>,<space/><link><target>glomerulonephritis</target></link>, systemic vasculitis and<space/><link><target>Wegener's granulomatosis</target></link></tablecell><tablecell>Myelosuppression, nausea and vomiting (&gt;30%),<space/><link><target>haemorrhagic cystitis</target></link>, heart failure (rare), pulmonary fibrosis (rare), hepatic sinusoidal obstruction syndrome (rare), water retention resembling SIADH (rare) and seizures (rare). Secondary malignancies.<extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Dacarbazine</target></link></tablecell><tablecell></tablecell><tablecell>Triazene</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Hodgkin lymphoma, metastatic malignant melanoma and soft tissue sarcoma</tablecell><tablecell>Myelosuppression,<space/><link><target>agranulocytosis</target></link><space/>(uncommon),<space/><link><target>hepatic vein thrombosis</target></link><space/>(rare) and hepatocellular necrosis (rare). Secondary malignancies.<extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Fotemustine</target></link></tablecell><tablecell></tablecell><tablecell>Nitrosourea</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Metastatic malignant melanoma.</tablecell><tablecell>Myelosuppression.</tablecell></tablerow><tablerow><tablecell><link><target>Ifosfamide</target></link></tablecell><tablecell></tablecell><tablecell>Nitrogen mustard</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Sarcomas, testicular cancer and lymphomas.</tablecell><tablecell>Myelosuppression, haemorrhagic cystitis, nephrotoxicity, neurotoxicity and cardiac toxicity (rare). Secondary malignancies.<extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Lomustine</target></link></tablecell><tablecell></tablecell><tablecell>Nitrosourea</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Glioma and medulloblastoma.</tablecell><tablecell>Myelosuppression, pulmonary infiltration and fibrosis. Secondary malignancies.<extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Melphalan</target></link></tablecell><tablecell></tablecell><tablecell>Nitrogen mustard</tablecell><tablecell>D (Au)</tablecell><tablecell>IV, PO</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell>Malignant melanoma of the extremities, multiple myeloma, conditioning treatment before<space/><link><target>haemopoietic stem cell transplant</target></link>.</tablecell><tablecell>Myelosuppression, pulmonary fibrosis and pneumonitis (uncommon), skin necrosis (uncommon), anaphylaxis, hepatic sinusoidal obstruction syndrome and SIADH. Secondary malignancies.<extension extension_name='ref' name="sec"></extension></tablecell></tablerow><tablerow><tablecell><link><target>Streptozotocin</target></link></tablecell><tablecell></tablecell><tablecell>Nitrosourea</tablecell><tablecell>D (Au)</tablecell><tablecell>IV, PO</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell><link><target>Pancreatic cancer</target></link><space/>and<space/><link><target>carcinoid syndrome</target></link>.</tablecell><tablecell>Nephrotoxicity,<space/><link><target>hypoglycaemia</target></link>, myelosuppression, nausea and vomiting (&gt;90%), jaundice and nephrogenic diabetes insipidus (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Temozolomide</target></link></tablecell><tablecell></tablecell><tablecell>Triazene</tablecell><tablecell>D (US)</tablecell><tablecell>PO</tablecell><tablecell>Alkylates DNA.</tablecell><tablecell><link><target>Anaplastic astrocytoma</target></link>,<space/><link><target>glioblastoma multiforme</target></link>, metastatic malignant melanoma</tablecell><tablecell>Myelosuppression, Stevens-Johnson syndrome (rare), pneumonitis (rare) and hepatitis (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.10 Platinum compounds</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Carboplatin</target></link></tablecell><tablecell></tablecell><tablecell>Platinum complex</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Reacts with DNA, inducing apoptosis, non-cell cycle specific.</tablecell><tablecell><link><target>Ovarian cancer</target></link>, lung cancer and squamous cell head and neck cancer</tablecell><tablecell>Myelosuppression, nausea and vomiting (30-90%), peripheral neuropathy, ototoxicity, anaphylaxis, acute kidney failure (rare), haemolytic uraemic syndrome (rare) and loss of vision (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Cisplatin</target></link></tablecell><tablecell></tablecell><tablecell>Platinum complex</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Germ cell tumours (including testicular cancer), ovarian cancer, cervical cancer, small cell and non-small cell lung cancer, mesothelioma, squamous cell head and neck cancer, oesophageal cancer, gastric cancer, bladder cancer and osteosarcoma</tablecell><tablecell>Nephrotoxicity, nausea and vomiting (30-100%), myelosuppression, electrolyte anomalies, peripheral neuropathy, ototoxicity and anaphylaxis,<space/><link><target>haemolytic anaemia</target></link><space/>(rare), optic neuritis (rare), reversible posterior leucoencephalopathy syndrome (rare), seizures (rare), ECG changes (rare) and heart failure (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Nedaplatin</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Shimada M, Itamochi H, Kigawa J<space/></arg><arg name="title"><space/>Nedaplatin: a cisplatin derivative in cancer chemotherapy<space/></arg><arg name="journal"><space/>Cancer Management and Research<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="pages"><space/>67–76<space/></arg><arg name="date"><space/>May 2013<space/></arg><arg name="pmid"><space/>23696716<space/></arg><arg name="pmc"><space/>3658440<space/></arg><arg name="doi"><space/>10.2147/CMAR.S35785<space/></arg></template></extension></tablecell><tablecell>Platinum complex</tablecell><tablecell>N/A</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Non-small cell lung cancer, oesophageal cancer, uterine cervical cancer, head and neck cancer and urothelial cancer</tablecell><tablecell>Nephrotoxicity, myelosuppression and nausea and vomiting (30-90%).</tablecell></tablerow><tablerow><tablecell><link><target>Oxaliplatin</target></link></tablecell><tablecell></tablecell><tablecell>Platinum complex</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>As above.</tablecell><tablecell>Colorectal cancer, oesophageal cancer and gastric cancer</tablecell><tablecell>Myelosuppression, peripheral neuropathy, anaphylaxis, nausea and vomiting (30-90%), hypokalaemia, metabolic acidosis, interstitial lung disease (uncommon), ototoxicity (rare), reversible posterior leucoencephalopathy syndrome (rare), immune-mediated cytopenias (rare) and hepatic sinusoidal obstruction syndrome (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>1.11 Miscellaneous others</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Altretamine</target></link></tablecell><tablecell></tablecell><tablecell>Triazine</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Unclear, reactive intermediates covalently bind to microsomal proteins and DNA, possibly causing DNA damage</tablecell><tablecell>Recurrent ovarian cancer</tablecell><tablecell>Myelosuppression, peripheral neuropathy, seizures and hepatotoxicity (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Bleomycin</target></link></tablecell><tablecell></tablecell><tablecell>Glycopeptide</tablecell><tablecell>D (Au)</tablecell><tablecell>IM, SC, IA, IV or IP</tablecell><tablecell>Inhibits DNA and to a lesser extent RNA synthesis, produces single and double strand breaks in DNA possibly by free radical formation.</tablecell><tablecell>Germ cell tumours,<space/><link><target>squamous cell carcinoma</target></link>, pancreatic cancer, non-Hodgkin's, pleural sclerosing and Hodgkin's lymphoma.</tablecell><tablecell>Pulmonary toxicity, hypersensitivity,<space/><link><target>scleroderma</target></link><space/>and<space/><link><target>Raynaud's phenomenon</target></link>.</tablecell></tablerow><tablerow><tablecell><link><target>Bortezomib</target></link></tablecell><tablecell></tablecell><tablecell>Dipeptidyl boronic acid</tablecell><tablecell>C (Au)</tablecell><tablecell>IV, SC</tablecell><tablecell><link><target>Proteasome</target></link><space/>inhibitor.</tablecell><tablecell>Multiple myeloma, mantle cell lymphoma and follicular lymphoma (orphan).</tablecell><tablecell>Peripheral neuropathy, neutropenia, thrombocytopenia, anaemia, orthostatic hypotension, hepatitis (uncommon/rare), haemorrhage (uncommon/rare), heart failure (uncommon/rare), seizures (uncommon/rare), progressive multifocal leucoencephalopathy (PML) and hearing loss.</tablecell></tablerow><tablerow><tablecell><link><target>Dactinomycin</target></link></tablecell><tablecell></tablecell><tablecell>Polypeptide</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Complexes with DNA interfering with DNA-dependent RNA synthesis</tablecell><tablecell>Gestational trophoblastic disease, Wilms' tumour and rhabdomyosarcoma</tablecell><tablecell>Myelosuppression, anaphylaxis, radiation recall, hepatotoxicity and hepatic sinusoidal obstruction syndrome (common in Wilms' tumour).</tablecell></tablerow><tablerow><tablecell><link><target>Estramustine</target></link></tablecell><tablecell></tablecell><tablecell>Nitrogen mustard and oestrogen analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Antimicrotubule and oestrogenic actions</tablecell><tablecell>Prostate cancer.</tablecell><tablecell>Cardiovascular complications, such as<space/><link><target>ischaemic heart disease</target></link>, venous thromboembolism, congestive heart failure, pulmonary embolism, myocardial infarction and cerebrovascular failure.</tablecell></tablerow><tablerow><tablecell><link><target>Ixabepilone</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Epothilone B</target></link><space/>analogue</tablecell><tablecell>D (US)</tablecell><tablecell>IV</tablecell><tablecell>Promotes tubulin polymerisation and stabilises microtubular function, causing cell cycle arrest at G2/M phase and subsequently induces apoptosis</tablecell><tablecell>Locally advanced or metastatic breast cancer.</tablecell><tablecell>Myelosuppression, peripheral neuropathy, myocardial ischaemia (uncommon/rare), supraventricular arrhythmia (uncommon/rare) and hypersensitivity reaction (uncommon/rare).</tablecell></tablerow><tablerow><tablecell><link><target>Mitomycin</target></link></tablecell><tablecell></tablecell><tablecell>Aziridine</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>Cross-links DNA</tablecell><tablecell>Anal and bladder cancer</tablecell><tablecell>Myelosuppression, pulmonary toxicity and haemolytic uraemic syndrome (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Procarbazine</target></link></tablecell><tablecell></tablecell><tablecell>Methylhydrazine</tablecell><tablecell>D (Au)</tablecell><tablecell>IM, IV</tablecell><tablecell>Inhibits DNA, RNA and protein synthesis.</tablecell><tablecell><link><target>Glioma</target></link><space/>and Hodgkin's lymphoma.</tablecell><tablecell>Myelosuppression, neurotoxicity, pulmonary fibrosis (uncommon/rare), pneumonitis (uncommon/rare), haemolysis (uncommon/rare) and hepatic dysfunction (uncommon/rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:span style="font-size:125%;">2. Targeted antineoplastics</xhtml:span></bold></tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>2.1 Monoclonal antibodies</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Alemtuzumab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>B2 (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>CD52</target></link><space/>antibody induces apoptosis in the tagged cells.</tablecell><tablecell>Chronic lymphocytic leukaemia</tablecell><tablecell><link><target>Pancytopenia</target></link>, pneumonitis, arrhythmias and hypersensitivity reactions (rare), autoimmune haemolytic anaemia (rare), autoimmune thrombocytopenia (rare) and<space/><link><target>progressive multifocal leucoencephalopathy</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Bevacizumab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>VEGF</target></link><space/>inhibitor.</tablecell><tablecell>Colorectal, breast, ovarian, renal cell and non-squamous non-small cell lung cancer and glioblastoma</tablecell><tablecell>Hypertension, thromboembolisms, heart failure, bleeding, neutropenia, thrombocytopenia, GI perforation, fistula formation, hypertensive encephalopathy, pulmonary hypertension, reversible posterior leucoencephalopathy syndrome, nasal septum perforation and osteonecrosis of the jaw.</tablecell></tablerow><tablerow><tablecell><link><target>Cetuximab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>Epidermal growth factor receptor</target><part>EGFR</part></link><space/>inhibitor.</tablecell><tablecell>Squamous cell head and neck cancer or EGFR-positive and KRAS wild-type metastatic colorectal cancer.</tablecell><tablecell>Infusion-related reactions, skin reactions, hypomagnesaemia, hypocalcaemia, hypokalaemia, blood clots, interstitial lung disease and aseptic meningitis.</tablecell></tablerow><tablerow><tablecell><link><target>Denosumab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>X (US)</tablecell><tablecell>SC</tablecell><tablecell><link><target>RANKL</target></link><space/>inhibitor.</tablecell><tablecell>Osteoporosis, including drug- and cancer-related osteoporosis,<space/><link><target>giant cell tumour of bone</target></link><space/>and hypercalcaemia of malignancies</tablecell><tablecell>Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis.</tablecell></tablerow><tablerow><tablecell><link><target>Gemtuzumab ozogamicin</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, Burnett AK, Kantarjian HM<space/></arg><arg name="title"><space/>Gemtuzumab ozogamicin: time to resurrect?<space/></arg><arg name="journal"><space/>Journal of Clinical Oncology<space/></arg><arg name="volume"><space/>30<space/></arg><arg name="issue"><space/>32<space/></arg><arg name="pages"><space/>3921–3923<space/></arg><arg name="date"><space/>Nov 2012<space/></arg><arg name="pmid"><space/>22987091<space/></arg><arg name="doi"><space/>10.1200/JCO.2012.43.0132<space/></arg><arg name="url"><space/>http://jco.ascopubs.org/content/30/32/3921.full.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg></template></extension></tablecell><tablecell>Protein</tablecell><tablecell>D (US)</tablecell><tablecell>IV</tablecell><tablecell><link><target>CD33</target></link><space/>antibody that induces apoptosis of the tagged cell.</tablecell><tablecell>Acute myeloid leukaemia</tablecell><tablecell>Hepatic veno-occlusive disease, myelosuppression, cytokine release syndrome, hypersensitivity and electrolyte anomalies.</tablecell></tablerow><tablerow><tablecell><link><target>Ibritumomab tiuxetan</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lehnert M, Ludwig H, Zojer N<space/></arg><arg name="title"><space/>Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma<space/></arg><arg name="journal"><space/>OncoTargets and Therapy<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="pages"><space/>199–208<space/></arg><arg name="date"><space/>February 2009<space/></arg><arg name="pmid"><space/>20616907<space/></arg><arg name="pmc"><space/>2886339<space/></arg><arg name="doi"><space/>10.2147/ott.s3975<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Cheson BD<space/></arg><arg name="title"><space/>The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma<space/></arg><arg name="journal"><space/>BioDrugs<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>309–22<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16207072<space/></arg><arg name="doi"><space/>10.2165/00063030-200519050-00004<space/></arg></template></extension></tablecell><tablecell>Protein</tablecell><tablecell>D (US)</tablecell><tablecell>IV</tablecell><tablecell><link><target>CD20</target></link><space/>antibody bound with the radioactive isotope,<space/><link><target>Yttrium-90</target><part>90Y</part></link>, induces radiation-dependent cell lysis.</tablecell><tablecell>Non-Hodgkin's lymphoma and follicular lymphoma.</tablecell><tablecell>Thrombocytopenia, neutropenia, anaemia, hypotension and secondary malignancies.</tablecell></tablerow><tablerow><tablecell><link><target>Ipilimumab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>C (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>CTLA4</target></link><space/>antibody that causes immune system-mediated lysis of the tagged cell</tablecell><tablecell>Unresectable or metastatic malignant melanoma.</tablecell><tablecell>Life-threatening immune mediated reactions and fever.</tablecell></tablerow><tablerow><tablecell><link><target>Ofatumumab</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Nabhan C, Kay NE<space/></arg><arg name="title"><space/>The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia<space/></arg><arg name="journal"><space/>Clinical Medicine Insights. Oncology<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="pages"><space/>45–53<space/></arg><arg name="date"><space/>March 2011<space/></arg><arg name="pmid"><space/>21499555<space/></arg><arg name="pmc"><space/>3076040<space/></arg><arg name="doi"><space/>10.4137/CMO.S4087<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Osterborg A<space/></arg><arg name="title"><space/>Ofatumumab, a human anti-CD20 monoclonal antibody<space/></arg><arg name="journal"><space/>Expert Opinion on Biological Therapy<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>439–49<space/></arg><arg name="date"><space/>Mar 2010<space/></arg><arg name="pmid"><space/>20109133<space/></arg><arg name="doi"><space/>10.1517/14712590903586239<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Sanford M, McCormack PL<space/></arg><arg name="title"><space/>Ofatumumab<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>70<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1013–1019<space/></arg><arg name="date"><space/>May 2010<space/></arg><arg name="pmid"><space/>20481657<space/></arg><arg name="doi"><space/>10.2165/11203850-000000000-00000<space/></arg></template></extension></tablecell><tablecell>Protein</tablecell><tablecell>C (US)</tablecell><tablecell>IV</tablecell><tablecell>Anti-<link><target>CD20</target></link><space/>antibody.</tablecell><tablecell><link><target>Chronic lymphocytic leukaemia</target></link></tablecell><tablecell>Neutropenia, pneumonia, infusion reactions, cytopenias</tablecell></tablerow><tablerow><tablecell><link><target>Panitumumab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>C (Au)</tablecell><tablecell>IV</tablecell><tablecell>EGFR inhibitor.</tablecell><tablecell>RAS (KRAS or NRAS) wild-type metastatic colorectal cancer</tablecell><tablecell>Skin reactions, electrolyte anomalies, anaphylaxis and angiooedema (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Pertuzumab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell><link><target>HER2</target></link><space/>inhibitor.</tablecell><tablecell>HER2-positive breast cancer.</tablecell><tablecell>Anaphylaxis, cardiac dysfunction and anaemia.</tablecell></tablerow><tablerow><tablecell><link><target>Rituximab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>C (Au)</tablecell><tablecell>IV</tablecell><tablecell>Anti-<link><target>CD20</target></link><space/>antibody.</tablecell><tablecell>CD20-positive B cell<space/><link><target>non-Hodgkin lymphoma</target></link>,<space/><link><target>chronic lymphocytic leukaemia</target></link>, rheumatoid arthritis,<space/><link><target>Wegener's granulomatosis</target></link><space/>and<space/><link><target>microscopic polyangiitis</target></link></tablecell><tablecell>Infusion-related reactions, neutropenia, arrhythmias, infection, thrombocytopenia (uncommon), anaemia (uncommon), angina (uncommon), myocardial infarction (uncommon), heart failure (uncommon), haemolytic anaemia (rare), aplastic anaemia (rare), serum sickness (rare), severe skin conditions (rare), pulmonary infiltrates (rare), pneumonitis (rare), cranial neuropathy (vision or hearing loss; rare) and progressive multifocal leucoencephalopathy (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Tositumomab</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Davies AJ<space/></arg><arg name="title"><space/>Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab<space/></arg><arg name="journal"><space/>Oncogene<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>25<space/></arg><arg name="pages"><space/>3614–3628<space/></arg><arg name="date"><space/>May 2007<space/></arg><arg name="pmid"><space/>17530015<space/></arg><arg name="doi"><space/>10.1038/sj.onc.1210378<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">Bexxar (tositumomab) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/bexxar-tositumomab-342244#showall</arg></template></extension></tablecell><tablecell>Protein</tablecell><tablecell>X (US)</tablecell><tablecell>IV</tablecell><tablecell>Anti-<link><target>CD20</target></link><space/>antibody which is tagged with<space/><link><target>Iodine 131</target><part>I131</part></link>.</tablecell><tablecell>Non-Hodgkin's lymphoma</tablecell><tablecell>Grade 3-4 cytopenias,<space/><link><target>methaemoglobinaemia</target></link>,<space/><link><target>acute myeloid leukaemia</target></link><space/>or<space/><link><target>myelodysplastic syndrome</target></link>, anaphylaxis and<space/><link><target>hyperthyroidism</target></link>.</tablecell></tablerow><tablerow><tablecell><link><target>Trastuzumab</target></link></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>B2 (Au)</tablecell><tablecell>IV</tablecell><tablecell>Anti-<link><target>HER2</target></link><space/>antibody.</tablecell><tablecell>HER2-positive breast cancer, gastric cancer, pancreatic cancer (orphan) and gastro-oesophageal junction cancer.</tablecell><tablecell>Cardiac dysfunction, infusion-related reactions, peripheral neuropathy and pulmonary toxicity (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>2.2 Tyrosine kinase inhibitor</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Afatinib</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Gilotrif (afatinib)</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/gilotrif-afatinib-999864#showall</arg></template></extension></tablecell><tablecell>Phenyl quinazolinamine</tablecell><tablecell>D (US)</tablecell><tablecell>PO</tablecell><tablecell><link><target>Epidermal growth factor receptor</target><part>EGFR</part></link>,<space/><link><target>HER2</target></link><space/>and<space/><link><target>HER4</target></link><space/>inhibitor.</tablecell><tablecell>Non-small cell lung cancer.</tablecell><tablecell>Diarrhoea, hypokalaemia, interstitial lung disease and hepatotoxicity.</tablecell></tablerow><tablerow><tablecell><link><target>Aflibercept</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Zaltrap (ziv-aflibercept) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/zaltrap-ziv-aflibercept-999765#showall</arg></template></extension></tablecell><tablecell>Protein</tablecell><tablecell>C (US)</tablecell><tablecell>IV</tablecell><tablecell><link><target>VEGF</target></link><space/>and<space/><link><target>Placental growth factor</target><part>PGF</part></link><space/>inhibitor.</tablecell><tablecell>Colorectal cancer.</tablecell><tablecell>Myelosuppression, hypertension, dehydration, blood clots, GI perforation and reversible posterior leucoencephalopathy syndrome (uncommon).</tablecell></tablerow><tablerow><tablecell><link><target>Axitinib</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Escudier B, Gore M<space/></arg><arg name="title"><space/>Axitinib for the management of metastatic renal cell carcinoma<space/></arg><arg name="journal"><space/>Drugs in R&D<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>113–26<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>21679004<space/></arg><arg name="pmc"><space/>3585900<space/></arg><arg name="doi"><space/>10.2165/11591240-000000000-00000<space/></arg></template></extension></tablecell><tablecell>Indazole &amp; pyridine analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Multikinase inhibitor.</tablecell><tablecell><link><target>Renal cell carcinoma</target></link></tablecell><tablecell>Hypertension, thyroid dysfunction, blood clots, electrolyte disturbances, GI perforation (rare), fistula formation (rare), reversible posterior leucoencephalopathy syndrome (rare) and<space/><link><target>polycythaemia</target></link><space/>(uncommon).</tablecell></tablerow><tablerow><tablecell><link><target>Bosutinib</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Bosulif (bosutinib) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/bosulif-bosutinib-999770#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Amsberg GK, Koschmieder S<space/></arg><arg name="title"><space/>Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia<space/></arg><arg name="journal"><space/>OncoTargets and Therapy<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="pages"><space/>99–106<space/></arg><arg name="date"><space/>March 2013<space/></arg><arg name="pmid"><space/>23493838<space/></arg><arg name="pmc"><space/>3594007<space/></arg><arg name="doi"><space/>10.2147/OTT.S19901<space/></arg></template></extension></tablecell><tablecell>Quinoline carbonitrile analogue</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>Philadelphia chromosome</target><part>Bcr-Abl</part></link><space/>and SRc kinase inhibitor.</tablecell><tablecell><link><target>Chronic myeloid leukaemia</target></link></tablecell><tablecell>Diarrhoea, thrombocytopenia, neutropenia, hepatotoxicity, QT interval prolongation, kidney failure, pleural effusion, pericarditis (uncommon/rare), acute pancreatitis (uncommon/rare), GI haemorrhage (uncommon/rare), anaphylactic shock (uncommon/rare), acute pulmonary oedema (uncommon/rare), respiratory failure (uncommon/rare),<space/><link><target>pulmonary hypertension</target></link>(uncommon/rare) and erythema multiforme (uncommon/rare).</tablecell></tablerow><tablerow><tablecell><link><target>Crizotinib</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Xalkori (crizotinib) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/xalkori-crizotinib-999682#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Forde PM, Rudin CM<space/></arg><arg name="title"><space/>Crizotinib in the treatment of non-small-cell lung cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1195–201<space/></arg><arg name="date"><space/>Jun 2012<space/></arg><arg name="pmid"><space/>22594847<space/></arg><arg name="doi"><space/>10.1517/14656566.2012.688029<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Frampton JE<space/></arg><arg name="title"><space/>Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer<space/></arg><arg name="journal"><space/>Drugs<space/></arg><arg name="volume"><space/>73<space/></arg><arg name="issue"><space/>18<space/></arg><arg name="pages"><space/>2031–2051<space/></arg><arg name="date"><space/>Dec 2013<space/></arg><arg name="pmid"><space/>24288180<space/></arg><arg name="doi"><space/>10.1007/s40265-013-0142-z<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Rothschild SI, Gautschi O<space/></arg><arg name="title"><space/>Crizotinib in the treatment of non--small-cell lung cancer<space/></arg><arg name="journal"><space/>Clinical Lung Cancer<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>473–480<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>23790969<space/></arg><arg name="doi"><space/>10.1016/j.cllc.2013.04.006<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Roskoski R<space/></arg><arg name="title"><space/>The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders<space/></arg><arg name="journal"><space/>Expert Opinion on Drug Discovery<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>1165–1179<space/></arg><arg name="date"><space/>Sep 2013<space/></arg><arg name="pmid"><space/>23805942<space/></arg><arg name="doi"><space/>10.1517/17460441.2013.813015<space/></arg></template></extension></tablecell><tablecell><link><target>Aminopyridine</target></link></tablecell><tablecell>D (US)</tablecell><tablecell>PO</tablecell><tablecell>ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and Recepteur d'Origine Nantais (RON) inhibitor.</tablecell><tablecell>Non-small cell lung cancer</tablecell><tablecell>Lymphopenia, neutropenia, hypophosphataemia, hypokalaemia, peripheral neuropathy, blood clots, QT interval prolongation, bradycardia, pneumonia, pneumonitis, kidney cyst,<space/><link><target>acute respiratory distress syndrome</target><part>ARDS</part></link><space/>and liver failure.</tablecell></tablerow><tablerow><tablecell><link><target>Dasatinib</target></link></tablecell><tablecell></tablecell><tablecell>Piperazine</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>BCR-ABL, SRC family,<space/><link><target>c-Kit</target></link>,<space/><link><target>EPHA2</target></link><space/>and<space/><link><target>PDGFR</target></link>- kinase inhibitor.</tablecell><tablecell>Philadelphia positive<space/><link><target>chronic myeloid leukaemia</target></link><space/>and<space/><link><target>acute lymphoblastic leukaemia</target></link>.</tablecell><tablecell>Fluid retention, myelosuppression, haemorrhage, hypertension, electrolyte anomalies, cardiac dysfunction (rare), heart failure (rare),<space/><link><target>myocardial infarction</target></link>, arrhythmia (rare), prolonged QT interval (rare),<space/><link><target>kidney failure</target></link><space/>(rare), hypersensitivity (rare) and hepatic failure (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Erlotinib</target></link></tablecell><tablecell></tablecell><tablecell>Quinazoline</tablecell><tablecell>C (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>Epidermal growth factor receptor</target><part>EGFR</part></link><space/>inhibitor.</tablecell><tablecell>Non-small cell lung cancer and pancreatic cancer.</tablecell><tablecell>Skin reactions, diarrhoea, GI bleeds, anaemia, dehydration, interstitial lung disease (uncommon), hepatic failure (rare), hepatorenal syndrome (rare), GI perforation (rare) and ulcerative keratitis (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Gefitinib</target></link></tablecell><tablecell></tablecell><tablecell>Quinazoline</tablecell><tablecell>C (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>Epidermal growth factor receptor</target><part>EGFR</part></link><space/>inhibitor.</tablecell><tablecell><link><target>Epidermal growth factor receptor</target><part>EGFR</part></link>-mutation positive non-small cell lung cancer.</tablecell><tablecell>Skin reactions, diarrhoea, dehydration, haemorrhage, interstitial lung disease (uncommon), pancreatitis (uncommon), hepatitis (uncommon), allergy (uncommon), hepatic failure (rare),<space/><link><target>toxic epidermal necrolysis</target></link><space/>(rare) and<space/><link><target>Stevens-Johnson syndrome</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Imatinib</target></link></tablecell><tablecell></tablecell><tablecell>Pyrimidine and piperazine.</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Bcr-Abl kinase inhibitor.</tablecell><tablecell>Philadelphia chromosome-positive acute lymphoblastic leukaemia, chronic myeloid leukaemia, GI stromal tumour and myelodysplastic/myeloproliferative diseases.</tablecell><tablecell>Myelosuppression, fluid retention, GI bleeding, electrolyte anomalies, left ventricular dysfunction (uncommon), heart failure (uncommon), pulmonary oedema (uncommon), kidney failure (uncommon), angiooedema (rare), anaphylaxis (rare), GI perforation (rare), hepatotoxicity (rare), avascular necrosis (rare), myopathy (rare) and<space/><link><target>rhabdomyolysis</target></link><space/>(rare).</tablecell></tablerow><tablerow><tablecell><link><target>Lapatinib</target></link></tablecell><tablecell></tablecell><tablecell>Quinazoline</tablecell><tablecell>C (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>HER2</target></link><space/>inhibitor.</tablecell><tablecell><link><target>HER2</target></link>-positive breast cancer, stomach cancer (orphan) and oesophageal cancer (orphan).</tablecell><tablecell>Diarrhoea, interstitial lung disease (uncommon), hepatotoxicity (uncommon) and anaphylaxis (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Nilotinib</target></link></tablecell><tablecell></tablecell><tablecell>Imidazole</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Bcr-Abl kinase inhibitor.</tablecell><tablecell>Chronic myeloid leukaemia.</tablecell><tablecell>Myelosuppression, electrolyte disturbances,<space/><link><target>hyperglycaemia</target></link>, prolonged QT interval (uncommon), peripheral arterial occlusive disease (uncommon), pancreatitis (uncommon), pleural effusion (uncommon) and pericardial effusion (uncommon).</tablecell></tablerow><tablerow><tablecell><link><target>Pazopanib</target></link></tablecell><tablecell></tablecell><tablecell>Indazole</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Multikinase inhibitor, including<space/><link><target>c-KIT</target></link>,<space/><link><target>FGFR</target></link>,<space/><link><target>PDGFR</target></link><space/>and<space/><link><target>VEGFR</target></link>.</tablecell><tablecell>Renal cell carcinoma and soft tissue sarcoma.</tablecell><tablecell>Hypertension, QT interval prolongation, haemorrhage, blood clots, neutropenia, thrombocytopenia, neutropenia, thrombocytopenia, elevated thyroid-stimulating hormone, hypothyroidism, electrolyte disturbances, hypo- or hyperglycaemia, torsades de pointes (uncommon), heart failure (uncommon), hepatic failure (uncommon), GI perforation (uncommon), fistula formation (uncommon) and reversible posterior leucoencephalopathy syndrome (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Ponatinib</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Iclusig (ponatinib) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/iclusig-ponatinib-999800#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Price KE, Saleem N, Lee G, Steinberg M<space/></arg><arg name="title"><space/>Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia<space/></arg><arg name="journal"><space/>OncoTargets and Therapy<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="pages"><space/>1111–8<space/></arg><arg name="date"><space/>August 2013<space/></arg><arg name="pmid"><space/>23986642<space/></arg><arg name="pmc"><space/>3754816<space/></arg><arg name="doi"><space/>10.2147/OTT.S36980<space/></arg></template></extension></tablecell><tablecell>Imidazopyridazine</tablecell><tablecell>D (US)</tablecell><tablecell>PO</tablecell><tablecell>Multikinase inhibitor (BEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2 and FLT3), that also inhibits T135I Bcr-Abl kinase.</tablecell><tablecell>T135I positive Chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia.</tablecell><tablecell>Hypertension, neutropenia, leucopenia, anaemia, thrombocytopenia, lymphopenia, pleural effusion, heart failure, peripheral neuropathy, haemorrhage, blood clots, pancreatitis and infection.</tablecell></tablerow><tablerow><tablecell><link><target>Regorafenib</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Stivarga (regorafenib) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/stivarga-regorafenib-999774#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Strumberg D, Schultheis B<space/></arg><arg name="title"><space/>Regorafenib for cancer<space/></arg><arg name="journal"><space/>Expert Opinion on Investigational Drugs<space/></arg><arg name="volume"><space/>21<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>879–889<space/></arg><arg name="date"><space/>Jun 2012<space/></arg><arg name="pmid"><space/>22577890<space/></arg><arg name="doi"><space/>10.1517/13543784.2012.684752<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Aprile G, Macerelli M, Giuliani F<space/></arg><arg name="title"><space/>Regorafenib for gastrointestinal malignancies : from preclinical data to clinical results of a novel multi-target inhibitor<space/></arg><arg name="journal"><space/>BioDrugs<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>213–224<space/></arg><arg name="date"><space/>Jun 2013<space/></arg><arg name="pmid"><space/>23435872<space/></arg><arg name="doi"><space/>10.1007/s40259-013-0014-9<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Shahda S, Saif MW<space/></arg><arg name="title"><space/>Regorafenib: from bench to bedside in colorectal cancer<space/></arg><arg name="journal"><space/>Expert Review of Clinical Pharmacology<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>243–248<space/></arg><arg name="date"><space/>May 2013<space/></arg><arg name="pmid"><space/>23656338<space/></arg><arg name="doi"><space/>10.1586/ecp.13.11<space/></arg></template></extension></tablecell><tablecell>4-phenoxypyridine</tablecell><tablecell>D (US)</tablecell><tablecell>PO</tablecell><tablecell>Multikinase inhibitor for RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, Trk2A, Eph2A, RAF-1, BRAF, BRAFV600E, SAPK2, PTK5, and Bcr-Abl.</tablecell><tablecell>Colorectal cancer and GI stromal tumours.</tablecell><tablecell>Anaemia, lymphopenia, thrombocytopenia, electrolyte anomalies, hepatotoxicity, hypertension, hypothyroidism, neutropenia, myocardial ischaemia or infarction.</tablecell></tablerow><tablerow><tablecell><link><target>Ruxolitinib</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">10 February 2014</arg><arg name="url">http://reference.medscape.com/drug/jakafi-ruxolitinib-999703#showall</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">JAKAVI® Ruxolitinib</arg><arg name="work">TGA eBusiness Services</arg><arg name="publisher">Novartis Pharmaceuticals Australia Pty Limited</arg><arg name="date">21 January 2014</arg><arg name="url">https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id</arg><arg name="format">PDF</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN<space/></arg><arg name="title"><space/>Ruxolitinib for myelofibrosis--an update of its clinical effects<space/></arg><arg name="journal"><space/>Clinical Lymphoma, Myeloma & Leukemia<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>638–645<space/></arg><arg name="date"><space/>Dec 2013<space/></arg><arg name="pmid"><space/>24238036<space/></arg><arg name="doi"><space/>10.1016/j.clml.2013.09.006<space/></arg><arg name="url"><space/>http://www.sciencedirect.com/science/article/pii/S2152265013004278/pdfft?md5</arg><arg name="format"><space/>PDF<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Vaddi K, Sarlis NJ, Gupta V<space/></arg><arg name="title"><space/>Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis<space/></arg><arg name="journal"><space/>Expert Opinion on Pharmacotherapy<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>16<space/></arg><arg name="pages"><space/>2397–2407<space/></arg><arg name="date"><space/>Nov 2012<space/></arg><arg name="pmid"><space/>23051187<space/></arg><arg name="doi"><space/>10.1517/14656566.2012.732998<space/></arg></template></extension></tablecell><tablecell>Pyrimidinylpyrazole</tablecell><tablecell>C (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>JAK1</target></link><space/>and<space/><link><target>JAK2</target></link><space/>inhibitor.</tablecell><tablecell><link><target>Myelofibrosis</target></link><space/>and pancreatic cancer (orphan).</tablecell><tablecell>Anaemia and thrombocytopenia.</tablecell></tablerow><tablerow><tablecell><link><target>Sorafenib</target></link></tablecell><tablecell></tablecell><tablecell>4-phenoxypyridine</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Multikinase inhibitor (including VEGF and PDGF receptor kinases).</tablecell><tablecell>Renal cell carcinoma and<space/><link><target>hepatocellular carcinoma</target></link>.</tablecell><tablecell>Hypertension, skin reactions, bleeding, neutropenia, thrombocytopenia, lymphopenia, peripheral neuropathy, thyroid dysfunction, electrolyte anomalies, myocardial ischaemia or infarctions, heart failure (uncommon), GI perforation (uncommon), pancreatitis (uncommon), reversible posterior leucoencephalopathy syndrome (rare), hepatitis (rare), nephrotic syndrome (rare) and prolonged QT interval (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Sunitinib</target></link></tablecell><tablecell></tablecell><tablecell>Oxindole</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell>Multikinase inhibitor (including VEGF &amp; PDGF receptor tyrosine kinases)</tablecell><tablecell>renal cell carcinoma, GI stromal tumour and pancreatic neuroendocrine tumour</tablecell><tablecell>Neutropenia, thrombocytopenia, lymphopenia, hypertension, left ventricular dysfunction, heart failure, blood clots, thyroid dysfunction, electrolyte anomalies, pancreatitis (uncommon), hepatic failure (uncommon), prolonged QT interval (rare), torsades de pointes (rare), GI perforation (rare), fistula formation (rare), seizures (rare), reversible posterior leucoencephalopathy syndrome (rare),<space/><link><target>haemolytic uraemic syndrome</target></link><space/>(rare), thrombotic thrombocytopenic purpura (rare), nephrotic syndrome (rare), hypersensitivity (rare), angiooedema (rare), toxic epidermal necrolysis (rare) and Stevens-Johnson syndrome (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Vandetanib</target></link><extension extension_name='ref'><template><target>cite web</target><arg name="title">Vandetanib dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/vandetanib-999645#showall</arg></template></extension></tablecell><tablecell></tablecell><tablecell>Quinazoline</tablecell><tablecell>D (US)</tablecell><tablecell>PO</tablecell><tablecell>Tyrosine kinase inhibitor (TKI) with selective activity against RET, VEGFR-2 and EGFR</tablecell><tablecell>Medullary thyroid cancer.</tablecell><tablecell>Diarrhoea, hypertension, QT interval prolongation, depression, electrolyte anomalies, hypothyroidism and GI perforation (uncommon).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>2.3<space/><link><target>Mammalian target of rapamycin</target><part>mTOR</part></link><space/>inhibitors</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Everolimus</target></link></tablecell><tablecell></tablecell><tablecell><link><target>Sirolimus</target></link><space/>analogue.</tablecell><tablecell>C (Au)</tablecell><tablecell>PO</tablecell><tablecell>mTOR inhibitor.</tablecell><tablecell>Renal cell cancer, pancreatic neuroendocrine tumour and breast cancer</tablecell><tablecell>Pleural effusion, hyperglycaemia, hypercholesterolaemia, hypertriglyceridaemia, neutropenia, lymphopenia, thrombocytopenia, anaemia, bleeding, kidney failure, hypokalaemia, hypophosphataemia, pneumonitis, impaired wound healing (uncommon), anaphylaxis (rare) and angiooedema (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Temsirolimus</target></link></tablecell><tablecell></tablecell><tablecell>Sirolimus analogue.</tablecell><tablecell>D (Au)</tablecell><tablecell>IV</tablecell><tablecell>mTOR inhibitor.</tablecell><tablecell>Renal cell cancer and mantle cell lymphoma.</tablecell><tablecell>Infusion reactions, impaired wound healing, hyperglycaemia, hypercholesterolaemia, hypertriglyceridaemia, neutropenia, lymphopenia, thrombocytopenia, anaemia, bleeding, kidney failure, hypokalaemia, hypophosphataemia, pneumonitis, bowel perforation (uncommon) and intracerebral bleeding and Stevens-Johnson syndrome (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>2.4 Retinoids</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Alitretinoin</target></link></tablecell><tablecell></tablecell><tablecell>9-cis retinoic acid</tablecell><tablecell>D (US)</tablecell><tablecell>Topical</tablecell><tablecell><link><target>Retinoic acid receptor</target></link><space/>(RAR) and<space/><link><target>retinoid X receptor</target></link><space/>(RXR) agonist.</tablecell><tablecell>Kaposi's sarcoma.</tablecell><tablecell>Oedema, rashes</tablecell></tablerow><tablerow><tablecell><link><target>Bexarotene</target></link><extension extension_name='ref'><template><target>cite web</target><arg name="title">Targretin (bexarotene) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/targretin-bexarotene-342234#showall</arg></template></extension></tablecell><tablecell></tablecell><tablecell>Phenethylnaphthalene</tablecell><tablecell>X (US)</tablecell><tablecell>PO, topical</tablecell><tablecell>RXR agonist.</tablecell><tablecell>Cutaneous T cell lymphoma</tablecell><tablecell>Leucopenia, anaemia, lactic dehydrogenase increased, hypochromic anaemia, hyperlipidaemia, hypercholesteraemia, hypothyroidism, haemorrhage, hypertension and kidney dysfunction.</tablecell></tablerow><tablerow><tablecell><link><target>Isotretinoin</target></link></tablecell><tablecell></tablecell><tablecell>13-cis retinoic acid</tablecell><tablecell>D (Au, topical), X (Au, oral)</tablecell><tablecell>PO, topical</tablecell><tablecell>RXR &amp; RAR agonist.</tablecell><tablecell>Neuroblastoma<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Matthay KK<space/></arg><arg name="title"><space/>Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption<space/></arg><arg name="journal"><space/>Clinical Cancer Research<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>311–313<space/></arg><arg name="date"><space/>Jan 2013<space/></arg><arg name="pmid"><space/>23209029<space/></arg><arg name="doi"><space/>10.1158/1078-0432.CCR-12-3313<space/></arg></template></extension><space/>and<space/><link><target>acne</target></link>.</tablecell><tablecell><bold>Topical:</bold><space/>Skin reactions, blood lipid anomalies, increased platelet count and osteoporosis.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Amnesteem, Claravis (isotretinoin) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/amnesteem-claravis-isotretinoin-343544#showall</arg></template></extension><space/><bold>Oral:</bold><space/>Anaemia, Red blood cell sedimentation rate increased, thrombocytopenia, thrombocytosis, neutropenia, anaphylaxis, hypersensitivity, diabetes mellitus, hyperuricaemia, psychiatric disturbances (rare), convulsions (very rare), conjunctivitis, vasculitis (very rare), GI haemorrhage (very rare), hepatitis (very rare), erythema multiforme, stevens-Johnson Syndrome, toxic epidermal necrolysis, arthritis (very rare), rhabdomyolysis and<space/><link><target>glomerulonephritis</target></link><space/>(very rare).<extension extension_name='ref'><template><target>cite web</target><arg name="title">Isotretinoin 20mg capsules – Summary of Product Characteristics (SPC)</arg><arg name="work">electronic Medicines Compendium</arg><arg name="publisher">Alliance Pharmaceuticals</arg><arg name="date">12 April 2013</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://www.medicines.org.uk/emc/medicine/15655/SPC/Isotretinoin+20mg+capsules/</arg></template></extension></tablecell></tablerow><tablerow><tablecell><link><target>Tamibarotene</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Miwako I, Kagechika H<space/></arg><arg name="title"><space/>Tamibarotene<space/></arg><arg name="journal"><space/>Drugs of Today<space/></arg><arg name="volume"><space/>43<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>563–8<space/></arg><arg name="date"><space/>Aug 2007<space/></arg><arg name="pmid"><space/>17925887<space/></arg><arg name="doi"><space/>10.1358/dot.2007.43.8.1072615<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fukasawa H, Nakagomi M, Yamagata N, Katsuki H, Kawahara K, Kitaoka K, Miki T, Shudo K<space/></arg><arg name="title"><space/>Tamibarotene: a candidate retinoid drug for Alzheimer's disease<space/></arg><arg name="journal"><space/>Biological & Pharmaceutical Bulletin<space/></arg><arg name="volume"><space/>35<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1206–12<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22863914<space/></arg><arg name="doi"><space/>10.1248/bpb.b12-00314<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Takeuchi M<space/></arg><arg name="title"><space/>[Clinical experience with a new synthetic retinoid, tamibarotene (Am-80) for relapsed or refractory acute promyelocytic leukemia]<space/></arg><arg name="language"><space/>Japanese<space/></arg><arg name="journal"><space/>Gan to Kagaku Ryoho. Cancer & Chemotherapy<space/></arg><arg name="volume"><space/>33<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>397–401<space/></arg><arg name="date"><space/>Mar 2006<space/></arg><arg name="pmid"><space/>16531727<space/></arg></template></extension></tablecell><tablecell>Naphthalene</tablecell><tablecell>N/A</tablecell><tablecell>PO</tablecell><tablecell>RAR agonist.</tablecell><tablecell>Refractory acute promyelocytic leukaemia and Alzheimer's disease.</tablecell><tablecell>Hypercholesterolaemia, hypertriglyceridaemia, gastrointestinal disturbances, liver damage, leucocytosis and<space/><link><target>differentiation syndrome</target></link>.</tablecell></tablerow><tablerow><tablecell><link><target>Tretinoin</target></link></tablecell><tablecell></tablecell><tablecell><italics>all-trans</italics><space/>retinoic acid</tablecell><tablecell>D (Au, topical), X (Au, oral)</tablecell><tablecell>PO, topical</tablecell><tablecell>RXR &amp; RAR agonist.</tablecell><tablecell>Acne and<space/><link><target>acute promyelocytic leukaemia</target></link>.</tablecell><tablecell><bold>Oral:</bold><space/>Differentiation syndrome, hyperleucocytosis, elevated cholesterol and triglycerides, arrhythmias, pancreatitis, elevated liver enzymes, thrombosis, intracranial hypertension and pseudotumour cerebri (mainly in children), anxiety, depression and genital ulceration (rare).<space/><bold>Topical:</bold><space/>Erythema.</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>2.4 Immunomodulatory Agents (IMiDs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Lenalidomide</target></link></tablecell><tablecell></tablecell><tablecell>Thalidomide analogue</tablecell><tablecell>X (Au)</tablecell><tablecell>PO</tablecell><tablecell>Numerous actions; anti-angiogenesis (via inhibition of VEGF release), anti-<link><target>Tumour necrosis factor</target><part>TNF</part></link>,<space/><link><target>Interleukin 6</target><part>IL-6</part></link><space/>and pro-<link><target>interleukin 2</target><part>IL-2</part></link>,<space/><link><target>interferon gamma</target><part>IFN-</part></link><space/>effects. Also stimulates T cells and apoptosis in cancer cells.</tablecell><tablecell><link><target>Multiple myeloma</target></link></tablecell><tablecell>Blood clots, neutropenia (dose-limiting), thrombocytopenia (dose-limiting), anaemia, infection, hypotension, hypokalaemia, hypothyroidism, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, pneumonitis, hepatotoxicity and secondary malignancies (mostly myelodysplastic syndrome and acute myeloid leukaemia).</tablecell></tablerow><tablerow><tablecell><link><target>Pomalidomide</target></link></tablecell><tablecell></tablecell><tablecell>Thalidomide analogue</tablecell><tablecell>X (US)</tablecell><tablecell>PO</tablecell><tablecell>As above.</tablecell><tablecell>Multiple myeloma and systemic sclerosis (orphan).</tablecell><tablecell>Neutropenia, anaemia, pneumonia, thrombocytopenia, hypercalcaemia, hyperglycaemia, kidney failure, lymphopenia, hyponatraemia, hypocalcaemia, hypokalaemia, peripheral neuropathy and thromboembolism.</tablecell></tablerow><tablerow><tablecell><link><target>Thalidomide</target></link></tablecell><tablecell></tablecell><tablecell>Thalidomide</tablecell><tablecell>X (Au)</tablecell><tablecell>PO</tablecell><tablecell>As above.</tablecell><tablecell>Multiple myeloma, erythema nodosum leprosum and the following orphan indications:<space/><link><target>graft versus host disease</target></link>, mycobacterial infection, recurrent aphthous ulcers, severe recurrent aphthous stomatitis, primary brain malignancies, HIV-associated wasting syndrome, Crohn's disease, Kaposi's sarcoma, myelodysplastic syndrome and haematopoietic stem cell transplantation.</tablecell><tablecell>Peripheral neuropathy, depression, thromboembolism, bradycardia, orthostatic hypotension, leucopenia, hypothyroidism, thrombocytopenia (uncommon), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), pneumonitis (rare), hepatotoxicity (rare) and hearing loss (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>2.5 Histone deacetylase inhibitors</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Romidepsin</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Istodax (romidepsin) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">10 February 2014</arg><arg name="url">http://reference.medscape.com/drug/istodax-romidepsin-999311#showall</arg></template></extension></tablecell><tablecell>Depsipeptide</tablecell><tablecell>D (US)</tablecell><tablecell>IV</tablecell><tablecell>Histone deacetylase inhibitor, hence inducing alterations in gene expression in the affected cells.</tablecell><tablecell>Peripheral and cutaneous T cell lymphoma.</tablecell><tablecell>Electrolyte anomalies, anaemia, thrombocytopenia, neutropenia, lymphopenia and ECG anomalies.</tablecell></tablerow><tablerow><tablecell><link><target>Valproate</target></link><extension extension_name='ref' group="Note">Its use in cancer treatment is purely investigational at this point in time</extension></tablecell><tablecell><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bellos F, Mahlknecht U<space/></arg><arg name="title"><space/>Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients<space/></arg><arg name="journal"><space/>Onkologie<space/></arg><arg name="volume"><space/>31<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>629–33<space/></arg><arg name="date"><space/>Nov 2008<space/></arg><arg name="pmid"><space/>19145098<space/></arg><arg name="doi"><space/>10.1159/000160599<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Blaheta RA, Nau H, Michaelis M, Cinatl J<space/></arg><arg name="title"><space/>Valproate and valproate-analogues: potent tools to fight against cancer<space/></arg><arg name="journal"><space/>Current Medicinal Chemistry<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>15<space/></arg><arg name="pages"><space/>1417–33<space/></arg><arg name="date"><space/>Aug 2002<space/></arg><arg name="pmid"><space/>12173980<space/></arg><arg name="doi"><space/>10.2174/0929867023369763<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Blaheta RA, Cinatl J<space/></arg><arg name="title"><space/>Anti-tumor mechanisms of valproate: a novel role for an old drug<space/></arg><arg name="journal"><space/>Medicinal Research Reviews<space/></arg><arg name="volume"><space/>22<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>492–511<space/></arg><arg name="date"><space/>Sep 2002<space/></arg><arg name="pmid"><space/>12210556<space/></arg><arg name="doi"><space/>10.1002/med.10017<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA<space/></arg><arg name="title"><space/>Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors<space/></arg><arg name="journal"><space/>Cancer Treatment Reviews<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>206–22<space/></arg><arg name="date"><space/>May 2008<space/></arg><arg name="pmid"><space/>18226465<space/></arg><arg name="doi"><space/>10.1016/j.ctrv.2007.11.003<space/></arg></template></extension></tablecell><tablecell>Branched short-chain fatty acids.</tablecell><tablecell>D (Au)</tablecell><tablecell>PO, IV</tablecell><tablecell>As above.</tablecell><tablecell>Migraine prophylaxis, mania, epilepsy,<space/><link><target>fragile X syndrome</target></link>(orphan),<space/><link><target>familial adenomatous polyposis</target></link><space/>(orphan) and the following off-label uses: cervical cancer, melanoma, mesothelioma, acute myeloid leukaemia and myelodysplastic syndrome.</tablecell><tablecell><link><target>Hyperammonaemia</target></link>, thrombocytopenia,<space/><link><target>polycystic ovaries</target></link>,<space/><link><target>syndrome of inappropriate antidiuretic hormone secretion</target><part>SIADH</part></link><space/>(uncommon), hepatic failure (rare), pancreatitis (rare), leucopenia (rare), neutropenia (rare), pure red cell aplasia (rare), agranulocytosis (rare), extrapyramidal syndrome (rare), reduced BMD with long-term use, pleural effusion (rare) and multiorgan hypersensitivity reaction (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Vorinostat</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Zolinza (vorinostat) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">10 February 2014</arg><arg name="url">http://reference.medscape.com/drug/zolinza-vorinostat-342102#showall</arg></template></extension></tablecell><tablecell>Phenyloctanediamide</tablecell><tablecell>D (US)</tablecell><tablecell>PO</tablecell><tablecell>As above.</tablecell><tablecell>As per romidepsin.</tablecell><tablecell>Thrombocytopenia, anaemia, QT interval prolongation and pulmonary embolism.</tablecell></tablerow><tablerow><tablecell colspan="8" align="center"><bold><xhtml:big>2.6 Other Agents</xhtml:big></bold></tablecell></tablerow><tablerow><tablecell><link><target>Anagrelide</target></link></tablecell><tablecell></tablecell><tablecell>Imidazoquinazoline</tablecell><tablecell>B3 (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>PDE3</target><part>Phosphodiesterase 3</part></link><space/>inhibitor.</tablecell><tablecell><link><target>Essential thrombocythaemia</target></link></tablecell><tablecell>Fluid retention, palpitations, tachycardia, hepatotoxicity (uncommon), heart failure (uncommon), hypertension (uncommon), arrhythmia (uncommon), syncope (uncommon), cardiomyopathy (rare), cardiomegaly (rare), MI (rare), pulmonary hypertension (rare), interstitial lung disease (rare) and pancreatitis (rare).</tablecell></tablerow><tablerow><tablecell><link><target>Arsenic trioxide</target></link><extension extension_name='ref' group="Note">There is no INN for arsenic trioxide, just the USAN</extension></tablecell><tablecell></tablecell><tablecell>Arsenic compound</tablecell><tablecell>X (Au)</tablecell><tablecell>IV</tablecell><tablecell>Not fully understood. Induces partial differentiation and promotes apoptosis of leukaemic cells and may also inhibit angiogenesis.</tablecell><tablecell>Refractory or relapsed acute promyelocytic leukaemia. Orphan indications include: acute myeloid leukaemia, chronic lymphocytic leukaemia, malignant glioma, myelodysplastic syndrome, multiple myeloma, liver cancer and chronic myeloid leukaemia.</tablecell><tablecell><link><target>Differentiation syndrome</target></link>, hyperleucocytosis, neutropenia, thrombocytopenia, ventricular tachycardia, prolonged QT interval, torsades de pointes, complete atrioventricular block, peripheral neuropathy, hyperglycaemia, hypokalaemia, hypomagnesaemia, elevation of bilirubin or aminotransferases, hepatotoxicity and secondary malignancies.</tablecell></tablerow><tablerow><tablecell><link><target>Asparaginase</target></link><xhtml:br></xhtml:br><extension extension_name='ref' group="Note">There is no INN for asparaginase, only a USAN</extension></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>D (Au)</tablecell><tablecell>IM, IV</tablecell><tablecell>Catalyses the conversion of the amino acid L-asparagine to aspartic acid and thereby reduces the availability of L-asparagine to leukaemic cells. Unlike normal cells, certain types of leukaemic cells do not synthesise L-asparagine, which is essential for cell growth and survival.</tablecell><tablecell>Acute lymphoblastic leukaemia and lymphoblastic lymphoma.</tablecell><tablecell>Allergic reactions, haemorrhagic and thrombotic events, uraemia, pancreatitis, hyperglycaemia,<space/><link><target>hyperammonaemia</target></link>, acute kidney failure and diabetic ketoacidosis.</tablecell></tablerow><tablerow><tablecell><link><target>Bacillus Calmette-Guerin</target><part>BCG</part></link><space/>vaccine<xhtml:br></xhtml:br><extension extension_name='ref' group="Note">There is no INN for BCG</extension></tablecell><tablecell></tablecell><tablecell>Protein</tablecell><tablecell>B2 (Au)</tablecell><tablecell>IB</tablecell><tablecell>Live, attenuated Mycobacterium bovis, which produces a local inflammatory reaction, resulting in elimination or reduction of superficial tumour lesions of the bladder.</tablecell><tablecell>Bladder cancer</tablecell><tablecell>Cystitis, BCG infection and contracted bladder.</tablecell></tablerow><tablerow><tablecell><link><target>Denileukin diftitox</target></link></tablecell><tablecell><extension extension_name='ref'><template><target>cite web</target><arg name="title">Ontak (denileukin) dosing, indications, interactions, adverse effects, and more</arg><arg name="work">Medscape Reference</arg><arg name="publisher">WebMD</arg><arg name="accessdate">9 February 2014</arg><arg name="url">http://reference.medscape.com/drug/ontak-denileukin-342205#showall</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lansigan F, Stearns DM, Foss F<space/></arg><arg name="title"><space/>Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma<space/></arg><arg name="journal"><space/>Cancer Management and Research<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="pages"><space/>53–59<space/></arg><arg name="date"><space/>February 2010<space/></arg><arg name="pmid"><space/>21188096<space/></arg><arg name="pmc"><space/>3004568<space/></arg><arg name="doi"><space/>10.2147/CMAR.S5009<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Manoukian G, Hagemeister F<space/></arg><arg name="title"><space/>Denileukin diftitox: a novel immunotoxin<space/></arg><arg name="journal"><space/>Expert Opinion on Biological Therapy<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1445–1451<space/></arg><arg name="date"><space/>Nov 2009<space/></arg><arg name="pmid"><space/>19817678<space/></arg><arg name="doi"><space/>10.1517/14712590903348135<space/></arg></template></extension><xhtml:br></xhtml:br><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kaminetzky D, Hymes KB<space/></arg><arg name="title"><space/>Denileukin diftitox for the treatment of cutaneous T-cell lymphoma<space/></arg><arg name="journal"><space/>Biologics<space/></arg><arg name="volume"><space/>2<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>717–724<space/></arg><arg name="date"><space/>Dec 2008<space/></arg><arg name="pmid"><space/>19707452<space/></arg><arg name="pmc"><space/>2727893<space/></arg><arg name="doi"><space/>10.2147/BTT.S3084<space/></arg></template></extension></tablecell><tablecell>Protein</tablecell><tablecell>C (US)</tablecell><tablecell>IV</tablecell><tablecell>Interleukin 2 combined with diphtheria toxin which binds to the interleukin receptor on immune cells and introduces the diphtheria toxin into the cell.</tablecell><tablecell>Cutaneous T cell lymphoma and peripheral T cell lymphoma (orphan).</tablecell><tablecell>Infusion reactions, hypocalcaemia, hypotension, thrombocytopenia, Acute renal insufficiency (uncommon/rare), Hyper/hypothyroidism (uncommon/rare), pancreatitis (uncommon/rare) and toxic epidermal necrolysis (uncommon/rare).</tablecell></tablerow><tablerow><tablecell><link><target>Vemurafenib</target></link></tablecell><tablecell></tablecell><tablecell>Pyrrolopyridine</tablecell><tablecell>D (Au)</tablecell><tablecell>PO</tablecell><tablecell><link><target>BRAF (gene)</target><part>BRAF</part></link><space/>kinase inhibitor.</tablecell><tablecell>BRAF kinase mutation V600E-positive Metastatic melanoma.</tablecell><tablecell>Skin reactions, secondary malignancies (mostly squamous cell carcinoma), anaphylaxis (rare) and hypotension (rare).</tablecell></tablerow><tablerow><tablecell colspan="8" style="background:transparent; font-size:88%;"><bold>Abbreviations/Acronyms:</bold><xhtml:br></xhtml:br>IM Intramuscular.IV Intravenous.IA Intra-arterial.SC Subcutaneous.PO Per os, oral.IP Intrapleural.IB Intrabladder.Preg. cat. -<space/><italics>Pregnancy category</italics>. The preferred pregnancy category is Australian, but if it is unavailable the pregnancy category given is American.</tablecell></tablerow><tablerow><tablecell colspan="8"><bold>Notes</bold><template><target>reflist</target><arg name="group"><space/>Note</arg></template></tablecell></tablerow></table><heading level='2'>History</heading><paragraph><template><target>Main</target><arg>History of cancer chemotherapy</arg></template><link><target>File:Sidney Farber nci-vol-1926-300.jpg</target><part>thumb</part><part>150px</part><part><link><target>Sidney Farber</target></link><space/>is regarded as the father of modern chemotherapy.</part></link>The first use of drugs to treat cancer was in the early 20th century, although it was not originally intended for that purpose.<space/><link><target>Mustard gas</target></link><space/>was used as a<space/><link><target>chemical warfare</target></link><space/>agent during<space/><link><target>World War I</target></link><space/>and was discovered to be a potent suppressor of<space/><link><target>hematopoiesis</target></link><space/>(blood production).<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Krumbhaar EB<space/></arg><arg name="title">Role of the blood and the bone marrow in certain forms of gas poisoning<space/></arg><arg name="journal">JAMA<space/></arg><arg name="volume">72<space/></arg><arg name="pages">39–41<space/></arg><arg name="year">1919<space/></arg><arg name="doi">10.1001/jama.1919.26110010018009f<space/></arg></template></extension><space/>A similar family of compounds known as<space/><link><target>nitrogen mustards</target></link><space/>were studied further during<space/><link><target>World War II</target></link><space/>at the<space/><link><target>Yale School of Medicine</target></link>.<extension extension_name='ref' name="Fenn"><template><target>cite journal</target><arg name="author"><space/>Fenn JE, Udelsman R<space/></arg><arg name="title"><space/>First use of intravenous chemotherapy cancer treatment: rectifying the record<space/></arg><arg name="journal"><space/>Journal of the American College of Surgeons<space/></arg><arg name="volume"><space/>212<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>413–417<space/></arg><arg name="date"><space/>Mar 2011<space/></arg><arg name="pmid"><space/>21247779<space/></arg><arg name="doi"><space/>10.1016/j.jamcollsurg.2010.10.018<space/></arg></template></extension><space/>It was reasoned that an agent that damaged the rapidly growing white blood cells might have a similar effect on cancer.<extension extension_name='ref' name="Fenn"></extension><space/>Therefore, in December 1942, several patients with advanced<space/><link><target>lymphomas</target></link><space/>(cancers of the lymphatic system and lymph nodes) were given the drug by vein, rather than by breathing the irritating gas.<extension extension_name='ref' name="Fenn"></extension><space/>Their improvement, although temporary, was remarkable.<extension extension_name='ref'><template><target>cite journal</target><arg name="author1">Goodman LS<space/></arg><arg name="author1-link">Louis S. Goodman<space/></arg><arg name="author2">Wintrobe MM<space/></arg><arg name="author3">Dameshek W<space/></arg><arg name="author4">Goodman MJ<space/></arg><arg name="author5">Gilman A<space/></arg><arg name="author5-link">Alfred Goodman, Sr.<space/></arg><arg name="author6">McLennan MT<space/></arg><arg name="title"><space/>Nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders<space/></arg><arg name="journal"><space/>JAMA</arg><arg name="volume"><space/>132<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>126–132<space/></arg><arg name="year"><space/>1946<space/></arg><arg name="doi"><space/>10.1001/jama.1946.02870380008004<space/></arg></template></extension><space/>Concurrently, during a military operation in World War II, following a German<space/><link><target>Air raid on Bari</target><part>air raid</part></link><space/>on the Italian harbour of Bari, several hundred people were accidentally exposed to mustard gas, which had been transported there by the<space/><link><target>Allies of World War II</target><part>Allied forces</part></link><space/>to prepare for possible retaliation in the event of German use of chemical warfare. The survivors were later found to have very low white blood cell counts.<extension extension_name='ref'>Faguet, p. 71</extension><space/>After WWII was over and the reports declassified, the experiences converged and led researchers to look for other substances that might have similar effects against cancer. The first chemotherapy drug to be developed from this line of research was<space/><link><target>mustine</target></link>. Since then, many other drugs have been developed to treat cancer, and drug development has exploded into a multibillion-dollar industry, although the principles and limitations of chemotherapy discovered by the early researchers still apply.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Joensuu H<space/></arg><arg name="title"><space/>Systemic chemotherapy for cancer: from weapon to treatment<space/></arg><arg name="journal"><space/>The Lancet. Oncology<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="page"><space/>304<space/></arg><arg name="date"><space/>Mar 2008<space/></arg><arg name="pmid"><space/>18308256<space/></arg><arg name="doi"><space/>10.1016/S1470-2045(08)70075-5<space/></arg></template></extension></paragraph><heading level='3'>The term<space/><italics>chemotherapy</italics></heading><paragraph>The word<space/><italics>chemotherapy</italics><space/>without a modifier usually refers to cancer treatment, but its historical meaning was broader. The term was coined in the early 1900s by<space/><link><target>Paul Ehrlich</target></link><space/>as meaning any use of chemicals to treat any disease (<italics><link><target>wikt:chemo-</target><part>chemo</part></link>-</italics><space/>+<space/><italics><link><target>wikt:-therapy</target><part>-therapy</part></link></italics>), such as the use of<space/><link><target>antibiotic</target><trail>s</trail></link><space/>(<italics>antibacterial chemotherapy</italics>).<extension extension_name='ref' name="DeVita"><template><target>cite journal</target><arg name="author"><space/>DeVita VT, Chu E<space/></arg><arg name="title"><space/>A history of cancer chemotherapy<space/></arg><arg name="journal"><space/>Cancer Research<space/></arg><arg name="volume"><space/>68<space/></arg><arg name="issue"><space/>21<space/></arg><arg name="pages"><space/>8643–53<space/></arg><arg name="date"><space/>Nov 2008<space/></arg><arg name="pmid"><space/>18974103<space/></arg><arg name="doi"><space/>10.1158/0008-5472.CAN-07-6611<space/></arg></template></extension><space/>Ehrlich was not optimistic that effective chemotherapy drugs would be found for the treatment of cancer.<extension extension_name='ref' name="DeVita"></extension><space/>The first modern chemotherapeutic agent was<space/><link><target>arsphenamine</target></link>, an arsenic compound discovered in 1907 and used to treat<space/><link><target>syphilis</target></link>.<extension extension_name='ref' name="pmid19868743"><template><target>cite journal</target><arg name="author"><space/>Nichols HJ, Walker JE<space/></arg><arg name="title"><space/>EXPERIMENTAL OBSERVATIONS ON THE PROPHYLAXIS AND TREATMENT OF SYPHILIS<space/></arg><arg name="journal"><space/>The Journal of Experimental Medicine<space/></arg><arg name="volume"><space/>37<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>525–42<space/></arg><arg name="date"><space/>Mar 1923<space/></arg><arg name="pmid"><space/>19868743<space/></arg><arg name="pmc"><space/>2128372<space/></arg><arg name="doi"><space/>10.1084/jem.37.4.525<space/></arg></template></extension><space/>This was later followed by<space/><link><target>Sulfonamide (medicine)</target><part>sulfonamides</part></link><space/>(sulfa drugs) and<space/><link><target>penicillin</target></link>. In today's<space/><link><target>usage</target></link>, the<space/><link><target>word sense</target><part>sense</part></link><space/>&quot;any treatment of disease with drugs&quot; is often expressed with the word<space/><italics><link><target>pharmacotherapy</target></link></italics>.</paragraph><heading level='2'>Sales</heading><paragraph>List of the top 10 best-selling cancer drugs of 2013:<extension extension_name='ref'><link type='external' href='http://www.fiercepharma.com/special-reports/top-10-best-selling-cancer-drugs-2013'>Top 10 best-selling cancer drugs of 2013; May 29, 2014</link></extension></paragraph><table class="wikitable"><tablerow><tablehead>No.</tablehead><tablehead>2013 Global Sales</tablehead><tablehead><link><target>International Nonproprietary Name</target><part>INN</part></link></tablehead><tablehead>Trade names</tablehead><tablehead>Companies</tablehead><tablehead>Indications</tablehead></tablerow><tablerow><tablecell>1</tablecell><tablecell>$7.78 billion</tablecell><tablecell><link><target>Rituximab</target></link></tablecell><tablecell>Rituxan/MabThera</tablecell><tablecell>Roche, Pharmstandard</tablecell><tablecell>non-Hodgkin's lymphoma, CLL</tablecell></tablerow><tablerow><tablecell>2</tablecell><tablecell>$6.75 billion</tablecell><tablecell><link><target>Bevacizumab</target></link></tablecell><tablecell>Avastin</tablecell><tablecell>Roche</tablecell><tablecell>Colorectal, lung, ovarian and brain cancer</tablecell></tablerow><tablerow><tablecell>3</tablecell><tablecell>$6.56 billion</tablecell><tablecell><link><target>Trastuzumab</target></link></tablecell><tablecell>Herceptin</tablecell><tablecell>Roche</tablecell><tablecell>Breast, esophagus and stomach cancer</tablecell></tablerow><tablerow><tablecell>4</tablecell><tablecell>$4.69 billion</tablecell><tablecell><link><target>Imatinib</target></link></tablecell><tablecell>Gleevec</tablecell><tablecell>Novartis</tablecell><tablecell>Leukemia, GI cancer</tablecell></tablerow><tablerow><tablecell>5</tablecell><tablecell>$1.09 billion</tablecell><tablecell><link><target>Lenalidomide</target></link></tablecell><tablecell>Revlimid</tablecell><tablecell>Celgene, Pharmstandard</tablecell><tablecell>Multiple myeloma, mantle cell lymphoma</tablecell></tablerow><tablerow><tablecell>6</tablecell><tablecell>$2.7 billion</tablecell><tablecell><link><target>Pemetrexed</target></link></tablecell><tablecell>Alimta</tablecell><tablecell>Eli Lilly</tablecell><tablecell>Lung cancer</tablecell></tablerow><tablerow><tablecell>7</tablecell><tablecell>$2.6 billion</tablecell><tablecell><link><target>Bortezomib</target></link></tablecell><tablecell>Velcade</tablecell><tablecell>Johnson &amp; Johnson, Takeda, Pharmstandard</tablecell><tablecell>Multiple myeloma</tablecell></tablerow><tablerow><tablecell>8</tablecell><tablecell>$1.87 billion</tablecell><tablecell><link><target>Cetuximab</target></link></tablecell><tablecell>Erbitux</tablecell><tablecell>Merck KGaA, Bristol-Myers Squibb</tablecell><tablecell>Colon and head and neck cancer</tablecell></tablerow><tablerow><tablecell>9</tablecell><tablecell>$1.73 billion</tablecell><tablecell><link><target>Leuprorelin</target></link></tablecell><tablecell>Lupron, Eligard</tablecell><tablecell>AbbVie and Takeda; Sanofi and Astellas Pharma</tablecell><tablecell>Prostate and ovarian cancer</tablecell></tablerow><tablerow><tablecell>10</tablecell><tablecell>$1.7 billion</tablecell><tablecell><link><target>Abiraterone</target></link></tablecell><tablecell>Zytiga</tablecell><tablecell>Johnson &amp; Johnson</tablecell><tablecell>Prostate cancer</tablecell></tablerow></table><heading level='2'>Research</heading><paragraph><link><target>File:Mesoporous silica SEM.jpg</target><part>thumb</part><part><link><target>Scanning electron micrograph</target></link><space/>of<space/><link><target>mesoporous silica</target></link>; a type of<space/><link><target>nanoparticle</target></link><space/>used in the delivery of chemotherapeutic drugs.</part></link><template><target>Main</target><arg>Experimental cancer treatments</arg></template></paragraph><heading level='3'>Targeted therapies</heading><paragraph>Specially targeted delivery vehicles aim to increase effective levels of chemotherapy for tumor cells while reducing effective levels for other cells. This should result in an increased tumor kill and/or reduced toxicity.<extension extension_name='ref' name="pmid21501554"><template><target>cite journal</target><arg name="author"><space/>Chidambaram M, Manavalan R, Kathiresan K<space/></arg><arg name="title"><space/>Nanotherapeutics to overcome conventional cancer chemotherapy limitations<space/></arg><arg name="journal"><space/>Journal of Pharmacy & Pharmaceutical Sciences<space/></arg><arg name="volume"><space/>14<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>67–77<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>21501554<space/></arg><arg name="doi"><space/></arg></template></extension></paragraph><heading level='4'>Antibody-drug conjugates</heading><paragraph><link><target>Antibody-drug conjugate</target><trail>s</trail></link><space/>(ADCs) comprise an<space/><link><target>antibody</target></link>, drug and a linker between them. The antibody will be targeted at a preferentially expressed protein in the tumour cells (known as a<space/><link><target>tumor antigen</target></link>) or on cells that the tumor can utilise, such as blood vessel<space/><link><target>endothelial cells</target></link>. They bind to the tumor antigen and are internalised, where the linker releases the drug into the cell. These specially targeted delivery vehicles vary in their stability, selectivity, and choice of target, but, in essence, they all aim to increase the maximum effective dose that can be delivered to the tumor cells.<extension extension_name='ref' name="pmid22003066"><template><target>cite journal</target><arg name="author"><space/>Teicher BA, Chari RV<space/></arg><arg name="title"><space/>Antibody conjugate therapeutics: challenges and potential<space/></arg><arg name="journal"><space/>Clinical Cancer Research<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>20<space/></arg><arg name="pages"><space/>6389–97<space/></arg><arg name="date"><space/>Oct 2011<space/></arg><arg name="pmid"><space/>22003066<space/></arg><arg name="doi"><space/>10.1158/1078-0432.CCR-11-1417<space/></arg></template></extension><space/>Reduced systemic toxicity means that they can also be used in sicker patients, and that they can carry new chemotherapeutic agents that would have been far too toxic to deliver via traditional systemic approaches.<template><target>citation needed</target><arg name="date">August 2013</arg></template></paragraph><paragraph>The first approved drug of this type was<space/><link><target>gemtuzumab ozogamicin</target></link><space/>(Mylotarg), released by<space/><link><target>Wyeth</target></link><space/>(now<space/><link><target>Pfizer</target></link>). The drug was approved to treat<space/><link><target>acute myeloid leukemia</target></link>, but has now been withdrawn from the market because the drug did not meet efficacy targets in further clinical trials.<extension extension_name='ref' name="pmid11673694"><template><target>cite journal</target><arg name="author"><space/>Sievers EL, Linenberger M<space/></arg><arg name="title"><space/>Mylotarg: antibody-targeted chemotherapy comes of age<space/></arg><arg name="journal"><space/>Current Opinion in Oncology<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>522–7<space/></arg><arg name="date"><space/>Nov 2001<space/></arg><arg name="pmid"><space/>11673694<space/></arg><arg name="doi"><space/>10.1097/00001622-200111000-00016<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="last">FDA</arg><arg name="title">Mylotarg (gemtuzumab ozogamicin): Market Withdrawal</arg><arg name="url">http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm216458.htm</arg><arg name="accessdate">18 August 2013</arg></template></extension><space/>Two other drugs,<space/><link><target>trastuzumab emtansine</target></link><space/>and<space/><link><target>brentuximab vedotin</target></link>, are both in late clinical trials, and the latter has been granted accelerated approval for the treatment of<space/><link><target>refractory</target></link><space/><link><target>Hodgkins lymphoma</target></link><space/>and systemic<space/><link><target>anaplastic large cell lymphoma</target></link>.<extension extension_name='ref' name="pmid22003066"></extension></paragraph><heading level='4'>Nanoparticles</heading><paragraph><link><target>Nanoparticles</target></link><space/>are 1-1000<space/><link><target>nanometer</target></link><space/>(nm) sized particles that can promote tumor selectivity and aid in delivering low-<link><target>solubility</target></link><space/>drugs. Nanoparticles can be targeted passively or actively. Passive targeting exploits the difference between tumor blood vessels and normal blood vessels. Blood vessels in tumors are &quot;leaky&quot; because they have gaps from 200-2000&amp;nbsp;nm, which allow nanoparticles to escape into the tumor. Active targeting uses biological molecules (<link><target>antibodies</target></link>,<space/><link><target>protein</target><trail>s</trail></link>,<space/><link><target>DNA</target></link><space/>and<space/><link><target>receptor ligand</target><trail>s</trail></link>) to preferentially target the nanoparticles to the tumor cells. There are many types of nanoparticle delivery systems, such as<space/><link><target>mesoporous silica</target><part>silica</part></link>,<space/><link><target>polymer</target><trail>s</trail></link>,<space/><link><target>liposome</target><trail>s</trail></link><space/>and magnetic particles. Nanoparticles made of magnetic material can also be used to concentrate agents at tumor sites using an externally applied magnetic field.<extension extension_name='ref' name="pmid21501554"></extension><space/>They have emerged as a useful vehicle for poorly soluble agents such as<space/><link><target>paclitaxel</target></link>.<extension extension_name='ref' name="pmid19554862"><template><target>cite journal</target><arg name="author"><space/>Vines T, Faunce T<space/></arg><arg name="title"><space/>Assessing the safety and cost-effectiveness of early nanodrugs<space/></arg><arg name="journal"><space/>Journal of Law and Medicine<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>822–45<space/></arg><arg name="date"><space/>May 2009<space/></arg><arg name="pmid"><space/>19554862<space/></arg><arg name="doi"><space/></arg></template></extension></paragraph><heading level='3'>Electrochemotherapy</heading><paragraph><template><target>Main</target><arg>Electrochemotherapy</arg></template></paragraph><paragraph>Electrochemotherapy is the combined treatment in which injection of a chemotherapeutic drug is followed by application of high-voltage electric pulses locally to the tumor. The treatment enables the chemotherapeutic drugs, which otherwise cannot or hardly go through the membrane of cells (such as bleomycin and cisplatin), to enter the cancer cells. Hence, greater effectiveness of antitumor treatment is achieved.</paragraph><paragraph>Clinical electrochemotherapy has been successfully used for treatment of cutaneous and subcutaneous tumors irrespective of their histological origin.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Heller R, Gilbert R, Jaroszeski MJ<space/></arg><arg name="title"><space/>Clinical applications of electrochemotherapy<space/></arg><arg name="journal"><space/>Advanced Drug Delivery Reviews<space/></arg><arg name="volume"><space/>35<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>119–129<space/></arg><arg name="date"><space/>Jan 1999<space/></arg><arg name="pmid"><space/>10837693<space/></arg><arg name="doi"><space/>10.1016/S0169-409X(98)00067-2<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Larkin JO, Collins CG, Aarons S, Tangney M, Whelan M, O'Reily S, Breathnach O, Soden DM, O'Sullivan GC<space/></arg><arg name="title"><space/>Electrochemotherapy: aspects of preclinical development and early clinical experience<space/></arg><arg name="journal"><space/>Annals of Surgery<space/></arg><arg name="volume"><space/>245<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>469–479<space/></arg><arg name="date"><space/>Mar 2007<space/></arg><arg name="pmid"><space/>17435555<space/></arg><arg name="pmc"><space/>1877027<space/></arg><arg name="doi"><space/>10.1097/01.sla.0000250419.36053.33<space/></arg></template></extension><extension extension_name='ref' name="Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavcic D, Pavlovic I, Paulin-Kosir SM, Cemazar M, Morsli N, Soden DM, Rudolf Z, Robert C, O'Sullivan GC, Mir LM. 2006"><template><target>cite journal</target><arg name="author">Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavcic D, Pavlovic I, Paulin-Kosir SM, Cemazar M, Morsli N, Soden DM, Rudolf Z, Robert C, O'Sullivan GC, Mir LM<space/></arg><arg name="title">Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases<space/></arg><arg name="pages">3–13<space/></arg><arg name="journal">Eur J Cancer Suppl<space/></arg><arg name="volume">4<space/></arg><arg name="issue">11<space/></arg><arg name="year">2006</arg><arg name="doi">10.1016/j.ejcsup.2006.08.002<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Möller MG, Salwa S, Soden DM, O'Sullivan GC<space/></arg><arg name="title"><space/>Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma<space/></arg><arg name="journal"><space/>Expert Review of Anticancer Therapy<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1611–1630<space/></arg><arg name="date"><space/>Nov 2009<space/></arg><arg name="pmid"><space/>19895245<space/></arg><arg name="doi"><space/>10.1586/era.09.129<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF<space/></arg><arg name="title"><space/>Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach<space/></arg><arg name="journal"><space/>Dermatologic Therapy<space/></arg><arg name="volume"><space/>23<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>651–661<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>21054709<space/></arg><arg name="doi"><space/>10.1111/j.1529-8019.2010.01370.x<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Hampton T<space/></arg><arg name="title"><space/>Electric pulses help with chemotherapy, may open new paths for other agents<space/></arg><arg name="journal"><space/>Jama<space/></arg><arg name="volume"><space/>305<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>549–551<space/></arg><arg name="date"><space/>Feb 2011<space/></arg><arg name="pmid"><space/>21304073<space/></arg><arg name="doi"><space/>10.1001/jama.2011.92<space/></arg></template></extension><space/>The method has been reported as safe, simple and highly effective in all reports on clinical use of electrochemotherapy. According to the ESOPE project (European Standard Operating Procedures of Electrochemotherapy), the Standard Operating Procedures (SOP) for electrochemotherapy were prepared, based on the experience of the leading European cancer centres on electrochemotherapy.<extension extension_name='ref' name="Marty M, Sersa G, Garbay JR, Gehl J, Collins CG, Snoj M, Billard V, Geertsen PF, Larkin JO, Miklavcic D, Pavlovic I, Paulin-Kosir SM, Cemazar M, Morsli N, Soden DM, Rudolf Z, Robert C, O'Sullivan GC, Mir LM. 2006"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author">Mir LM, Gehl J, Sersa G, Collins CG, Garbay JR, Billard V, Geertsen PF, Rudolf Z, O'Sullivan GC, Marty M<space/></arg><arg name="title">Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes<space/></arg><arg name="journal">Eur J Cancer Suppl<space/></arg><arg name="volume">4<space/></arg><arg name="issue">11<space/></arg><arg name="pages">14–25<space/></arg><arg name="year">2006<space/></arg><arg name="doi">10.1016/j.ejcsup.2006.08.003<space/></arg></template></extension><space/>Recently, new electrochemotherapy modalities have been developed for treatment of internal tumors using surgical procedures, endoscopic routes or percutaneous approaches to gain access to the treatment area.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Soden DM, Larkin JO, Collins CG, Tangney M, Aarons S, Piggott J, Morrissey A, Dunne C, O'Sullivan GC<space/></arg><arg name="title"><space/>Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours<space/></arg><arg name="journal"><space/>Cancer Letters<space/></arg><arg name="volume"><space/>232<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>300–310<space/></arg><arg name="date"><space/>Feb 2006<space/></arg><arg name="pmid"><space/>15964138<space/></arg><arg name="doi"><space/>10.1016/j.canlet.2005.03.057<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, Bracko M, Pecnik T, Gadzijev E, Sersa G<space/></arg><arg name="title"><space/>Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy<space/></arg><arg name="journal"><space/>Biomedical Engineering Online<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="page"><space/>10<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20178589<space/></arg><arg name="pmc"><space/>2843684<space/></arg><arg name="doi"><space/>10.1186/1475-925X-9-10<space/></arg></template></extension></paragraph><heading level='3'>Hyperthermia therapy</heading><paragraph><link><target>Hyperthermia therapy</target></link><space/>is heat treatment for cancer that can be a powerful tool when used in combination with chemotherapy (thermochemotherapy) or radiation for the control of a variety of cancers. The heat can be applied locally to the tumor site, which will dilate blood vessels to the tumor, allowing more chemotherapeutic medication to enter the tumor. Additionally, the bi-lipid layer of the tumor cell membrane will become more porous, further allowing more of the chemotherapeutic medicine to enter the tumor cell.</paragraph><paragraph>Hyperthermia has also been shown to help prevent or reverse &quot;chemo-resistance.&quot; Chemotherapy resistance sometimes develops over time as the tumors adapt and can overcome the toxicity of the chemo medication. &quot;Overcoming chemoresistance has been extensively studied within the past, especially using CDDP-resistant cells. In regard to the potential benefit that drug-resistant cells can be recruited for effective therapy by combining chemotherapy with hyperthermia, it was important to show that chemoresistance against several anticancer drugs (e.g. mitomycin C, anthracyclines, BCNU, melphalan) including CDDP could be reversed at least partially by the addition of heat.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Issels</arg><arg name="first">R.</arg><arg name="title">Hyperthermia Combined with Chemotherapy – Biological Rationale, Clinical Application, and Treatment Results</arg><arg name="journal">Onkologie</arg><arg name="year">1999</arg><arg name="volume">22</arg><arg name="issue">5</arg><arg name="pages">374–381</arg><arg name="doi">10.1159/000026986</arg></template></extension></paragraph><heading level='2'>Other animals</heading><paragraph>Chemotherapy is used in veterinary medicine similar to how it is used in human medicine.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>McKnight JA<space/></arg><arg name="title"><space/>Principles of chemotherapy<space/></arg><arg name="journal"><space/>Clinical Techniques in Small Animal Practice<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>67–72<space/></arg><arg name="date"><space/>May 2003<space/></arg><arg name="pmid"><space/>12831063<space/></arg><arg name="doi"><space/>10.1053/svms.2003.36617<space/></arg></template></extension></paragraph><heading level='2'>See also</heading><paragraph><template><target>columns-list</target><arg>2</arg><arg>
* [[Anti-Cancer Drugs (journal)]]
* [[Antimicrobial chemotherapy]]
* [[Cancer and nausea]]
* [[Cancer-related fatigue]]
* [[Chemo brain]]
* [[Chemotherapy regimens]]
* [[Cytostasis]]
* [[Experimental cancer treatment]]s
* [[Hazardous drugs#Safe handling|Safe Handling of Hazardous Drugs]]
* [[Hyperthermia therapy]]
* [[Immunotherapy]]
* [[National Comprehensive Cancer Network]]
* [[Radiation induced cognitive decline]]
* [[Radiotherapy]]
* [[Virotherapy]]
</arg></template></paragraph><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>2</arg></template></paragraph><heading level='2'>Bibliography</heading><paragraph><template><target>refbegin</target></template></paragraph><list type='bullet'><listitem><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="author">Rachel Airley</arg><arg name="title">Cancer chemotherapy<space/></arg><arg name="publisher">Wiley-Blackwell</arg><arg name="location"><space/></arg><arg name="year">2009<space/></arg><arg name="isbn">0-470-09254-8</arg></template></listitem><listitem><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="author">Wood, Miriam; David Brighton</arg><arg name="title">The Royal Marsden Hospital handbook of cancer chemotherapy: a guide for the multidisciplinary team</arg><arg name="publisher">Elsevier Churchill Livingstone</arg><arg name="location">St. Louis, Mo<space/></arg><arg name="year">2005</arg><arg name="isbn">0-443-07101-2</arg></template></listitem><listitem><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="author">Fergus Macbeth; Hanna, Louise; Crosby, Tom<space/></arg><arg name="title">Practical clinical oncology<space/></arg><arg name="publisher">Cambridge University Press<space/></arg><arg name="location">Cambridge, UK<space/></arg><arg name="year">2008</arg></template></listitem><listitem><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="author">Perry, Michael J.<space/></arg><arg name="title">The Chemotherapy source book<space/></arg><arg name="publisher">Wolters Kluwer Health/Lippincott Williams & Wilkins</arg><arg name="location">Philadelphia<space/></arg><arg name="year">2008</arg></template></listitem><listitem><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last"><space/>Faguet</arg><arg name="first"><space/>Guy B.</arg><arg name="title"><space/>The War on Cancer</arg><arg name="publisher"><space/>Springer</arg><arg name="year"><space/>2005</arg><arg name="page"><space/>71</arg><arg name="isbn"><space/>1-4020-3618-3</arg></template></listitem><listitem><template><target>cite journal</target><arg name="author"><space/>Hirsch J<space/></arg><arg name="title"><space/>An anniversary for cancer chemotherapy<space/></arg><arg name="journal"><space/>Jama<space/></arg><arg name="volume"><space/>296<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1518–20<space/></arg><arg name="date"><space/>Sep 2006<space/></arg><arg name="pmid"><space/>17003400<space/></arg><arg name="doi"><space/>10.1001/jama.296.12.1518<space/></arg></template></listitem><listitem><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1"><space/>Huang<space/></arg><arg name="first1"><space/>Elbert S.<space/></arg><arg name="title"><space/>Internal medicine: handbook for clinicians, resident survival guide<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="publisher"><space/>Scrub Hill Press<space/></arg><arg name="location"><space/>Arlington, VA<space/></arg><arg name="isbn"><space/>978-0-9645467-5-2<space/></arg><arg name="page"><space/>130</arg></template></listitem><listitem><template><target>cite book</target><arg name="last">Randall</arg><arg name="first">[edited by] William J. Hoskins, Carlos A. Perez, Robert C. Young, Richard R. Barakat, [[Maurie Markman]], Marcus E.</arg><arg name="title">Principles and practice of gynecologic oncology</arg><arg name="year">2005</arg><arg name="publisher">Lippincott Williams & Wilkins</arg><arg name="location">Baltimore, Md.</arg><arg name="isbn">0-7817-4689-2</arg><arg name="pages">93–94</arg><arg name="edition">4.</arg></template></listitem></list><paragraph><template><target>refend</target></template></paragraph><heading level='2'>External links</heading><list type='bullet'><listitem><link type='external' href='http://www.cancer.gov/clinicaltrials/search/'>Search for chemotherapy trials</link></listitem><listitem><link type='external' href='http://www.cancer.org/docroot/ETO/content/ETO_1_2X_Chemotherapy_What_It_Is_How_It_Helps.asp'>American Cancer Society Chemotherapy</link></listitem><listitem><link type='external' href='http://chemocare.com/chemotherapy/drug-info/default.aspx'>Chemotherapy side effects</link></listitem></list><paragraph><template><target>Chemotherapeutic agents</target></template><template><target>Extracellular chemotherapeutic agents</target></template><template><target>Tumors</target></template><template><target>Major Drug Groups</target></template></paragraph><paragraph><template><target>Authority control</target></template></paragraph><paragraph><link><target>Category:Antineoplastic drugs</target></link><link><target>Category:Oncology</target></link><link><target>Category:Cancer treatments</target></link><link><target>Category:Chemotherapy</target><part></part></link></paragraph></article>